

CITATION REPORT

List of articles citing

The amyloid hypothesis of Alzheimerts disease:
progress and problems on the road to therapeutics

DOI: 10.1126/science.1072994
Science, 2002, 297, 353-6.

Source: <https://exaly.com/paper-pdf/34124643/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2287	Brain Dysfunction Associated with Amyloid Fibrils and Other Aggregated Proteins. 355-382		
2286	The effect of epinephrine on the uptake of ¹³¹ I by the rat thyroid, with particular reference to the trapping process. 1974 , 77, 35-42		2
2285	Polyadenylation of nascent RNA during the embryogenesis of <i>Ilyanassa obsoleta</i> . 1975 , 95, 263-8		8
2284	Pharmacotherapy of agitation and psychotic symptoms in Alzheimer's disease. 2002 , 2, 655-64		1
2283	Induction of the cholesterol transporter ABCA1 in central nervous system cells by liver X receptor agonists increases secreted Abeta levels. 2002 , 277, 48508-13		122
2282	Cerebrospinal fluid shunting for Alzheimer's disease?. 2002 , 59, 1126-7		1
2281	Protein kinase C inhibits amyloid beta peptide neurotoxicity by acting on members of the Wnt pathway. 2002 , 16, 1982-4		138
2280	High b value q-space-analyzed diffusion MRI in vascular dementia: a preliminary study. 2002 , 203-204, 235-9		44
2279	Acetylcholinesterase inhibitors in the context of therapeutic strategies to combat Alzheimer's disease. 2002 , 12, 1853-1865		12
2278	Immunological approaches as therapy for Alzheimer's disease. 2002 , 2, 907-17		11
2277	Chaperone priming of pilus subunits facilitates a topological transition that drives fiber formation. 2002 , 111, 543-51		217
2276	Tissue cultures from adult human postmortem subcortical brain areas. 2002 , 6, 429-32		20
2275	Translational diffusion measured by PFG-NMR on full length and fragments of the Alzheimer Aβ(1-40) peptide. Determination of hydrodynamic radii of random coil peptides of varying length. 2002 , 40, S89-S97		113
2274	Therapeutic strategies for Alzheimer's disease. 2002 , 1, 859-66		144
2273	Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. 2002 , 3, 862-72		778
2272	Kinetic modeling and determination of reaction constants of Alzheimer's beta-amyloid fibril extension and dissociation using surface plasmon resonance. 2002 , 41, 13489-98		114
2271	Femtomole immunodetection of synthetic and endogenous amyloid-beta oligomers and its application to Alzheimer's disease drug candidate screening. 2003 , 20, 305-13		66

2270	Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. 2003 , 3, 65-94	369
2269	Alzheimer's amyloid beta-peptide enhances ATP/gap junction-mediated calcium-wave propagation in astrocytes. 2003 , 3, 173-80	74
2268	Structure-activity relationship of imidazo[1,2-a]pyridines as ligands for detecting beta-amyloid plaques in the brain. 2003 , 46, 237-43	197
2267	Learning and memory deficits in APP transgenic mouse models of amyloid deposition. 2003 , 28, 1029-34	47
2266	A metabolic basis for Alzheimer disease. 2003 , 28, 1549-52	45
2265	The neuropathological spectrum of neurodegenerative tauopathies. 2003 , 55, 299-305	42
2264	From Alzheimer to Huntington: why is a structural understanding so difficult?. 2003 , 22, 355-61	125
2263	Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. 2003 , 100, 10417-22	906
2262	Anesthesia, the aging brain, and the surgical patient. 2003 , 50, R60-R64	16
2261	Vaccine trial in Alzheimer's disease is halted. 2003 , 3, 371-2	2
2260	Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. 2003 , 81, 678-99	1272
2259	Emerging ideas on the molecular basis of protein and peptide aggregation. 2003 , 13, 146-59	289
2258	Dissecting the assembly of Abeta16-22 amyloid peptides into antiparallel beta sheets. 2003 , 11, 295-307	325
2257	Immunotherapy for Alzheimer's disease. 2003 , 2, 215-20	89
2256	Treatment of Alzheimer's disease: current status and new perspectives. 2003 , 2, 539-47	590
2255	Pathological and functional amyloid formation orchestrated by the secretory pathway. 2003 , 13, 674-82	57
2254	Neurofibrillary degeneration of the Alzheimer-type: an alternate pathway to neuronal apoptosis?. 2003 , 66, 1619-25	43
2253	Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease. 2003 , 137, 32-41	96

2252	Could inhibition of the proteasome cause mad cow disease?. 2003 , 21, 144-5	13
2251	Age-related changes in neuronal glucose uptake in response to glutamate and beta-amyloid. 2003 , 72, 527-36	51
2250	Toward a molecular neuropsychiatry of neurodegenerative diseases. 2003 , 54, 147-54	80
2249	Alzheimer's disease: genetic evidence points to a single pathogenesis. 2003 , 54, 143-4	22
2248	Chronically mad as a hatter: anticholinergics and Alzheimer's disease pathology. 2003 , 54, 144-6	3
2247	Mirror-image phage display: aiming at the mirror. 2003 , 4, 811-5	50
2246	Peptide binding by one-armed receptors in water: screening of a combinatorial library for the binding of Val-Val-Ile-Ala. 2003 , 4, 1232-8	50
2245	Alzheimer vaccine: amyloid-beta on trial. 2003 , 25, 283-8	22
2244	High affinity, bioavailable 3-amino-1,4-benzodiazepine-based gamma-secretase inhibitors. 2003 , 13, 4143-5	36
2243	Predicting the conformations of carvedilol based on its pharmacophore fragments: a gas phase and solvation ab initio and density functional study. 2003 , 666-667, 537-545	5
2242	RS-4252 inhibits amyloid beta-induced cytotoxicity in HeLa cells. 2003 , 93, 29-32	9
2241	Melatonin prevents free radical formation due to the interaction between beta-amyloid peptides and metal ions [Al(III), Zn(II), Cu(II), Mn(II), Fe(II)]. 2003 , 35, 98-103	43
2240	Efficient inhibition of beta-secretase gene expression in HEK293 cells by tRNAVal-driven and CTE-helicase associated hammerhead ribozymes. 2003 , 270, 3962-70	8
2239	Localization of presenilin-nicastrin complexes and gamma-secretase activity to the trans-Golgi network. 2003 , 84, 1143-53	45
2238	Biochemical and molecular studies using human autopsy brain tissue. 2003 , 85, 543-62	202
2237	A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114. 2003 , 86, 1359-68	106
2236	Involvement of Rho-associated kinase in neurite sprouting and amyloid beta production of rat cortical neurons cultured in insulin-free medium. 2003 , 3, 21-28	
2235	Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. 2003 , 17, 388-96	197

2234	6-Ethyl-N,N'-bis(3-hydroxyphenyl)[1,3,5]triazine-2,4-diamine (RS-0466) enhances the protective effect of brain-derived neurotrophic factor on amyloid beta-induced cytotoxicity in cortical neurones. 2003 , 93, 264-8	2
2233	Alzheimer's disease: Mental plaque removal. 2003 , 423, 392-3	31
2232	Extracellular amyloid formation and associated pathology in neural grafts. 2003 , 6, 370-7	104
2231	Human and mouse proteases: a comparative genomic approach. 2003 , 4, 544-58	725
2230	The impact of systemic infection on the progression of neurodegenerative disease. 2003 , 4, 103-12	341
2229	Alzheimer's disease and Parkinson's disease. 2003 , 348, 1356-64	929
2228	Interventions for Mild Cognitive Impairment and Alzheimer Disease: New Strategies, New Hope. 2003 , 11, 120-122	7
2227	Self-assembly of Abeta(1-42) into globular neurotoxins. 2003 , 42, 12749-60	462
2226	Clinically tested drugs for Alzheimer's disease. 2003 , 12, 1143-51	20
2225	Neural stem cell therapy in the aging brain: pitfalls and possibilities. 2003 , 12, 615-23	32
2224	Amphotericin B binds to amyloid fibrils and delays their formation: a therapeutic mechanism?. 2003 , 42, 6228-33	32
2223	The intact human acetylcholinesterase C-terminal oligomerization domain is alpha-helical in situ and in isolation, but a shorter fragment forms beta-sheet-rich amyloid fibrils and protofibrillar oligomers. 2003 , 42, 10863-73	22
2222	The transcriptional activity of the APP intracellular domain-Fe65 complex is inhibited by activation of the NF-kappaB pathway. 2003 , 42, 3627-34	30
2221	gamma-Secretase cleavage and binding to FE65 regulate the nuclear translocation of the intracellular C-terminal domain (ICD) of the APP family of proteins. 2003 , 42, 6664-73	91
2220	Iodinated tracers for imaging amyloid plaques in the brain. 2003 , 5, 418-26	32
2219	A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease. 2003 , 14, 365-79	94
2218	Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. 2003 , 24, 1063-70	736
2217	Structure of the Alzheimer's disease amyloid precursor protein copper binding domain. A regulator of neuronal copper homeostasis. 2003 , 278, 17401-7	208

2216	3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy. 2003 , 46, 2279-82	237
2215	Divergent roles of GSK3 and CDK5 in APP processing. 2003 , 312, 922-9	110
2214	Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. 2003 , 26, 267-98	1439
2213	Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. <i>Science</i> , 2003 , 300, 486-9	33-3 3389
2212	Biomarkers of Alzheimer's disease and mild cognitive impairment: are we there yet?. 2003 , 183, 7-10	17
2211	Genes for schizophrenia? Recent findings and their pathophysiological implications. 2003 , 361, 417-9	488
2210	Alzheimer's disease and angiogenesis. 2003 , 361, 1299-1300	2
2209	Comparative studies of active site-ligand interactions among various recombinant constructs of human beta-amyloid precursor protein cleaving enzyme. 2003 , 410, 307-16	18
2208	Fullerene inhibits beta-amyloid peptide aggregation. 2003 , 303, 576-9	185
2207	APH1, PEN2, and Nicastrin increase Abeta levels and gamma-secretase activity. 2003 , 305, 502-9	41
2206	Role of kallikrein enzymes in the central nervous system. 2003 , 329, 1-8	67
2205	Hypothesis for a common basis for neuroprotection in glaucoma and Alzheimer's disease: anti-apoptosis by alpha-2-adrenergic receptor activation. 2003 , 48 Suppl 1, S25-37	57
2204	Short peptide amyloid organization: stabilities and conformations of the islet amyloid peptide NFGAIL. 2003 , 84, 1884-94	113
2203	Thiorphan-induced neprilysin inhibition raises amyloid beta levels in rabbit cortex and cerebrospinal fluid. 2003 , 350, 178-80	24
2202	Effect of PPF and ALCAR on the induction of NGF- and p75-mRNA and on APP processing in Tg2576 brain. 2003 , 43, 225-33	35
2201	Is there a future for vaccination as a treatment for Alzheimer's disease?. 2003 , 24, 391-5	34
2200	AVaccination of a genetic model of Alzheimer's disease. 2003 , 1252, 405-409	
2199	Red cell perturbations by amyloid beta-protein. 2003 , 1622, 20-8	60

2198	The impact of Abeta-plaques on cortical cholinergic and non-cholinergic presynaptic boutons in alzheimer's disease-like transgenic mice. 2003 , 121, 421-32	84
2197	The Wnt pathway, cell-cycle activation and beta-amyloid: novel therapeutic strategies in Alzheimer's disease?. 2003 , 24, 233-8	114
2196	Molecular mechanisms of amyloidosis. 2003 , 349, 583-96	1335
2195	BACE1 (beta-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes. 2003 , 24, 646-55	134
2194	Effects of beta-amyloid protein on serotonergic, noradrenergic, and cholinergic markers in neurons of the pontomesencephalic tegmentum in the rat. 2003 , 26, 153-69	35
2193	Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. 2003 , 38, 547-54	677
2192	Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. 2003 , 39, 409-21	3031
2191	The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. 2003 , 40, 427-46	790
2190	Do disorders of movement cause movement disorders and dementia?. 2003 , 40, 415-25	69
2189	Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer's disease. 2003 , 35, 1505-35	152
2188	Monitoring the ubiquitin/proteasome system in conformational diseases. 2003 , 2, 433-49	38
2187	¹¹ C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease. 2003 , 30, 565-71	189
2186	Dimethylamino-fluorenes: ligands for detecting beta-amyloid plaques in the brain. 2003 , 30, 573-80	45
2185	BACE1 (beta-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time. 2003 , 14, 81-8	143
2184	Gleevec inhibits beta-amyloid production but not Notch cleavage. 2003 , 100, 12444-9	159
2183	Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. 2003 , 306, 772-7	172
2182	Synaptic plasticity in animal models of early Alzheimer's disease. 2003 , 358, 821-8	155
2181	Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease. 2003 , 20, 101-13	79

2180	In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. 2003 , 278, 11612-22	749
2179	JNK-interacting protein-1 promotes transcription of A beta protein precursor but not A beta precursor-like proteins, mechanistically different than Fe65. 2003 , 100, 1729-34	64
2178	Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: a magnetic resonance microscopy and stereologic analysis. 2003 , 100, 1381-6	164
2177	The renin-angiotensin-aldosterone system and Alzheimer s disease?. 2003 , 4, 80-93	34
2176	Cholesterol: from heart attacks to Alzheimer's disease. 2003 , 44, 1423-30	56
2175	Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. <i>Science</i> , 2003 , 302, 1215-7	333 278
2174	Expression of liver X receptor target genes decreases cellular amyloid beta peptide secretion. 2003 , 278, 27688-94	136
2173	Specific compositions of amyloid-beta peptides as the determinant of toxic beta-aggregation. 2003 , 278, 23648-55	81
2172	Amyloid deposition in the hippocampus and entorhinal cortex: quantitative analysis of a transgenic mouse model. 2003 , 100, 4837-42	129
2171	Identification of a mutant amyloid peptide that predominantly forms neurotoxic protofibrillar aggregates. 2003 , 278, 23187-95	36
2170	Insulin and Alzheimer's disease: an amyloid connection. 2003 , 60, 1886-7	19
2169	Polyserase-I, a human polyprotease with the ability to generate independent serine protease domains from a single translation product. 2003 , 100, 9185-90	51
2168	Microtubular interactions of presenilin direct kinesin of Abeta peptide and its precursors. 2003 , 17, 1322-4	16
2167	The application of functional genomics to Alzheimer's disease. 2003 , 4, 597-621	64
2166	Antibody therapy for Alzheimer's disease. 2003 , 2, 53-9	5
2165	Alzheimer's disease: from molecular pathogenesis to innovative therapies. 2003 , 3, 619-30	7
2164	Evidence for defective retinoid transport and function in late onset Alzheimer's disease. 2003 , 100, 2901-5	137
2163	Amyloid beta protein precursor is phosphorylated by JNK-1 independent of, yet facilitated by, JNK-interacting protein (JIP)-1. 2003 , 278, 42058-63	39

2162	Alzheimer's disease skin fibroblasts selectively express a bradykinin signaling pathway mediating tau protein Ser phosphorylation. 2003 , 17, 2319-21	20
2161	IL-4 down-regulates lipopolysaccharide-induced formyl peptide receptor 2 in murine microglial cells by inhibiting the activation of mitogen-activated protein kinases. 2003 , 171, 5482-8	26
2160	Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo. 2003 , 100, 6221-6	257
2159	Unraveling the secrets of Alzheimer's beta-amyloid fibrils. 2003 , 100, 383-5	46
2158	Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. 2003 , 100, 10032-7	646
2157	The neuronal adaptor protein X11alpha reduces Abeta levels in the brains of Alzheimer's APPswe Tg2576 transgenic mice. 2003 , 278, 47025-9	60
2156	The transmembrane domain region of nicastrin mediates direct interactions with APH-1 and the gamma-secretase complex. 2003 , 278, 43284-91	63
2155	Targeted control of kinetics of beta-amyloid self-association by surface tension-modifying peptides. 2003 , 278, 40730-5	23
2154	Nicastrin interacts with gamma-secretase complex components via the N-terminal part of its transmembrane domain. 2003 , 278, 52519-23	52
2153	Frameshifted beta-amyloid precursor protein (APP+1) is a secretory protein, and the level of APP+1 in cerebrospinal fluid is linked to Alzheimer pathology. 2003 , 278, 39637-43	9
2152	Amyloid, presenilins, and Alzheimer's disease. 2003 , 9, 117-26	25
2151	An Alzheimer's disease hypothesis based on transcriptional dysregulation. 2003 , 10, 80-5	30
2150	A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. 2003 , 4, 97-112	170
2149	A beta, aging, and Alzheimer's disease: a tale, models, and hypotheses. 2003 , 25, 581-9	24
2148	The risk of dementia in relation to statins and other lipid lowering agents. 2003 , 25, 601-4	18
2147	Role of cdk5 in the pathogenesis of Alzheimer's disease. 2003 , 12, 209-14	51
2146	Pharmakotherapie der Demenzen. 2003 , 30, 512-518	
2145	Molecular identification of AMY, an Alzheimer disease amyloid-associated protein. 2003 , 62, 1108-17	14

2144	Current treatment for Alzheimer disease and future prospects. 2003 , 17 Suppl 4, S105-13	148
2143	Organische Chemie 2002. 2003 , 51, 286-315	3
2142	Toward an early diagnosis and treatment of Alzheimer's disease. 2003 , 15, 223-37	20
2141	[Amyloid-beta peptide metabolism and Alzheimer's disease]. 2003 , 122, 5-14	5
2140	Chapter 5. Secretase inhibitors for Alzheimer's disease. 2003 , 38, 41-50	11
2139	Emerging therapeutics for Alzheimer's disease: an avenue of hope. 2003 , 8, 834-45	8
2138	Formation of complement membrane attack complex in mammalian cerebral cortex evokes seizures and neurodegeneration. 2003 , 23, 955-60	111
2137	Nicastrin is required for assembly of presenilin/gamma-secretase complexes to mediate Notch signaling and for processing and trafficking of beta-amyloid precursor protein in mammals. 2003 , 23, 3272-7	161
2136	Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. 2003 , 23, 7084-92	378
2135	Apolipoprotein is required for the formation of filamentous amyloid, but not for amorphous Abeta deposition, in an AbetaPP/PS double transgenic mouse model of Alzheimer's disease. 2004 , 6, 509-14	12
2134	Cholesterol-independent effects of statins and new therapeutic targets: ischemic stroke and dementia. 2004 , 11, 253-64	82
2133	Incubation of nerve endings with a physiological concentration of Abeta1-42 activates CaV2.2(N-Type)-voltage operated calcium channels and acutely increases glutamate and noradrenaline release. 2004 , 6, 243-55	40
2132	Nitric oxide neurotoxicity in neurodegenerative diseases. 2004 , 9, 763-76	121
2131	Linking lipids, Alzheimer's and LXRs?. 2004 , 2, e001	8
2130	Islet-brain (IB)/JNK-interacting proteins (JIPs): future targets for the treatment of neurodegenerative diseases?. 2004 , 1, 111-27	12
2129	Exploring the early steps of aggregation of amyloid-forming peptide KFFE. 2004 , 16, S5047-S5054	10
2128	Future directions in the treatment of Alzheimer's disease. 2004 , 13, 303-14	21
2127	Drug therapy in Alzheimer's disease. 2004 , 351, 1911-3; author reply 1911-3	9

2126	Molecular mechanisms, emerging etiological insights and models to test potential therapeutic interventions in Alzheimer's disease. 2004 , 1, 295-306	5
2125	Amyloid beta-peptide: the inside story. 2004 , 1, 231-9	62
2124	RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. 2004 , 35, 2628-31	311
2123	The human amyloid-beta precursor protein770 mutation V717F generates peptides longer than amyloid-beta-(40-42) and flocculent amyloid aggregates. 2004 , 279, 5829-36	24
2122	The N-terminal copper-binding domain of the amyloid precursor protein protects against Cu ²⁺ neurotoxicity in vivo. 2004 , 18, 1701-3	37
2121	Facilitation of stress-induced phosphorylation of beta-amyloid precursor protein family members by X11-like/Mint2 protein. 2004 , 279, 21628-36	38
2120	Dissection of amyloid-beta precursor protein-dependent transcriptional transactivation. 2004 , 279, 24601-11	240
2119	Young onset dementia. 2004 , 80, 125-39	106
2118	Glycogen synthase kinase 3 beta induces caspase-cleaved tau aggregation in situ. 2004 , 279, 54716-23	82
2117	Expression profiling of lymphocyte plasma membrane proteins. 2004 , 3, 56-65	76
2116	Growth factor receptor-bound protein 2 interaction with the tyrosine-phosphorylated tail of amyloid beta precursor protein is mediated by its Src homology 2 domain. 2004 , 279, 25374-80	39
2115	Nuclear Medicine in Psychiatry. 2004 ,	3
2114	Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications. 2004 , 541, 135-52	127
2113	Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques. 2004 , 24, 4535-40	179
2112	Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. 2004 , 279, 12876-82	572
2111	Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles. 2004 , 32, 661-8	121
2110	Membrane topology and nicastrin-enhanced endoproteolysis of APH-1, a component of the gamma-secretase complex. 2004 , 279, 3685-93	58
2109	A nontransgenic mouse model shows inducible amyloid-beta (Abeta) peptide deposition and elucidates the role of apolipoprotein E in the amyloid cascade. 2004 , 101, 13909-14	93

2108	Mouse models of Alzheimer's disease: insight into treatment. 2004 , 15, 353-69	87
2107	Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. 2004 , 24, 991-8	201
2106	Abnormality of G-protein-coupled receptor kinases at prodromal and early stages of Alzheimer's disease: an association with early beta-amyloid accumulation. 2004 , 24, 3444-52	53
2105	Search strategies used by APP transgenic mice during navigation in the Morris water maze. 2004 , 11, 337-46	161
2104	Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. 2004 , 101, 2173-8	788
2103	Pauling and Corey's alpha-pleated sheet structure may define the prefibrillar amyloidogenic intermediate in amyloid disease. 2004 , 101, 11622-7	119
2102	Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis. 2004 , 101, 10132-6	222
2101	Association of late-onset Alzheimer's disease with genetic variation in multiple members of the GAPD gene family. 2004 , 101, 15688-93	123
2100	Transient cerebral ischemia induces aberrant neuronal cell cycle re-entry and Alzheimer's disease-like tauopathy in female rats. 2004 , 279, 22684-92	105
2099	Functional studies of cholinergic activity in normal and Alzheimer disease states by imaging technique. 2004 , 145, 301-10	12
2098	Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. 2004 , 13, 1225-40	259
2097	Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. 2004 , 61, 378-84	375
2096	Neuronal structure is altered by amyloid plaques. 2004 , 15, 267-78	85
2095	Assessment of the bioactivity of antibodies against beta-amyloid peptide in vitro and in vivo. 2004 , 1, 160-7	11
2094	The biochemical and genetic odyssey to the function of a nicastrin-like protein. 2004 , 1, 192-5	4
2093	Influence of beta-amyloid fibrils on the interactions between red blood cells and endothelial cells. 2004 , 26, 579-85	15
2092	Alzheimer's disease: from bench to bedside. 2004 , 18, 177-195	
2091	Animal models of tau phosphorylation and tauopathy □what have they taught us?. 2004 , 16, 153-175	

2090	Development of bivalent acetylcholinesterase inhibitors as potential therapeutic drugs for Alzheimer's disease. 2004 , 10, 3141-56	70
2089	3' untranslated region in a light neurofilament (NF-L) mRNA triggers aggregation of NF-L and mutant superoxide dismutase 1 proteins in neuronal cells. 2004 , 24, 2716-26	24
2088	Protein trafficking and Alzheimer's disease. 2004 , 1, 1-10	19
2087	White matter lesions and hippocampal atrophy in Alzheimer's disease. 2004 , 62, 310-2	96
2086	Styrylbenzoxazole derivatives for in vivo imaging of amyloid plaques in the brain. 2004 , 24, 2535-41	87
2085	TGF-beta1 disrupts endotoxin signaling in microglial cells through Smad3 and MAPK pathways. 2004 , 173, 962-8	50
2084	Processing amyloid precursor protein at the beta-site requires proper orientation to be accessed by BACE1. 2004 , 279, 39010-6	24
2083	Increased soluble amyloid-beta peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein. 2004 , 101, 1075-80	120
2082	The Caenorhabditis elegans IMPAS gene, imp-2, is essential for development and is functionally distinct from related presenilins. 2004 , 101, 14955-60	52
2081	Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection. 2004 , 279, 37061-8	220
2080	Presence of a "CAGA box" in the APP gene unique to amyloid plaque-forming species and absent in all APLP-1/2 genes: implications in Alzheimer's disease. 2004 , 18, 1288-90	41
2079	Dissecting the pathological effects of human Abeta40 and Abeta42 in Drosophila: a potential model for Alzheimer's disease. 2004 , 101, 6623-8	380
2078	Aqueous urea solution destabilizes Abeta(16-22) oligomers. 2004 , 101, 14760-5	140
2077	Exploring amyloid formation by a de novo design. 2004 , 101, 4435-40	156
2076	Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPSW mice resulting in tau phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis. 2004 , 24, 7707-17	216
2075	Phytochemicals in Alzheimer Disease: The Development of Clinical Trials. 2004 , 42, 64-73	6
2074	The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer's disease. 2004 , 13, 1469-81	39
2073	Transgenic mouse models of Alzheimer's disease: how useful have they been for therapeutic development?. 2004 , 3, 47-59	74

2072	Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism. 2004 , 279, 43419-26	151
2071	Identification of distinct gamma-secretase complexes with different APH-1 variants. 2004 , 279, 41340-5	136
2070	Phytochemicals in Alzheimer Disease: The Development of Clinical Trials. 2004 , 42, 64-73	
2069	Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. 2004 , 63, 828-31	100
2068	Inhibition of beta-amyloid toxicity by short peptides containing N-methyl amino acids. 2004 , 63, 324-8	44
2067	Differential involvement of protein kinase C alpha and epsilon in the regulated secretion of soluble amyloid precursor protein. 2004 , 271, 3068-75	40
2066	The peptide sequence Arg-Glu-Arg, present in the amyloid precursor protein, protects against memory loss caused by A beta and acts as a cognitive enhancer. 2004 , 19, 1933-8	30
2065	Protein misfolding in neurodegenerative diseases. 2004 , 30, 215-24	80
2064	MRI and CSF studies in the early diagnosis of Alzheimer's disease. 2004 , 256, 205-23	156
2063	A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes. 2004 , 88, 623-34	126
2062	Clearing amyloid through the blood-brain barrier. 2004 , 89, 807-11	298
2061	Presenilin-directed inhibitors of gamma-secretase trigger caspase 3 activation in presenilin-expressing and presenilin-deficient cells. 2004 , 90, 800-6	14
2060	Frame-shifted amyloid precursor protein found in Alzheimer's disease and Down's syndrome increases levels of secreted amyloid beta40. 2004 , 90, 712-23	11
2059	Mechanism of promoter activity of the beta-amyloid precursor protein gene in different cell lines: identification of a specific 30 bp fragment in the proximal promoter region. 2004 , 90, 1432-44	25
2058	U-box protein carboxyl terminus of Hsc70-interacting protein (CHIP) mediates poly-ubiquitylation preferentially on four-repeat Tau and is involved in neurodegeneration of tauopathy. 2004 , 91, 299-307	104
2057	MAPK recruitment by beta-amyloid in organotypic hippocampal slice cultures depends on physical state and exposure time. 2004 , 91, 349-61	97
2056	Detecting bioactive amyloid beta peptide species in Alzheimer's disease. 2004 , 91, 648-56	11
2055	Macrophage colony stimulatory factor and interferon-gamma trigger distinct mechanisms for augmentation of beta-amyloid-induced microglia-mediated neurotoxicity. 2004 , 91, 623-33	33

2054	Up-regulation of the Kv3.4 potassium channel subunit in early stages of Alzheimer's disease. 2004 , 91, 547-57	68
2053	Genetically-Linked Syndromes in Intellectual Disabilities. 2004 , 1, 31-41	4
2052	Nicotine reduces A beta in the brain and cerebral vessels of APPsw mice. 2004 , 19, 2703-10	110
2051	Targeted introduction of V642I mutation in amyloid precursor protein gene causes functional abnormality resembling early stage of Alzheimer's disease in aged mice. 2004 , 19, 2826-38	44
2050	Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. 2004 , 6, 1054-61	697
2049	Potential role of presenilin-regulated signaling pathways in sporadic neurodegeneration. 2004 , 10 Suppl, S26-33	138
2048	Protein aggregation and neurodegenerative disease. 2004 , 10 Suppl, S10-7	2281
2047	Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. 2004 , 10, 1055-63	547
2046	Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. 2004 , 7, 1181-3	428
2045	WNT and beta-catenin signalling: diseases and therapies. 2004 , 5, 691-701	1524
2044	Biomarkers of neurodegenerative disorders: how good are they?. 2004 , 14, 347-58	67
2043	Take five--BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation. 2004 , 23, 483-8	472
2042	Nicalin and its binding partner Nomo are novel Nodal signaling antagonists. 2004 , 23, 3041-50	45
2041	Beta-sheet breaker peptide prevents Abeta-induced spatial memory impairments with partial reduction of amyloid deposits. 2004 , 9, 953-61	116
2040	Endothelin-converting enzyme-1 is expressed in human cerebral cortex and protects against Alzheimer's disease. 2004 , 9, 1122-8, 1059	47
2039	Strategies for disease modification in Alzheimer's disease. 2004 , 5, 677-85	361
2038	Neuroprotective effects of resveratrol against beta-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. 2004 , 141, 997-1005	238
2037	Accumulation of protein O-GlcNAc modification inhibits proteasomes in the brain and coincides with neuronal apoptosis in brain areas with high O-GlcNAc metabolism. 2004 , 89, 1044-55	88

2036	Pinning down cell signaling, cancer and Alzheimer's disease. 2004 , 29, 200-9	201
2035	Mimotopes of conformational epitopes in fibrillar beta-amyloid. 2004 , 156, 10-20	10
2034	Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. 2004 , 3, 184-90	669
2033	PET imaging of amyloid in Alzheimer's disease. 2004 , 3, 519-27	358
2032	Biomarkers in non-Alzheimer dementias. 2004 , 3, 375-381	2
2031	Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. 2004 , 490, 115-25	308
2030	Mechanisms of the inhibitory effects of amyloid beta-protein on synaptic plasticity. 2004 , 39, 1661-7	50
2029	Overexpression of the human beta-amyloid precursor protein downregulates cortistatin mRNA in PDAPP mice. 2004 , 1023, 157-62	13
2028	Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease. 2004 , 1025, 98-105	116
2027	Akt/GSK3beta serine/threonine kinases: evidence for a signalling pathway mediated by familial Alzheimer's disease mutations. 2004 , 16, 187-200	78
2026	Microarray analysis in Alzheimer's disease and normal aging. 2004 , 56, 349-54	69
2025	Proteases and lipoprotein receptors in Alzheimer's disease. 2004 , 41, 139-78	4
2024	Molecular genetics approaches in yeast to study amyloid diseases. 2004 , 23, 49-60	35
2023	Apolipoprotein E: diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer's disease. 2004 , 23, 189-204	144
2022	ApoE and Abeta1-42 interactions: effects of isoform and conformation on structure and function. 2004 , 23, 235-46	72
2021	Development and evaluation of iodinated tracers targeting amyloid plaques for SPECT imaging. 2004 , 24, 49-53	17
2020	Amyloid precursor protein compartmentalization restricts beta-amyloid production: therapeutic targets based on BACE compartmentalization. 2004 , 24, 137-43	35
2019	A novel imaging probe for in vivo detection of neuritic and diffuse amyloid plaques in the brain. 2004 , 24, 247-55	28

2018	Rapid characterization of amyloid-beta side-chain oxidation by tandem mass spectrometry and the scoring algorithm for spectral analysis. 2004 , 21, 1094-102	16
2017	Intramembrane proteolysis: theme and variations. <i>Science</i> , 2004 , 305, 1119-23	333 308
2016	Challenging the amyloid cascade hypothesis: senile plaques and amyloid-beta as protective adaptations to Alzheimer disease. 2004 , 1019, 1-4	150
2015	Role of the APP promoter in Alzheimer's disease: cell type-specific expression of the beta-amyloid precursor protein. 2004 , 1030, 310-6	21
2014	Targeting amyloid-degrading enzymes as therapeutic strategies in neurodegeneration. 2004 , 1035, 1-20	60
2013	Effect of hypoxia/ischemia and hypoxic preconditioning/reperfusion on expression of some amyloid-degrading enzymes. 2004 , 1035, 21-33	74
2012	Microglia as a potential bridge between the amyloid beta-peptide and tau. 2004 , 1035, 85-103	104
2011	Chasing genes in Alzheimer's and Parkinson's disease. 2004 , 114, 413-38	39
2010	Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. 2004 , 37, 230-7	36
2009	Characterization of IMPY as a potential imaging agent for beta-amyloid plaques in double transgenic PSAPP mice. 2004 , 31, 1136-45	59
2008	Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer's disease in vivo?. 2004 , 31, 1539-40	3
2007	Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer's disease in vivo?. 2004 , 31, 1540-3	4
2006	Proteolytic generation and aggregation of peptides from transmembrane regions: lung surfactant protein C and amyloid beta-peptide. 2004 , 61, 326-35	25
2005	The immunotherapy of Alzheimer's disease. 2004 , 1, 2	18
2004	Effect of tissue transglutaminase on the solubility of proteins containing expanded polyglutamine repeats. 2004 , 88, 1253-60	38
2003	Solid-phase synthesis of styryl dyes and their application as amyloid sensors. 2004 , 43, 6331-5	112
2002	Structural analysis of amyloid beta peptide fragment (25-35) in different microenvironments. 2004 , 76, 421-34	22
2001	Solid-Phase Synthesis of Styryl Dyes and their Application as Amyloid Sensors. 2004 , 116, 6491-6495	17

2000	Vaccination with autoantigen protects against aggregated beta-amyloid and glutamate toxicity by controlling microglia: effect of CD4+CD25+ T cells. 2004 , 34, 3434-45	56
1999	Capillary electrophoresis studies on the aggregation process of beta-amyloid 1-42 and 1-40 peptides. 2004 , 25, 3186-94	67
1998	High mobility group box protein-1 inhibits microglial Abeta clearance and enhances Abeta neurotoxicity. 2004 , 78, 880-91	64
1997	In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. 2004 , 52, 1263-71	154
1996	Alzheimer's disease and immune activation: A translational perspective. 2004 , 35, 193-201	
1995	Phosphorylation of the amyloid precursor protein (APP): Is this a mechanism in favor or against Alzheimer's disease?. 2004 , 35, 213-231	8
1994	Hydrogen-bonded dimer can mediate supramolecular β sheet formation and subsequent amyloid-like fibril formation: a model study. 2004 , 60, 5935-5944	26
1993	Characterization of N-terminal processing of group VIA phospholipase A2 and of potential cleavage sites of amyloid precursor protein constructs by automated identification of signature peptides in LC/MS/MS analyses of proteolytic digests. 2004 , 15, 1780-93	15
1992	Monitoring for dynamic biological processing by intramolecular bioluminescence resonance energy transfer system using secreted luciferase. 2004 , 329, 230-7	25
1991	Abeta aggregation inhibitors. Part 1: Synthesis and biological activity of phenylazo benzenesulfonamides. 2004 , 14, 1173-6	18
1990	Religious Orders Study: Overview and Change in Cognitive and Motor Speed. 2004 , 11, 280-303	44
1989	Metabolite-initiated protein misfolding may trigger Alzheimer's disease. 2004 , 101, 4752-7	195
1988	Combination therapy in Alzheimer's disease: a review of current evidence. 2004 , 18, 827-44	81
1987	Magnetic resonance and PET studies in the early diagnosis of Alzheimer's disease. 2004 , 4, 831-49	34
1986	Oligomeric assembly of native-like precursors precedes amyloid formation by beta-2 microglobulin. 2004 , 43, 7808-15	117
1985	Proteolytic antibody light chains alter beta-amyloid aggregation and prevent cytotoxicity. 2004 , 43, 9999-10007	7
1984	Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. 2004 , 24, 3592-9	377
1983	Toward Alzheimer therapies based on genetic knowledge. 2004 , 55, 15-25	32

1982	AATF inhibits aberrant production of amyloid beta peptide 1-42 by interacting directly with Par-4. 2004 , 279, 4596-603	44
1981	Harnessing chaperones to generate small-molecule inhibitors of amyloid beta aggregation. <i>Science</i> , 2004 , 306, 865-9	33.3 168
1980	Resolution of Carvedilol's Conformational Surface via Gas and Solvent Phase Density Functional Theory Optimizations and NMR Spectroscopy. 2004 , 108, 7719-7729	7
1979	Two-site binding of beta-cyclodextrin to the Alzheimer Abeta(1-40) peptide measured with combined PFG-NMR diffusion and induced chemical shifts. 2004 , 43, 6261-9	64
1978	Transient aggregation and stable dimerization induced by introducing an Alzheimer sequence into a water-soluble protein. 2004 , 43, 12964-78	16
1977	Increased hippocampal neurogenesis in Alzheimer's disease. 2004 , 101, 343-7	824
1976	Pharmacophore Fragment-Based Prediction and Gas-Phase ab Initio Optimization of Carvedilol Conformations. 2004 , 108, 6239-6247	4
1975	Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. 2004 , 24, 6021-7	291
1974	Inhibitors of amyloid aggregation: technologies for the discovery of novel lead compounds. 2004 , 21, 197-212	3
1973	Small assemblies of unmodified amyloid β protein are the proximate neurotoxin in Alzheimer's disease. 2004 , 25, 569-569	
1972	Biomarkers in non-Alzheimer dementias. 2004 ,	
1971	Development of A β terminal end-specific antibodies and sensitive ELISA for A β variant. 2004 , 319, 733-733	
1970	β Secretase inhibitors: still in the running as Alzheimer's therapeutics. 2004 , 1, 1-6	2
1969	Inhibitors of beta-amyloid aggregation: still an issue of structure and function?. 2004 , 1, 7-12	1
1968	Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. 2004 , 56, 670-6	155
1967	Genetics of neurological disorders. 2004 , 4, 317-32	13
1966	Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues. 2004 , 47, 5945-52	108
1965	Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons. 2004 , 24, 6799-809	191

1964	Meat-adaptive genes and the evolution of slower aging in humans. 2004 , 79, 3-50	146
1963	Neurodegenerative diseases caused by protein aggregation: a phenomenon at the borderline between molecular evolution and ageing. 2004 , 50, 419-31	16
1962	The stability and dynamics of the human calcitonin amyloid peptide DFNKF. 2004 , 87, 146-58	44
1961	Neuroprotective strategies in Alzheimer's disease. 2004 , 1, 117-27	55
1960	Sampling the self-assembly pathways of KFFE hexamers. 2004 , 87, 3648-56	69
1959	Per-6-substituted-per-6-deoxy beta-cyclodextrins inhibit the formation of beta-amyloid peptide derived soluble oligomers. 2004 , 47, 3329-33	41
1958	A model system to study intracellular trafficking and processing of the Alzheimer's amyloid precursor protein. 2004 , 1, 196-204	15
1957	Physiological roles of amyloid-beta and implications for its removal in Alzheimer's disease. 2004 , 21, 621-30	39
1956	Synaptic targeting by Alzheimer's-related amyloid beta oligomers. 2004 , 24, 10191-200	805
1955	Gene structure and organization of the human beta-secretase (BACE) promoter. 2004 , 18, 1034-6	155
1954	Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. 2004 , 43, 6899-908	263
1953	Alzheimer's disease. 2004 , 351, 56-67	1096
1952	Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. 2004 , 43, 7365-81	281
1951	Oxidative stress: a theoretical model or a biological reality?. 2004 , 327, 649-62	123
1950	Got RIP? Presenilin-dependent intramembrane proteolysis in growth factor receptor signaling. 2004 , 15, 337-51	72
1949	Lineage-specific and ubiquitous biological roles of the mammalian transcription factor LSF. 2004 , 343, 23-40	47
1948	Noradrenergic mechanisms in neurodegenerative diseases: a theory. 2004 , 45, 38-78	319
1947	Amyloid-beta: phylogenesis of a chameleon. 2004 , 46, 118-20	12

1946	Signal transduction during amyloid-beta-peptide neurotoxicity: role in Alzheimer disease. 2004 , 47, 275-89	105
1945	Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration. 2004 , 78, 243-56	255
1944	Complement C1q expression induced by Abeta in rat hippocampal organotypic slice cultures. 2004 , 185, 241-53	27
1943	Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease. 2004 , 188, 52-64	85
1942	Suppression of the caspase cleavage of beta-amyloid precursor protein by its cytoplasmic phosphorylation. 2004 , 567, 248-52	9
1941	Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant. 2004 , 319, 733-7	73
1940	Beta-amyloid-derived pentapeptide RIIGLa inhibits Abeta(1-42) aggregation and toxicity. 2004 , 324, 64-9	37
1939	Wnt-3a overcomes beta-amyloid toxicity in rat hippocampal neurons. 2004 , 297, 186-96	175
1938	Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge. 2004 , 25, 92-7	181
1937	Cell cycle regulation of neuronal apoptosis in development and disease. 2004 , 72, 1-25	245
1936	Alzheimer's disease: intraneuronal alterations precede insoluble amyloid-beta formation. 2004 , 25, 713-8; discussion 743-6	65
1935	Alzheimer's disease--a sum greater than its parts?. 2004 , 25, 725-33; discussion 743-6	24
1934	ApoE genotype accounts for the vast majority of AD risk and AD pathology. 2004 , 25, 641-50	422
1933	Lethal weapon: amyloid beta-peptide, role in the oxidative stress and neurodegeneration of Alzheimer's disease. 2004 , 25, 581-7	21
1932	Evidence supporting a role for anti-Abeta antibodies in the treatment of Alzheimer's disease. 2004 , 25, 605-8	30
1931	Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. 2004 , 25, 569-80	437
1930	Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome. 2004 , 25, 1263-72	281
1929	Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. 2004 , 43, 321-32	670

1928	LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. 2004 , 43, 333-44	661
1927	Clearing tau pathology with Abeta immunotherapy--reversible and irreversible stages revealed. 2004 , 43, 293-4	17
1926	Clearance of Alzheimer's Abeta peptide: the many roads to perdition. 2004 , 43, 605-8	186
1925	Deciphering the molecular basis of memory failure in Alzheimer's disease. 2004 , 44, 181-93	1004
1924	Presenilin-1-deficient neurons are nitric oxide-dependently killed by hydrogen peroxide in vitro. 2004 , 125, 563-8	5
1923	Central cholinergic functions in human amyloid precursor protein knock-in/presenilin-1 transgenic mice. 2004 , 125, 1009-17	36
1922	Gamma-secretase subunit composition and distribution in the presenilin wild-type and mutant mouse brain. 2004 , 129, 615-28	35
1921	Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities. 2004 , 164, 975-85	177
1920	Building a more perfect beast: APP transgenic mice with neuronal loss. 2004 , 164, 1143-6	23
1919	Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. 2004 , 164, 1495-502	212
1918	Staying connected: synapses in Alzheimer disease. 2004 , 165, 1461-4	15
1917	Synaptic changes in Alzheimer's disease: increased amyloid-beta and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence. 2004 , 165, 1809-17	194
1916	Cdk5 deregulation in the pathogenesis of Alzheimer's disease. 2004 , 10, 452-8	205
1915	Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. 2004 , 15, 11-20	166
1914	Neuroprotective effect of genistein against beta amyloid-induced neurotoxicity. 2004 , 16, 21-8	105
1913	AATF protects neural cells against oxidative damage induced by amyloid beta-peptide. 2004 , 16, 150-7	23
1912	Late onset loss of hippocampal 5-HT and NE is accompanied by increases in BDNF protein expression in mice co-expressing mutant APP and PS1. 2004 , 16, 572-80	36
1911	Longitudinal observation on CSF Abeta42 levels in young to middle-aged amyloid precursor protein/presenilin-1 doubly transgenic mice. 2004 , 17, 516-23	32

1910	Inhibition of fibril formation and toxicity of a fragment of alpha-synuclein by an N-methylated peptide analogue. 2004 , 359, 89-93	54
1909	Insulin degrading enzyme is expressed in the human cerebrovascular endothelium and in cultured human cerebrovascular endothelial cells. 2004 , 371, 6-11	21
1908	Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. 2004 , 25, 5-18; author reply 49-62	681
1907	Age- and sex-dependent development of adrenocortical hyperactivity in a transgenic mouse model of Alzheimer's disease. 2004 , 25, 893-904	62
1906	Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical "disconnection" in aging and Alzheimer's disease. 2004 , 25, 843-51	309
1905	Soluble Abeta homeostasis in AD and DS: impairment of anti-amyloidogenic protection by lipoproteins. 2004 , 25, 833-41	26
1904	Imaging of A β plaques in the brain of Alzheimer's disease. 2004 , 1264, 3-9	6
1903	DHEAS improves learning and memory in aged SAMP8 mice but not in diabetic mice. 2004 , 75, 2775-85	33
1902	BACE (beta-secretase) modulates the processing of APLP2 in vivo. 2004 , 25, 642-9	103
1901	High carbohydrate diets and Alzheimer's disease. 2004 , 62, 689-700	51
1900	Brain cholinesterases: II. The molecular and cellular basis of Alzheimer's disease. 2004 , 63, 308-21	46
1899	Brain cholinesterases: III. Future perspectives of AD research and clinical practice. 2004 , 63, 298-307	23
1898	Apo and inhibitor complex structures of BACE (beta-secretase). 2004 , 343, 407-16	171
1897	Direct observation of Abeta amyloid fibril growth and inhibition. 2004 , 344, 757-67	202
1896	BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. 2004 , 41, 27-33	457
1895	PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. 2004 , 116, 671-82	275
1894	Anti-amyloid activity of neprilysin in plaque-bearing mouse models of Alzheimer's disease. 2004 , 562, 16-21	32
1893	Why biphenyl configuration still matters. 2004 , 17, 735-739	7

1892	A computational study of the binding of propidium to the peripheral anionic site of human acetylcholinesterase. 2004 , 47, 3991-9	57
1891	Co-accumulation of vascular endothelial growth factor with beta-amyloid in the brain of patients with Alzheimer's disease. 2004 , 25, 283-90	127
1890	A novel drug target in Alzheimer's disease. 2004 , 364, 1738-9	6
1889	Complex regional pain syndromes--how do we escape the diagnostic trap?. 2004 , 364, 1739-41	45
1888	Advances in the Development of Biomarkers for Alzheimer's Disease - From CSF Total Tau and Amyloid-β(1-42) Proteins to Phosphorylated Tau and Amyloid-β-Antibodies. 2004 , 134-156	2
1887	Early changes in neurons of the hippocampus and neocortex in transgenic rats expressing intracellular human a-beta. 2004 , 6, 421-31; discussion 443-9	30
1886	Clearance of Alzheimer's AβPeptideThe Many Roads to Perdition. 2004 , 43, 605-608	349
1885	Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. 2004 , 10, 1469-92	218
1884	The systemic amyloidoses. 2004 , 16, 67-75	100
1883	Drug use in the elderly: risk or protection?. 2004 , 17, 443-447	2
1882	Inhibition of amyloid-beta-induced neurotoxicity and apoptosis by moderate ethanol preconditioning. 2004 , 15, 2093-6	46
1881	Contact regions in the dimer of Alzheimer beta-amyloid domain [1-28] studied by mass spectrometry. 2004 , 10, 309-16	4
1880	Do antiangiogenic protein fragments have amyloid properties?. 2004 , 104, 1601-5	23
1879	Hereditary dementia with intracerebral hemorrhages and cerebral amyloid angiopathy. 2004 , 63, 234-40	27
1878	Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Aβ42 in a manner which may have consequences for metal chelation therapy in Alzheimer's disease. 2004 , 6, 291-301	264
1877	Pathogenesis of Alzheimer Disease: Metabolic Factors. 2004 , 303-353	
1876	[Stress proteins and regulation of microglial amyloid-beta phagocytosis]. 2004 , 124, 407-13	1
1875	Acidic oligosaccharide sugar chain, a marine-derived acidic oligosaccharide, inhibits the cytotoxicity and aggregation of amyloid beta protein. 2004 , 95, 248-55	58

1874	Perspectives on the amyloid-beta cascade hypothesis. 2004 , 6, 137-45	51
1873	Amyloid beta prevents activation of calcium/calmodulin-dependent protein kinase II and AMPA receptor phosphorylation during hippocampal long-term potentiation. 2004 , 92, 2853-8	123
1872	Advances on biological markers in early diagnosis of Alzheimer disease. 2005 , 39, 107-29	2
1871	CLAC binds to aggregated Abeta and Abeta fragments, and attenuates fibril elongation. 2005 , 44, 15602-9	28
1870	Amyloid- β as a Biologically Active Peptide in CNS. 2005 , 529-538	0
1869	Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients. 2005 , 7, 221-32; discussion 255-62	235
1868	Plasma C peptide level and cognitive function among older women without diabetes mellitus. 2005 , 165, 1651-6	44
1867	Alzheimer's Disease and Other Dementias. 2005 , 283-311	
1866	APP23 mice as a model of Alzheimer's disease: an example of a transgenic approach to modeling a CNS disorder. 2005 , 10, 207-22	46
1865	[Brain aging and insulin signals]. 2005 , 125, 137-40	
1864	Proteases and Alzheimer's Disease: Present Knowledge and Emerging Concepts of Therapy. 2005 , 1-23	5
1863	Neuroprotective effects of sigma-1 receptor agonists against beta-amyloid-induced toxicity. 2005 , 16, 1223-6	100
1862	HIV-1 Tat inhibits neprilysin and elevates amyloid beta. 2005 , 19, 127-35	142
1861	BACE Inhibitors for the Treatment of Alzheimer's Disease. 2005 , 40, 35-48	12
1860	The Amyloid β Protein. 384-491	2
1859	Roles of proteolysis and lipid rafts in the processing of the amyloid precursor protein and prion protein. 2005 , 33, 335-8	94
1858	'Nature-inspired' drug-protein complexes as inhibitors of Abeta aggregation. 2005 , 33, 543-7	20
1857	Disease modifying strategies for the treatment of Alzheimer's disease targeted at modulating levels of the beta-amyloid peptide. 2005 , 33, 553-8	50

1856	Synaptic plasticity disruption by amyloid beta protein: modulation by potential Alzheimer's disease modifying therapies. 2005 , 33, 563-7	63
1855	The role of cell-derived oligomers of A β in Alzheimer's disease and avenues for therapeutic intervention. 2005 , 33, 1087-1090	97
1854	Molecular Genetics of Neurological Disorders. 2005 , 393-437	
1853	Understanding molecular mechanisms of proteolysis in Alzheimer's disease: progress toward therapeutic interventions. 2005 , 1751, 60-7	56
1852	Eugenol and its structural analogs inhibit monoamine oxidase A and exhibit antidepressant-like activity. 2005 , 13, 4777-88	70
1851	Supramolecular parallel β -sheet and amyloid-like fibril forming peptides using β -aminovaleric acid residue. 2005 , 61, 5906-5914	13
1850	Aryl sulfones: a new class of gamma-secretase inhibitors. 2005 , 15, 2685-8	78
1849	Synthesis and biological evaluation of functionalized coumarins as acetylcholinesterase inhibitors. 2005 , 40, 1307-15	66
1848	Amyloid precursor protein: from synaptic plasticity to Alzheimer's disease. 2005 , 1048, 149-65	11
1847	Role of formyl peptide receptor-like 1 (FPRL1/FPR2) in mononuclear phagocyte responses in Alzheimer disease. 2005 , 31, 165-76	72
1846	Characterization of the signaling pathway downstream p75 neurotrophin receptor involved in beta-amyloid peptide-dependent cell death. 2005 , 25, 141-56	57
1845	RNA interference technologies for understanding and treating neurodegenerative diseases. 2004 , 6, 1-12	2
1844	Copper brain homeostasis: role of amyloid precursor protein and prion protein. 2005 , 57, 645-50	21
1843	Drosophila as a model for human neurodegenerative disease. 2005 , 39, 153-71	334
1842	Reduced neuronal expression of synaptic transmission modulator HNK-1/neural cell adhesion molecule as a potential consequence of amyloid beta-mediated oxidative stress: a proteomic approach. 2005 , 92, 705-17	27
1841	Aph-1 interacts at the cell surface with proteins in the active gamma-secretase complex and membrane-tethered Notch. 2005 , 92, 1010-20	20
1840	Specific interaction of VEGF165 with beta-amyloid, and its protective effect on beta-amyloid-induced neurotoxicity. 2005 , 93, 118-27	30
1839	Familial Alzheimer's disease mutations inhibit gamma-secretase-mediated liberation of beta-amyloid precursor protein carboxy-terminal fragment. 2005 , 94, 1189-201	57

1838	Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. 2005 , 95, 834-47	467
1837	The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide. 2005 , 21, 733-40	110
1836	Brain-derived neurotrophic factor induces a rapid dephosphorylation of tau protein through a PI-3 Kinase signalling mechanism. 2005 , 22, 1081-9	91
1835	The Alzheimer disease-related calcium-binding protein Calmyrin is present in human forebrain with an altered distribution in Alzheimer's as compared to normal ageing brains. 2005 , 31, 314-24	20
1834	Rational targeting for prion therapeutics. 2005 , 6, 23-34	72
1833	Molecular motors and mechanisms of directional transport in neurons. 2005 , 6, 201-14	666
1832	The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. 2005 , 146, 1041-59	290
1831	In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe. 2005 , 23, 577-83	270
1830	Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. 2005 , 7, 1118-23	337
1829	Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. 2005 , 11, 434-9	294
1828	Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. 2005 , 11, 545-50	254
1827	¹⁹ F and ¹ H MRI detection of amyloid beta plaques in vivo. 2005 , 8, 527-33	304
1826	Regulation of NMDA receptor trafficking by amyloid-beta. 2005 , 8, 1051-8	1238
1825	NF-kappaB factor c-Rel mediates neuroprotection elicited by mGlu5 receptor agonists against amyloid beta-peptide toxicity. 2005 , 12, 761-72	80
1824	Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. 2005 , 10, 40-68; image 5	1654
1823	Design and Implementation of a Multicenter Trial of Vitamin E in Aging Individuals with Down Syndrome. 2005 , 2, 86-93	7
1822	The Alzheimer beta-peptide shows temperature-dependent transitions between left-handed 3-helix, beta-strand and random coil secondary structures. 2005 , 272, 3938-49	103
1821	Invertebrate models of Alzheimer's disease. 2005 , 4, 147-56	77

1820	A case for a non-transgenic animal model of Alzheimer's disease. 2005 , 4, 157-72	47
1819	Genetic and molecular aspects of Alzheimer's disease shed light on new mechanisms of transcriptional regulation. 2005 , 4, 134-46	60
1818	Estrogen stimulates release of secreted amyloid precursor protein from primary rat cortical neurons via protein kinase C pathway. 2005 , 26, 171-6	25
1817	Role of water-soluble amyloid-beta in the pathogenesis of Alzheimer's disease. 2005 , 86, 139-45	30
1816	Calcium dysregulation in Alzheimer's disease: recent advances gained from genetically modified animals. 2005 , 38, 427-37	127
1815	Inhibition of angiogenesis and tumor growth by beta and gamma-secretase inhibitors. 2005 , 514, 1-15	72
1814	Neurogenetics: insights into degenerative diseases and approaches to schizophrenia. 2005 , 5, 3-14	9
1813	Signaling via NF-kappaB in the nervous system. 2005 , 1745, 287-99	218
1812	Emerging prospects for the disease-modifying treatment of Alzheimer's disease. 2005 , 69, 1001-8	45
1811	Nicergoline, a drug used for age-dependent cognitive impairment, protects cultured neurons against beta-amyloid toxicity. 2005 , 1047, 30-7	21
1810	Chronic treatment with amyloid beta(1-42) inhibits non-cholinergic high-affinity choline transport in NG108-15 cells through protein kinase C signaling. 2005 , 1062, 101-10	14
1809	Heterocyclic inhibitors of AChE acylation and peripheral sites. 2005 , 60, 465-73	17
1808	Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. 2005 , 108, 193-214	301
1807	In search of genes involved in neurodegenerative disorders. 2005 , 592, 89-101	20
1806	Alzheimer's disease-like neuropathology of gene-targeted APP-SLxPS1mut mice expressing the amyloid precursor protein at endogenous levels. 2005 , 20, 528-40	29
1805	Protective effect of colostrinin on neuroblastoma cell survival is due to reduced aggregation of beta-amyloid. 2005 , 39, 419-26	38
1804	Metabolism of amyloid-beta peptide and Alzheimer's disease. 2005 , 108, 129-48	161
1803	Soy isoflavone glycitein protects against beta amyloid-induced toxicity and oxidative stress in transgenic <i>Caenorhabditis elegans</i> . 2005 , 6, 54	99

1802	Alzheimer's disease, estrogens, and clinical trials: a case study in drug development for complex disorders. 2005 , 66, 53-77	5
1801	Methodology for multi-site ligand-protein docking identification developed for the optimization of spirostenol inhibition of beta-amyloid-induced neurotoxicity. 2005 , 2, 1571-9	6
1800	PTB Domains. 2005 , 117-141	
1799	Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease. 2005 , 57, 832-42	70
1798	Model-guided microarray implicates the retromer complex in Alzheimer's disease. 2005 , 58, 909-19	294
1797	Amyloid-beta aggregates formed at polar-nonpolar interfaces differ from amyloid-beta protofibrils produced in aqueous buffers. 2005 , 67, 164-74	30
1796	Hydrolysis of the amyloid beta-peptide (A beta) 1-40 between Asp23-Val24 produces non-aggregating fragments. An electrospray mass spectrometric study. 2005 , 40, 142-5	7
1795	Quantification of the A beta peptide in Alzheimer's plaques by laser dissection microscopy combined with mass spectrometry. 2005 , 40, 193-201	36
1794	Homocysteic acid induces intraneuronal accumulation of neurotoxic Abeta42: implications for the pathogenesis of Alzheimer's disease. 2005 , 80, 869-76	61
1793	Lovastatin stimulates up-regulation of alpha7 nicotinic receptors in cultured neurons without cholesterol dependency, a mechanism involving production of the alpha-form of secreted amyloid precursor protein. 2005 , 82, 531-41	20
1792	Parkinson's disease: a broken nosology. 2005 , 20 Suppl 12, S2-4	17
1791	Inhibition of fibril formation of Abeta by guanidiniocarbonyl pyrrole receptors. 2005 , 6, 628-31	21
1790	Characterization of the ZnII binding to the peptide amyloid-beta1-16 linked to Alzheimer's disease. 2005 , 6, 1663-71	69
1789	Metal-binding properties of the peptide APP170-188: a model of the ZnII-binding site of amyloid precursor protein (APP). 2005 , 11, 903-9	39
1788	Therapeutic gene silencing in neurological disorders, using interfering RNA. 2005 , 83, 413-9	25
1787	Deciphering cryptic proteases. 2005 , 62, 989-1002	16
1786	Aluminum-triggered structural modifications and aggregation of beta-amyloids. 2005 , 62, 1724-33	109
1785	Statins: drugs for Alzheimer's disease?. 2005 , 112, 1057-71	45

1784	Emerging treatment strategies for alzheimerβ disease. 2005 , 3, 15-19	
1783	Three-dimensional reconstruction and analysis of structure characteristics on senile plaques of Alzheimerβ disease. 2005 , 50, 868-874	
1782	Understanding and treating neurodegeneration: insights from the flies. 2005 , 27, 225-39	
1781	Neuroprotection by adenosine in the brain: From A(1) receptor activation to A (2A) receptor blockade. 2005 , 1, 111-34	383
1780	The protective role of DL-alpha-lipoic acid in the oxidative vulnerability triggered by Abeta-amyloid vaccination in mice. 2005 , 270, 29-37	15
1779	Two sides of the same coin: Wnt signaling in neurodegeneration and neuro-oncology. 2005 , 25, 309-27	61
1778	RNA interference in neuroscience: progress and challenges. 2005 , 25, 1195-207	17
1777	Amyloid-beta induced cell death is independent of free radicals. 2004 , 6, 633-8; discussion 673-81	20
1776	Genetic mouse models of Alzheimer's disease. 2005 , 12, 299-310	18
1775	Neuronal cell death in human neurodegenerative diseases and their animal/cell models. 2005 , 96-155	1
1774	. 2005 ,	36
1773	A genetic outline of the pathways to cell death in Alzheimer's disease, Parkinson's disease, frontal dementias and related disorders. 2005 , 222-226	
1772	. 2005 ,	4
1771	Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging. 2005 , 64, 378-85	66
1770	The neuropathology of Alzheimer's disease in the year 2005. 2005 , 433-440	11
1769	Alzheimer's Disease: Clinical Features, Neuropathologies and Biochemical Abnormalities, Genetics, Models, and Experimental Therapeutics. 2005 , 445-458	2
1768	Immunotherapy for Alzheimers Disease: Potential Problems and Possible Solutions. 2005 , 1, 139-155	11
1767	Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. 2005 , 25, 7278-87	458

1766	Diversity of senile plaques in Alzheimer's disease as revealed by a new monoclonal antibody that recognizes an internal sequence of the Abeta peptide. 2005 , 2, 409-17	3
1765	F-18 stilbenes as PET imaging agents for detecting beta-amyloid plaques in the brain. 2005 , 48, 5980-8	132
1764	3D structure of Alzheimer's amyloid-beta(1-42) fibrils. 2005 , 102, 17342-7	1675
1763	Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. 2005 , 25, 9096-101	146
1762	Protofibril formation of amyloid beta-protein at low pH via a non-cooperative elongation mechanism. 2005 , 280, 30001-8	96
1761	Vascular remodeling versus amyloid beta-induced oxidative stress in the cerebrovascular dysfunctions associated with Alzheimer's disease. 2005 , 25, 11165-74	132
1760	Sleep-wake states in transgenic mouse models overexpressing the human beta-amyloid precursor protein. 2005 , 20, 87-90	14
1759	IL-4 inhibits the expression of mouse formyl peptide receptor 2, a receptor for amyloid beta1-42, in TNF-alpha-activated microglia. 2005 , 175, 6100-6	31
1758	Interaction of N-terminal acetyltransferase with the cytoplasmic domain of beta-amyloid precursor protein and its effect on A beta secretion. 2005 , 137, 147-55	33
1757	IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. 2005 , 25, 11495-503	198
1756	Proteomic determination of widespread detergent-insolubility including Abeta but not tau early in the pathogenesis of Alzheimer's disease. 2005 , 19, 1923-5	44
1755	Electroactivity of Proteins: Possibilities in Biomedicine and Proteomics. 2005 , 1, 689-750	4
1754	Peroxisomal proliferation protects from beta-amyloid neurodegeneration. 2005 , 280, 41057-68	115
1753	βSecretase, APP and Aβ in Alzheimer's Disease. 2005 , 79-103	44
1752	Beyond the signal sequence: protein routing in health and disease. 2005 , 26, 479-503	68
1751	Estrogen therapy fails to alter amyloid deposition in the PDAPP model of Alzheimer's disease. 2005 , 146, 2774-81	51
1750	Transgenic C. elegans as a model in Alzheimer's research. 2005 , 2, 37-45	66
1749	Protein aggregation in Alzheimer's disease and other neuropathological disorders. 2005 , 2, 19-28	30

1748	Acetylcholinergic neurotransmission and the beta-amyloid cascade: implications for Alzheimer's disease. 2005 , 5, 277-84	22
1747	Autophagy and aging: the importance of maintaining "clean" cells. 2005 , 1, 131-40	637
1746	BACE1 cytoplasmic domain interacts with the copper chaperone for superoxide dismutase-1 and binds copper. 2005 , 280, 17930-7	96
1745	Selenomethionine prevents degeneration induced by overexpression of wild-type human alpha-synuclein during differentiation of neuroblastoma cells. 2005 , 24, 516-23	13
1744	Advanced glycation end products in intervertebral discs and hip joint capsules: correlation with senile amyloid?. 2005 , 12, 167-73	3
1743	Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. 2005 , 280, 37377-82	544
1742	Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice. 2005 , 25, 6755-64	134
1741	Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. 2005 , 25, 10874-83	202
1740	The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. 2005 , 33, 1087-90	171
1739	Direct observation of protein folding, aggregation, and a prion-like conformational conversion. 2005 , 280, 40235-40	67
1738	Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of colivelin-mediated neuroprotection against Alzheimer's disease-relevant insults in vitro and in vivo. 2005 , 25, 10252-61	69
1737	Beta-secretase-cleaved amyloid precursor protein accumulates at actin inclusions induced in neurons by stress or amyloid beta: a feedforward mechanism for Alzheimer's disease. 2005 , 25, 11313-21	105
1736	Alzheimer's Disease. 2005 ,	7
1735	Amyloid accumulation and pathogenesis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar Abeta. 2005 , 38, 167-77	149
1734	Gamma-secretase complex assembly within the early secretory pathway. 2005 , 280, 6471-8	73
1733	Conformational transition of amyloid beta-peptide. 2005 , 102, 5403-7	222
1732	beta-amyloid is different in normal aging and in Alzheimer disease. 2005 , 280, 34186-92	148
1731	Energy landscape of amyloidogenic peptide oligomerization by parallel-tempering molecular dynamics simulation: significant role of Asn ladder. 2005 , 102, 8174-9	106

1730	Amyloid-beta protofibrils differ from amyloid-beta aggregates induced in dilute hexafluoroisopropanol in stability and morphology. 2005 , 280, 2471-80	86
1729	Differential contribution of the three Aph1 genes to gamma-secretase activity in vivo. 2005 , 102, 1719-24	159
1728	Intersheet rearrangement of polypeptides during nucleation of {beta}-sheet aggregates. 2005 , 102, 14272-7	112
1727	Compounds that bind APP and inhibit Abeta processing in vitro suggest a novel approach to Alzheimer disease therapeutics. 2005 , 280, 17792-7	27
1726	Characterization of a possible amyloidogenic precursor in glutamine-repeat neurodegenerative diseases. 2005 , 102, 13433-8	70
1725	Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. 2005 , 174, 1580-6	170
1724	In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice. 2005 , 25, 10041-8	142
1723	CD147 is a regulatory subunit of the gamma-secretase complex in Alzheimer's disease amyloid beta-peptide production. 2005 , 102, 7499-504	170
1722	Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease. 2005 , 25, 5217-24	386
1721	Transforming growth factor beta2 is a neuronal death-inducing ligand for amyloid-beta precursor protein. 2005 , 25, 9304-17	44
1720	Neurogenetics II: complex disorders. 2005 , 76, 623-31	10
1719	Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). 2005 , 25, 10637-47	454
1718	Cholesterol and apolipoprotein E in Alzheimer's disease. 2005 , 20, 91-6	35
1717	Neuronal and nonneuronal quantitative BACE immunocytochemical expression in the entorhinohippocampal and frontal regions in Alzheimer's disease. 2005 , 19, 171-83	40
1716	The amyloid precursor protein (APP) of Alzheimer disease and its paralog, APLP2, modulate the Cu/Zn-Nitric Oxide-catalyzed degradation of glypican-1 heparan sulfate in vivo. 2005 , 280, 13913-20	40
1715	Neuritogenesis and neuronal differentiation promoted by 2,4-dinitrophenol, a novel anti-amyloidogenic compound. 2005 , 19, 1627-36	37
1714	Amyloid and interleukin-1 induce persistent NF- κ B activation in rat primary glial cells. 2005 , 16, 449	3
1713	Promises and challenges in developing RNAi as a research tool and therapy for neurodegenerative diseases. 2005 , 2, 220-31	16

1712	Cardiovascular risk factors and cognitive function in adults 30-59 years of age (NHANES III). 2005 , 24, 42-50	61
1711	Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer's disease. 2005 , 27, 869-81	100
1710	Metales de transición y enfermedad de Alzheimer. 2005 , 40, 365-370	1
1709	Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. 2005 , 25, 8807-14	534
1708	The expression of p75 neurotrophin receptor protects against the neurotoxicity of soluble oligomers of beta-amyloid. 2005 , 311, 126-34	29
1707	Mutation screening and association study of the neprilysin gene in sporadic Alzheimer's disease in Chinese persons. 2005 , 60, 301-6	21
1706	Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. 2005 , 102, 2273-6	699
1705	Rapid assembly of amyloid-beta peptide at a liquid/liquid interface produces unstable beta-sheet fibers. 2005 , 44, 165-73	39
1704	Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. 2005 , 280, 17294-300	761
1703	Stress proteins in Alzheimer's disease. 2005 , 21, 421-31	24
1702	The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. 2005 , 14, 2399-404	173
1701	The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors. 2005 , 19, 989-96	68
1700	Therapeutic potential of neurotrophic factors in neurodegenerative diseases. 2005 , 19, 97-127	58
1699	Role of fibrillar Abeta25-35 in the inflammation induced rat model with respect to oxidative vulnerability. 2005 , 39, 603-12	13
1698	Aggregation of a slow-folding mutant of a beta-clam protein proceeds through a monomeric nucleus. 2005 , 44, 7266-74	57
1697	beta-site specific intrabodies to decrease and prevent generation of Alzheimer's Abeta peptide. 2005 , 168, 863-8	92
1696	Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-a	97
1695	Design of peptidyl compounds that affect beta-amyloid aggregation: importance of surface tension and context. 2005 , 44, 8898-907	59

1694	Conformational dynamics of amyloid beta-protein assembly probed using intrinsic fluorescence. 2005 , 44, 13365-76	58
1693	An inhibitor binding pocket distinct from the catalytic active site on human beta-APP cleaving enzyme. 2005 , 44, 11567-73	40
1692	Proteomic analysis of neurofibrillary tangles in Alzheimer disease identifies GAPDH as a detergent-insoluble paired helical filament tau binding protein. 2005 , 19, 869-71	142
1691	Propidium-based polyamine ligands as potent inhibitors of acetylcholinesterase and acetylcholinesterase-induced amyloid-beta aggregation. 2005 , 48, 24-7	127
1690	Adenosine and brain function. 2005 , 63, 191-270	488
1689	Probing the initial stage of aggregation of the Abeta(10-35)-protein: assessing the propensity for peptide dimerization. 2005 , 345, 1141-56	94
1688	Sequential generation of two structurally distinct ovine prion protein soluble oligomers displaying different biochemical reactivities. 2005 , 347, 665-79	86
1687	Multiple assembly pathways underlie amyloid-beta fibril polymorphisms. 2005 , 352, 282-98	260
1686	Protein interactions and misfolding analyzed by AFM force spectroscopy. 2005 , 354, 1028-42	107
1685	Alzheimer's disease: Abeta, tau and synaptic dysfunction. 2005 , 11, 170-6	331
1684	Cerebrovascular gene linked to Alzheimer's disease pathology. 2005 , 11, 534-6	10
1683	ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42. 2005 , 18, 75-82	74
1682	Red cell interactions with amyloid-beta(1-40) fibrils in a murine model. 2005 , 19, 28-37	14
1681	Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation. 2005 , 18, 459-65	181
1680	Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice. 2005 , 20, 814-22	124
1679	Amyloid-beta fibril formation is not necessarily required for microglial activation by the peptides. 2005 , 47, 369-76	28
1678	Evidence for increased lysyl oxidase, the extracellular matrix-forming enzyme, in Alzheimer's disease brain. 2005 , 376, 210-4	38
1677	Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia. 2005 , 383, 12-6	72

1676	Reduced synaptic vesicle density and active zone size in mice lacking amyloid precursor protein (APP) and APP-like protein 2. 2005 , 384, 66-71	80
1675	Cholesterol depletion inhibits the degradation of amyloid beta-peptide in rat pheochromocytoma (PC12) cells. 2005 , 391, 71-5	8
1674	Involvement of tyrosine kinases and STAT3 in Humanin-mediated neuroprotection. 2005 , 77, 3092-104	86
1673	S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. 2005 , 28, 195-204	311
1672	Age-related impairments in operant DMTP performance in the PS2APP mouse, a transgenic mouse model of Alzheimer's disease. 2005 , 161, 220-8	10
1671	Implanted cannula-mediated repetitive administration of Abeta25-35 into the mouse cerebral ventricle effectively impairs spatial working memory. 2005 , 164, 139-46	55
1670	Widespread gamma-secretase activity in the cell, but do we need it at the mitochondria?. 2005 , 328, 1-5	17
1669	A hybrid molecule that prohibits amyloid fibrils and alleviates neuronal toxicity induced by beta-amyloid (1-42). 2005 , 328, 816-23	35
1668	Single particle detection and characterization of synuclein co-aggregation. 2005 , 333, 1202-10	46
1667	Determination of hypoxic effect on neprilysin activity in human neuroblastoma SH-SY5Y cells using a novel HPLC method. 2005 , 334, 380-5	10
1666	Effect of D-amino acids at Asp23 and Ser26 residues on the conformational preference of Abeta20-29 peptides. 2005 , 335, 712-22	11
1665	Nobiletin and its related flavonoids with CRE-dependent transcription-stimulating and neuritegenic activities. 2005 , 337, 1330-6	123
1664	The future of aging therapies. 2005 , 120, 557-67	81
1663	Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. 2005 , 120, 545-55	1439
1662	The amyloid precursor protein and its network of interacting proteins: physiological and pathological implications. 2005 , 48, 257-64	56
1661	Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model mice. 2005 , 193, 469-80	92
1660	High selective expression of alpha7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer's disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques. 2005 , 192, 215-25	105
1659	Apoptotic signals within the basal forebrain cholinergic neurons in Alzheimer's disease. 2005 , 195, 484-96	68

1658	Neprylisin decreases uniformly in Alzheimer's disease and in normal aging. 2005 , 579, 6027-30	55
1657	Transgenic potato expressing Abeta reduce Abeta burden in Alzheimer's disease mouse model. 2005 , 579, 6737-44	25
1656	Age-related loss of synaptophysin immunoreactive presynaptic boutons within the hippocampus of APP751SL, PS1M146L, and APP751SL/PS1M146L transgenic mice. 2005 , 167, 161-73	98
1655	The insect homologue of the amyloid precursor protein interacts with the heterotrimeric G protein Go alpha in an identified population of migratory neurons. 2005 , 288, 160-78	29
1654	Neurovascular mechanisms of Alzheimer's neurodegeneration. 2005 , 28, 202-8	732
1653	The darker side of Ca ²⁺ signaling by neuronal Ca ²⁺ -sensor proteins: from Alzheimer's disease to cancer. 2005 , 26, 345-51	72
1652	Modulation of the humoral and cellular immune response in Abeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G). 2005 , 23, 5149-59	32
1651	Developmental origins of aging in brain and blood vessels: an overview. 2005 , 26, 281-91	58
1650	Beta-Amyloid peptide ₂₅₋₃₅ depresses excitatory synaptic transmission in the rat basolateral amygdala "in vitro". 2005 , 26, 419-28	32
1649	Human monoclonal antibodies against amyloid-beta from healthy adults. 2005 , 26, 597-606	46
1648	Age-dependent differential expression of BACE splice variants in brain regions of tg2576 mice. 2005 , 26, 1167-75	20
1647	Characterization of two APP gene promoter polymorphisms that appear to influence risk of late-onset Alzheimer's disease. 2005 , 26, 1329-41	39
1646	Abeta ₄₂ is essential for parenchymal and vascular amyloid deposition in mice. 2005 , 47, 191-199	463
1645	The bad seed in Alzheimer's disease. 2005 , 47, 167-8	17
1644	Lengthening of G ₂ /mitosis in cortical precursors from mice lacking beta-amyloid precursor protein. 2005 , 130, 51-60	28
1643	Characterization of a double (amyloid precursor protein-tau) transgenic: tau phosphorylation and aggregation. 2005 , 130, 339-47	64
1642	Lifelong immunization with human beta-amyloid (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging. 2005 , 130, 667-84	54
1641	Selective cholinergic denervation, independent from oxidative stress, in a mouse model of Alzheimer's disease. 2005 , 132, 73-86	53

1640	Intraneuronal Aβeta, non-amyloid aggregates and neurodegeneration in a <i>Drosophila</i> model of Alzheimer's disease. 2005 , 132, 123-35	285
1639	Biphenyls labeled with technetium 99m for imaging beta-amyloid plaques in the brain. 2005 , 32, 171-84	52
1638	Cholinesterase inhibitors: xanthostigmine derivatives blocking the acetylcholinesterase-induced beta-amyloid aggregation. 2005 , 48, 4444-56	76
1637	Novel Aβeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease. 2005 , 2, 28	29
1636	Fusogenic Alzheimer's peptide fragment Aβeta (29-42) in interaction with lipid bilayers: secondary structure, dynamics, and specific interaction with phosphatidyl ethanolamine polar heads as revealed by solid-state NMR. 2005 , 14, 1181-9	23
1635	Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics. 2005 , 48, 5175-90	70
1634	Transgenic models of Alzheimer's disease: learning from animals. 2005 , 2, 423-37	154
1633	Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease. 2005 , 2, 612-26	72
1632	New prospects and strategies for drug target discovery in neurodegenerative disorders. 2005 , 2, 627-37	10
1631	Decreased serum amyloid beta(1-42) autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta(1-42) peptide. 2005 , 57, 813-6	58
1630	The use of biomarkers in the elderly: current and future challenges. 2005 , 58, 272-6	30
1629	Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation. 2005 , 48, 1576-87	94
1628	Pathophysiology of Alzheimer's disease. 2005 , 15, 727-53, ix	52
1627	Metal ion-dependent effects of clioquinol on the fibril growth of an amyloid {beta} peptide. 2005 , 280, 16157-62	134
1626	Rational approach to discover multipotent anti-Alzheimer drugs. 2005 , 48, 360-3	206
1625	A continuous time-resolved fluorescence assay for identification of BACE1 inhibitors. 2005 , 3, 287-97	16
1624	Certain inhibitors of synthetic amyloid beta-peptide (Aβeta) fibrillogenesis block oligomerization of natural Aβeta and thereby rescue long-term potentiation. 2005 , 25, 2455-62	262
1623	Developing novel immunogens for an effective, safe Alzheimer's disease vaccine. 2005 , 2, 267-72	24

1622	Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins?. 2006 , 39, 167-201	325
1621	The fallacy of amyloid and cognition in Alzheimer's disease. 2006 , 23, 179	1
1620	From peptide-based material science to protein fibrils: discipline convergence in nanobiology. 2006 , 3, S80-90	18
1619	Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. <i>Science</i> , 2006 , 313, 1781-4	33-3 749
1618	Alzheimer therapeutics-what after the cholinesterase inhibitors?. 2006 , 35, 332-5	11
1617	Structural study of metastable amyloidogenic protein oligomers by photo-induced cross-linking of unmodified proteins. 2006 , 413, 217-36	73
1616	Alzheimer: 100 Years and Beyond. 2006 ,	5
1615	Cytotoxic Intermediates in the Fibrillation Pathway: Aβ Oligomers in Alzheimer's Disease as a Case Study. 2006 , 60-81	1
1614	An individualized approach to treatment for alzheimer's disease, pick's disease, and other dementias. 2006 , 21, 354-9	1
1613	Mutations of presenilin genes in dilated cardiomyopathy and heart failure. 2006 , 79, 1030-9	123
1612	Axonal transport and Alzheimer's disease. 2006 , 75, 607-27	229
1611	A dynamic relationship between intracellular and extracellular pools of Aβ. 2006 , 168, 184-94	189
1610	Caspase-mediated cleavage of glial fibrillary acidic protein within degenerating astrocytes of the Alzheimer's disease brain. 2006 , 168, 936-46	95
1609	Amyloid-beta vaccination: testing the amyloid hypothesis?: heads we win, tails you lose!. 2006 , 169, 738-9	18
1608	Activated double-stranded RNA-dependent protein kinase and neuronal death in models of Alzheimer's disease. 2006 , 139, 1343-54	87
1607	Mecanismos reparadores neuronales en la enfermedad de Alzheimer. 2006 , 41, 74-80	
1606	Alzheimer's disease. 2006 , 368, 387-403	2621
1605	Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. 2006 , 33, 94-102	105

1604	Inhibition of the formation of amyloid beta-protein fibrils using biocompatible nanogels as artificial chaperones. 2006 , 580, 6587-95	92
1603	Amyloidogenicity and pitrilysin sensitivity of a lysine-free derivative of amyloid beta-peptide cleaved from a recombinant fusion protein. 2006 , 122, 186-97	1
1602	[From physiopathology to treatment of Alzheimer's disease]. 2006 , 162, 909-12	7
1601	Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. 2006 , 15, 1437-49	852
1600	The spice sage and its active ingredient rosmarinic acid protect PC12 cells from amyloid-beta peptide-induced neurotoxicity. 2006 , 317, 1143-9	177
1599	Alzheimer amyloid beta(1-40) peptide: interactions with cationic gemini and single-chain surfactants. 2006 , 110, 18040-5	26
1598	Plasma C-peptide and cognitive performance in older men without diabetes. 2006 , 14, 1041-50	11
1597	Early events in insulin fibrillization studied by time-lapse atomic force microscopy. 2006 , 90, 589-97	45
1596	Effects of solvent on the structure of the Alzheimer amyloid-beta(25-35) peptide. 2006 , 91, 1638-47	132
1595	Phenol red interacts with the protofibril-like oligomers of an amyloidogenic hexapeptide NFGAIL through both hydrophobic and aromatic contacts. 2006 , 91, 3664-72	55
1594	Stability and structure of oligomers of the Alzheimer peptide Abeta16-22: from the dimer to the 32-mer. 2006 , 91, 3217-29	98
1593	Intracranial administration of deglycosylated C-terminal-specific anti-Abeta antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. 2006 , 3, 11	36
1592	Dexamethasone diminishes the pro-inflammatory and cytotoxic effects of amyloid beta-protein in cerebrovascular smooth muscle cells. 2006 , 3, 18	20
1591	Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. 2006 , 3, 27	317
1590	Interferon-gamma increases neuronal death in response to amyloid-beta1-42. 2006 , 3, 7	46
1589	Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer's disease: insights into mechanism of neurodegeneration from redox proteomics. 2006 , 8, 2021-37	192
1588	In situ localization of P-glycoprotein (ABCB1) in human and rat brain. 2006 , 54, 1159-67	173
1587	Synaptic targeting by A beta oligomers (ADDLS) as a basis for memory loss in early Alzheimer's disease. 2006 , 2, 43-55	86

1586	Aminoethylenes: a tetrahedral intermediate isostere yielding potent inhibitors of the aspartyl protease BACE-1. 2006 , 49, 839-42	56
1585	Abeta-immunotherapy for Alzheimer's disease using mannan-amyloid-Beta peptide immunoconjugates. 2006 , 25, 571-80	24
1584	A QXP-based multistep docking procedure for accurate prediction of protein-ligand complexes. 2006 , 46, 1174-87	13
1583	From the polymorphism of amyloid fibrils to their assembly mechanism and cytotoxicity. 2006 , 73, 217-33	39
1582	Toward a reliable distinction between patients with mild cognitive impairment and Alzheimer-type dementia versus major depression. 2006 , 59, 858-62	25
1581	Imaging and in vivo quantitation of beta-amyloid: an exemplary biomarker for Alzheimer's disease?. 2006 , 59, 940-7	22
1580	Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42. 2006 , 45, 5503-16	169
1579	Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. 2006 , 26, 6011-8	408
1578	Single chain Fv antibodies against the 25-35 Abeta fragment inhibit aggregation and toxicity of Abeta42. 2006 , 45, 11532-9	41
1577	Synthesis of biphenyltrienes as probes for beta-amyloid plaques. 2006 , 49, 2841-4	23
1576	Secondary structure and interfacial aggregation of amyloid-beta(1-40) on sodium dodecyl sulfate micelles. 2006 , 45, 8639-48	67
1575	Alpha-sheet: The toxic conformer in amyloid diseases?. 2006 , 39, 594-602	83
1574	Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains. 2006 , 49, 2725-30	89
1573	High cholesterol content in neurons increases BACE, beta-amyloid, and phosphorylated tau levels in rabbit hippocampus. 2006 , 200, 460-7	120
1572	Emerging evidence for the neuroprotective role of alpha-synuclein. 2006 , 200, 1-7	25
1571	Tau phosphorylation and aggregation in Alzheimer's disease pathology. 2006 , 580, 2922-7	182
1570	Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. 2006 , 580, 2994-3005	335
1569	Serum amyloid A (SAA)-induced remodeling of CSF-HDL. 2006 , 1761, 424-33	32

1568	Sphingolipids in apoptosis, survival and regeneration in the nervous system. 2006 , 1758, 1995-2015	52
1567	Inhibition of neprilysin by thiorphan (i.c.v.) causes an accumulation of amyloid beta and impairment of learning and memory. 2006 , 168, 83-91	40
1566	Detection of presenilin-1 homodimer formation in intact cells using fluorescent lifetime imaging microscopy. 2006 , 340, 668-74	24
1565	The amyloid precursor protein and postnatal neurogenesis/neuroregeneration. 2006 , 341, 1-5	33
1564	Cytosolic amyloid-beta peptide 42 escaping from degradation induces cell death. 2006 , 344, 471-7	16
1563	Altered localization of amyloid precursor protein under endoplasmic reticulum stress. 2006 , 344, 525-30	47
1562	Deletion of vitamin E enhances phenotype of Alzheimer disease model mouse. 2006 , 350, 530-6	77
1561	Assembly, trafficking and function of gamma-secretase. 2006 , 3, 275-83	112
1560	Involvement of apoptosis and cholinergic dysfunction in Alzheimer's disease. 2006 , 6, S57-S63	1
1559	A novel alternative splice variant of nicastrin and its implication in Alzheimer disease. 2006 , 78, 2444-8	3
1558	Alzheimer's disease, the nematode <i>Caenorhabditis elegans</i> , and ginkgo biloba leaf extract. 2006 , 78, 2066-72	50
1557	Autophagy: a cell repair mechanism that retards ageing and age-associated diseases and can be intensified pharmacologically. 2006 , 27, 403-10	78
1556	High-resolution atomic force microscopy of soluble Abeta42 oligomers. 2006 , 358, 106-19	188
1555	Folding landscapes of the Alzheimer amyloid-beta(12-28) peptide. 2006 , 362, 567-79	74
1554	Mapping of interaction domains mediating binding between BACE1 and RTN/Nogo proteins. 2006 , 363, 625-34	37
1553	Abeta42 is more rigid than Abeta40 at the C terminus: implications for Abeta aggregation and toxicity. 2006 , 364, 853-62	214
1552	Toward prevention of Alzheimer's disease--potential nutraceutical strategies for suppressing the production of amyloid beta peptides. 2006 , 67, 682-97	28
1551	Alzheimer's amyloid story finds its star. 2006 , 12, 395-6	12

1550	Amyloid beta peptide (25-35) activates protein kinase C leading to cyclooxygenase-2 induction and prostaglandin E2 release in primary midbrain astrocytes. 2006 , 48, 663-72	44
1549	Modulation of microglial activation state following passive immunization in amyloid depositing transgenic mice. 2006 , 49, 190-4	41
1548	Novel approaches for immunotherapeutic intervention in Alzheimer's disease. 2006 , 49, 113-26	33
1547	Amyloid-beta at sublethal level impairs BDNF-induced arc expression in cortical neurons. 2006 , 398, 78-82	39
1546	Nobiletin restoring beta-amyloid-impaired CREB phosphorylation rescues memory deterioration in Alzheimer's disease model rats. 2006 , 400, 230-4	106
1545	Phospholipase D1 is up-regulated in the mitochondrial fraction from the brains of Alzheimer's disease patients. 2006 , 407, 263-7	34
1544	Beta-site APP cleaving enzyme 1 (BACE1) is increased in remaining neurons in Alzheimer's disease brains. 2006 , 54, 24-9	50
1543	Metabolism of amyloid beta peptide and pathogenesis of Alzheimer's disease. Towards presymptomatic diagnosis, prevention and therapy. 2006 , 54, 235-53	82
1542	Functional characterization of the brain-to-blood efflux clearance of human amyloid-beta peptide (1-40) across the rat blood-brain barrier. 2006 , 56, 246-52	104
1541	Strategies for dissecting genetic-environmental interactions in neurodegenerative disorders. 2006 , 27, 637-57	14
1540	Modulation of neutrophil apoptosis by beta-amyloid proteins. 2006 , 6, 1061-9	9
1539	Metal exposure and Alzheimer's pathogenesis. 2006 , 155, 45-51	106
1538	Mechanical manipulation of Alzheimer's amyloid beta1-42 fibrils. 2006 , 155, 316-26	55
1537	Oxidative stress, accumulation of biological 'garbage', and aging. 2006 , 8, 197-204	283
1536	A novel RNAi library based on partially randomized consensus sequences of nuclear receptors: identifying the receptors involved in amyloid beta degradation. 2006 , 88, 282-92	13
1535	Expression in Escherichia coli and in vitro refolding of the human protein pLG72. 2006 , 46, 150-5	35
1534	Ion channel formation by Alzheimer's disease amyloid beta-peptide (Abeta40) in unilamellar liposomes is determined by anionic phospholipids. 2006 , 27, 95-104	50
1533	PEGylated phospholipid nanomicelles interact with beta-amyloid((1-42)) and mitigate its beta-sheet formation, aggregation and neurotoxicity in vitro. 2006 , 27, 2858-66	64

1532	Transcriptional and translational regulation of BACE1 expression--implications for Alzheimer's disease. 2006 , 79, 95-111	152
1531	Insulin signaling in the central nervous system: learning to survive. 2006 , 79, 205-21	322
1530	Comparative analysis of cortical gene expression in mouse models of Alzheimer's disease. 2006 , 27, 377-86	73
1529	Progenitor cells from the adult mouse brain acquire a neuronal phenotype in response to beta-amyloid. 2006 , 27, 606-13	27
1528	The cAMP-specific phosphodiesterase 4B mediates Abeta-induced microglial activation. 2006 , 27, 691-701	31
1527	Mapping cellular transcriptosomes in autopsied Alzheimer's disease subjects and relevant animal models. 2006 , 27, 1060-77	59
1526	Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. 2006 , 27, 570-5	457
1525	Activity changes and marked stereotypic behavior precede Abeta pathology in TgCRND8 Alzheimer mice. 2006 , 27, 955-64	74
1524	Cellular environment facilitates protein accumulation in aged rat hippocampus. 2006 , 27, 973-82	152
1523	Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis. 2006 , 27, 1250-7	124
1522	The amyloid pathology progresses in a neurotransmitter-specific manner. 2006 , 27, 1644-57	102
1521	Volume reduction of the entorhinal cortex in subjective memory impairment. 2006 , 27, 1751-6	206
1520	M1 receptors play a central role in modulating AD-like pathology in transgenic mice. 2006 , 49, 671-82	348
1519	gamma-cleavage-independent functions of presenilin, nicastrin, and Aph-1 regulate cell-junction organization and prevent tau toxicity in vivo. 2006 , 50, 359-75	20
1518	A genomic screen for modifiers of tauopathy identifies puromycin-sensitive aminopeptidase as an inhibitor of tau-induced neurodegeneration. 2006 , 51, 549-60	116
1517	Anti-amyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. 2006 , 51, 703-14	300
1516	Platelet-activating factor antagonists protect amyloid-beta damaged neurons from microglia-mediated death. 2006 , 51, 173-81	27
1515	Inducible proteopathies. 2006 , 29, 438-43	81

1514	Lipoprotein receptors in Alzheimer's disease. 2006 , 29, 687-94	38
1513	Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch. 2006 , 24, 2275-82	66
1512	Immunization with fibrillar Abeta(1-42) in young and aged canines: Antibody generation and characteristics, and effects on CSF and brain Abeta. 2006 , 24, 2824-34	16
1511	Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses. 2006 , 24, 6321-31	87
1510	The nucleation growth and reversibility of Amyloid-beta deposition in vivo. 2006 , 10, 291-301	11
1509	[APP duplication causes autosomal dominant Alzheimer disease with cerebral amyloid angiopathy]. 2006 , 22, 468-9	0
1508	Abeta species removal after abeta42 immunization. 2006 , 65, 1040-8	218
1507	Neurogenesis and Alzheimer's Disease. 2006 , 1, 117739280600100	
1506	An antibody to the beta-secretase cleavage site on amyloid-beta-protein precursor inhibits amyloid-beta production. 2006 , 10, 379-90	15
1505	Alzheimer's disease immunotherapy: from in vitro amyloid immunomodulation to in vivo vaccination. 2006 , 9, 433-8	8
1504	Stoichiometric Inhibition of Amyloid Fibrillogenesis using C-Disubstituted Amino Acid Containing Peptides. 2006 , 471-472	
1503	Processing of amyloid precursor protein as a biochemical link between atherosclerosis and Alzheimer's disease. 2006 , 6, 21-34	20
1502	Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease. 2005 , 8, 359-67	18
1501	Email a Friend. 2006 , 63, 646	
1500	Genetics and pathology of alpha-secretase site AbetaPP mutations in the understanding of Alzheimer's disease. 2006 , 9, 389-98	6
1499	Models of Alzheimer's Disease. 2006 , 121-134	2
1498	. 2006 ,	2
1497	. 2006 ,	19

1496	Zinc Neurotoxicity and its Role in Neurodegenerative Diseases. 2006 , 52, 1-8	24
1495	Characterization of anti-neurodegenerative effects of Polygala tenuifolia in Abeta(25-35)-treated cortical neurons. 2006 , 29, 1892-6	56
1494	Protease Substrate Profiling. 2006 , 303-331	
1493	Gene therapy for neurodegenerative and ocular diseases using lentiviral vectors. 2006 , 110, 37-46	25
1492	Alzheimer's Disease. 2006 ,	
1491	Mitochondrial dysfunction induced by disease relevant AbetaPP and tau protein mutations. 2006 , 9, 139-46	31
1490	Dementia: What is it All About?. 2006 , 19, 433-40	1
1489	La lunga attesa: towards a molecular approach to neuroimaging and therapeutics in Alzheimer's disease. 2006 , 19, 453-74	11
1488	Drosophila and C. elegans Models of Human Age-Associated Neurodegenerative Diseases. 2006 , 347-369	1
1487	Maladie d'Alzheimer. 2006 , 3, 1-12	2
1486	Amyloid-beta immunotherapies in mice and men. 2006 , 20, 118-23	14
1485	Of mice and men: more neurobiology in dementia. 2006 , 19, 555-63	21
1484	White matter lesions are associated with progression of medial temporal lobe atrophy in Alzheimer disease. 2006 , 37, 2248-52	40
1483	New developments in mild cognitive impairment and Alzheimer's disease. 2006 , 19, 552-8	17
1482	Increased tau phosphorylation at the Ser396 epitope after amyloid beta-exposure in organotypic cultures. 2006 , 17, 907-11	18
1481	Medicinal Chemistry of Ginkgolides from Ginkgo Biloba. 2006 , 301-323	3
1480	Aluminum and Alzheimer's disease: a new look. 2006 , 10, 179-201	81
1479	GSK-3 is essential in the pathogenesis of Alzheimer's disease. 2006 , 9, 309-17	300

- 1478 GSK-3, a Key Player in Alzheimer's Disease. 105-124
- 1477 Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. **2006**, 9, 151-3 355
- 1476 The key role of mitochondria in Alzheimer's disease. **2006**, 9, 101-10 239
- 1475 [Amyloid-beta protein vaccine therapy for alzheimer's disease]. **2006**, 95, 1122-8
- 1474 Autoinsertion of soluble oligomers of Alzheimer's Abeta(1-42) peptide into cholesterol-containing membranes is accompanied by relocation of the sterol towards the bilayer surface. **2006**, 6, 21 37
- 1473 Modulation of Abeta42 low-n oligomerization using a novel yeast reporter system. **2006**, 4, 32 57
- 1472 ABCB1 genotypes and haplotypes in patients with dementia and age-matched non-demented control patients. **2006**, 1, 13 9
- 1471 Liquid chromatography/tandem mass spectrometry characterization of oxidized amyloid beta peptides as potential biomarkers of Alzheimer's disease. **2006**, 20, 911-8 40
- 1470 Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. **2006**, 23, 251-60 221
- 1469 Protective effects of EUK4010 on beta-amyloid(1-42) induced degeneration of neuronal cells. **2006**, 24, 1011-9 7
- 1468 A1 adenosine receptors accumulate in neurodegenerative structures in Alzheimer disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation. **2003**, 13, 440-51 120
- 1467 Will preventing protein aggregates live up to its promise as prophylaxis against neurodegenerative diseases?. **2003**, 13, 630-8 17
- 1466 Apolipoprotein Abeta: black sheep in a good family. **2004**, 14, 433-47 13
- 1465 Neurovascular pathways and Alzheimer amyloid beta-peptide. **2005**, 15, 78-83 85
- 1464 The Abeta hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. **2005**, 15, 84-7 82
- 1463 Conventional protein kinase C isoforms mediate neuroprotection induced by phorbol ester and estrogen. **2006**, 96, 204-17 26
- 1462 The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice. **2006**, 96, 533-40 132
- 1461 PGH2-derived levuglandin adducts increase the neurotoxicity of amyloid beta1-42. **2006**, 96, 917-23 39

1460	Sialylation enhances the secretion of neurotoxic amyloid-beta peptides. 2006 , 96, 924-33	59
1459	Tomoregulin-2 is found extensively in plaques in Alzheimer's disease brain. 2006 , 98, 34-44	15
1458	Bis(7)-tacrine attenuates beta amyloid-induced neuronal apoptosis by regulating L-type calcium channels. 2006 , 98, 1400-10	95
1457	The genetics of neurodegenerative diseases. 2006 , 97, 1690-9	54
1456	Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. 2006 , 97, 1700-25	190
1455	Toxicity mediated by soluble oligomers of beta-amyloid(1-42) on cholinergic SN56.B5.G4 cells. 2006 , 98, 1930-45	43
1454	BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice. 2006 , 99, 1555-63	95
1453	Disease modifying therapy for AD?. 2006 , 99, 689-707	105
1452	FAD mutants unable to increase neurotoxic Abeta 42 suggest that mutation effects on neurodegeneration may be independent of effects on Abeta. 2007 , 101, 674-81	65
1451	Humanin and colivelin: neuronal-death-suppressing peptides for Alzheimer's disease and amyotrophic lateral sclerosis. 2006 , 12, 113-22	36
1450	Protein-misfolding diseases and chaperone-based therapeutic approaches. 2006 , 273, 1331-49	263
1449	The aggregation potential of human amylin determines its cytotoxicity towards islet beta-cells. 2006 , 273, 3614-24	185
1448	Progressive cognitive decline in a transgenic mouse model of Alzheimer's disease overexpressing mutant hAPP ^{swe} . 2006 , 5, 249-56	24
1447	Amyloid double trouble. 2006 , 38, 11-2	32
1446	Beyond the beta cell in diabetes. 2006 , 38, 12-3	10
1445	Pinpointing plaques with PIB. 2006 , 12, 753-4; discussion 754	19
1444	Alzheimer protease hitches a ride. 2006 , 12, 1352-4	1
1443	Cancer gets the Chk'ered flag. 2006 , 12, 1354-6	0

1442	Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies. 2006 , 5, 64-74	34
1441	Immunology and immunotherapy of Alzheimer's disease. 2006 , 6, 404-16	262
1440	Presenilin 1 expression on the cell surface in motile polarized cells. 2006 , 51, 740-743	
1439	The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. 2006 , 440, 528-34	385
1438	A century-old debate on protein aggregation and neurodegeneration enters the clinic. 2006 , 443, 774-9	554
1437	The role of seladin-1/DHCR24 in cholesterol biosynthesis, APP processing and Abeta generation in vivo. 2006 , 25, 432-43	144
1436	The genetics of the amyloidoses: interactions with immunity and inflammation. 2006 , 7, 439-49	8
1435	Hyperforin prevents beta-amyloid neurotoxicity and spatial memory impairments by disaggregation of Alzheimer's amyloid-beta-deposits. 2006 , 11, 1032-48	84
1434	The ups and downs of Wnt signaling in prevalent neurological disorders. 2006 , 25, 7545-53	180
1433	Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. 2006 , 572, 477-92	472
1432	Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging. 2006 , 16, 1350-2	39
1431	BACE-1 inhibitory activities of new substituted phenyl-piperazine coupled to various heterocycles: chromene, coumarin and quinoline. 2006 , 16, 1995-9	44
1430	Structural analysis of amyloid aggregates by multifunctional fluorescence nanoscopy. 2006 , 6, e257-e260	7
1429	Probing the pressure-temperature stability of amyloid fibrils provides new insights into their molecular properties. 2006 , 1764, 452-60	133
1428	How to improve guanidinium cations for oxoanion binding in aqueous solution?. 2006 , 250, 3053-3067	178
1427	All-atom molecular dynamics studies of the full-length β amyloid peptides. 2006 , 323, 138-147	35
1426	A positron emission tomography microdosing study with a potential anti-amyloid drug in healthy volunteers and patients with Alzheimer's disease. 2006 , 80, 216-27	45
1425	Search for dual function inhibitors for Alzheimer's disease: synthesis and biological activity of acetylcholinesterase inhibitors of pyridinium-type and their Abeta fibril formation inhibition capacity. 2006 , 14, 472-8	48

1424	Liquid chromatography with tandem mass spectrometry-based proteomic discovery in aging and Alzheimer's disease. 2006 , 3, 336-43	20
1423	A comparative assessment of gamma-secretase activity in transgenic and non-transgenic rodent brain. 2006 , 157, 246-52	4
1422	Zinc(II) binds to the neuroprotective peptide humanin. 2006 , 100, 1672-8	35
1421	A century of Alzheimer's disease. <i>Science</i> , 2006 , 314, 777-81	33-3 1478
1420	Localized surface plasmon resonance biosensors. 2006 , 1, 219-28	374
1419	Linking molecular motors to Alzheimer's disease. 2006 , 99, 193-200	25
1418	Yeast as a drug discovery platform in Huntington's and Parkinson's diseases. 2006 , 1, 258-69	47
1417	Catabolic insufficiency and aging. 2006 , 1067, 27-36	43
1416	LRP in amyloid-beta production and metabolism. 2006 , 1086, 35-53	89
1415	Amyloid precursor protein modulates ERK-1 and -2 signaling. 2006 , 1090, 455-65	17
1414	Evidence against the overexpression of APP in Down syndrome. 2006 , 58, 103-6	11
1413	Amyloid beta-protein monomer structure: a computational and experimental study. 2006 , 15, 420-8	211
1412	Structure of the 21-30 fragment of amyloid beta-protein. 2006 , 15, 1239-47	130
1411	alpha-Synuclein fission yeast model: concentration-dependent aggregation without plasma membrane localization or toxicity. 2006 , 28, 179-91	23
1410	BACE1 gene promoter is differentially regulated: detection of a novel promoter region for its cell type-specific regulation. 2006 , 28, 193-210	12
1409	Functional domains of the BACE1 and BACE2 promoters and mechanisms of transcriptional suppression of the BACE2 promoter in normal neuronal cells. 2006 , 29, 65-80	22
1408	Characterization of the human beta-secretase 2 (BACE2) 5'-flanking region: identification of a 268-bp region as the basal BACE2 promoter. 2006 , 29, 81-99	12
1407	Natural secretory products of human neural and microvessel endothelial cells: Implications in pathogenic "spreading" and Alzheimer's disease. 2006 , 34, 181-92	35

1406	Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. 2006 , 1, 151-70	293
1405	Screening a series of sialyltransferases for possible BACE1 substrates. 2006 , 23, 437-41	10
1404	Invited Lectures : Overviews Purinergic signalling: past, present and future. 2006 , 2, 1-324	1
1403	Overexpression of amyloid precursor protein induces susceptibility to oxidative stress in human neuroblastoma SH-SY5Y cells. 2006 , 113, 125-35	28
1402	Carboxyl-terminal fragment of amyloid precursor protein and hydrogen peroxide induce neuronal cell death through different pathways. 2006 , 113, 1837-45	10
1401	Endogenous overproduction of beta-amyloid induces tau hyperphosphorylation and decreases the solubility of tau in N2a cells. 2006 , 113, 1723-32	14
1400	The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. 2006 , 113, 1625-44	392
1399	Alois Alzheimer revisited: differences in origin of the disease carrying his name. 2006 , 113, 1645-58	23
1398	Relative paucity of tau accumulation in the small areas with abundant Abeta42-positive capillary amyloid angiopathy within a given cortical region in the brain of patients with Alzheimer pathology. 2006 , 111, 510-8	15
1397	Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. 2006 , 111, 503-9	108
1396	Koch's postulates and infectious proteins. 2006 , 112, 1-4	53
1395	Structural and thermodynamical properties of Cull amyloid-beta16/28 complexes associated with Alzheimer's disease. 2006 , 11, 1024-38	118
1394	Cholesterol inhibits the insertion of the Alzheimer's peptide Abeta(25-35) in lipid bilayers. 2006 , 35, 523-31	50
1393	Reticulon proteins: emerging players in neurodegenerative diseases. 2006 , 63, 877-89	83
1392	Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer's disease. 2006 , 63, 1538-52	74
1391	NMR spectroscopy of basic/aromatic amino acid clusters in membrane proteins. 2006 , 48, 183-199	7
1390	Synthesis and evaluation of two 18F-labeled imidazo[1,2-a]pyridine analogues as potential agents for imaging beta-amyloid in Alzheimer's disease. 2006 , 16, 3015-8	44
1389	Separation and analysis of the soluble trimer of A β 40 and its effects on the rise in intracellular calcium. 2006 , 51, 830-838	3

1388	Amyloid imaging of Alzheimer's disease using Pittsburgh Compound B. 2006 , 6, 496-503	20
1387	New pathways in drug discovery for Alzheimer's disease. 2006 , 6, 372-8	12
1386	Epistemological and moral lessons from the history of neurodegenerative diseases. 2006 , 17, 377-392	1
1385	Genetic basis of Alzheimer's dementia: role of mtDNA mutations. 2006 , 5 Suppl 2, 92-107	33
1384	Synaptic dysfunction and oxidative stress in Alzheimer's disease: emerging mechanisms. 2006 , 10, 796-805	68
1383	Aging sensitizes toward ROS formation and lipid peroxidation in PS1M146L transgenic mice. 2006 , 40, 850-62	78
1382	Presenilin mutation: a deadly first hit in Alzheimer disease. A commentary on "aging sensitizes towards ROS formation and lipid peroxidation in PS1M146L transgenic mice". 2006 , 40, 737-9	6
1381	Amyloid-beta, BACE, and oxidative stress in Alzheimer's disease, a commentary on "The different aggregation state of beta-amyloid 1-42 mediates different effects on oxidative stress, neurodegeneration and BACE-1 expression". 2006 , 41, 188-9	5
1380	Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics. 2006 , 545, 39-50	267
1379	Altered synaptic function in Alzheimer's disease. 2006 , 545, 11-21	79
1378	Neuroprotective effects of galanthamine and tacrine against glutamate neurotoxicity. 2006 , 549, 19-26	35
1377	Mitochondrial dysfunction in sporadic and genetic Alzheimer's disease. 2006 , 41, 668-73	98
1376	C. elegans models of age-associated neurodegenerative diseases: lessons from transgenic worm models of Alzheimer's disease. 2006 , 41, 1007-13	143
1375	Interactions of volatile anesthetics with neurodegenerative-disease-associated proteins. 2006 , 24, 381-405	13
1374	Imaging Alzheimer's disease pathology: one target, many ligands. 2006 , 11, 1093-9	50
1373	Loss of nicastrin elicits an apoptotic phenotype in mouse embryos. 2006 , 1086, 76-84	22
1372	Nicotine modulates expression of amyloid precursor protein and amyloid precursor-like protein 2 in mouse brain and in SH-SY5Y neuroblastoma cells. 2006 , 1093, 12-9	27
1371	Aluminum complexing enhances amyloid beta protein penetration of blood-brain barrier. 2006 , 1116, 215-21	83

1370	A new insight on Al-maltolate-treated aged rabbit as Alzheimer's animal model. 2006 , 52, 275-92	63
1369	A life-course approach to the aetiology of late-onset dementias. 2006 , 5, 87-96	219
1368	Plasma Abeta in Alzheimer's disease--up or down?. 2006 , 5, 638-9	30
1367	Progression of atrophy in Alzheimer's disease. 2006 , 5, 805-6	
1366	Treatment of Alzheimer's disease: from pharmacology to a better understanding of disease pathophysiology. 2006 , 127, 148-57	41
1365	Active immunization trial in Abeta42-injected P301L tau transgenic mice. 2006 , 22, 50-6	18
1364	Age-related evolution of amyloid burden, iron load, and MR relaxation times in a transgenic mouse model of Alzheimer's disease. 2006 , 22, 199-208	74
1363	Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. 2006 , 23, 502-11	79
1362	Neuronal neprilysin overexpression is associated with attenuation of Abeta-related spatial memory deficit. 2006 , 24, 475-83	54
1361	The modular systems biology approach to investigate the control of apoptosis in Alzheimer's disease neurodegeneration. 2006 , 7 Suppl 1, S2	36
1360	Self-assembly of amylin(20-29) amide-bond derivatives into helical ribbons and peptide nanotubes rather than fibrils. 2006 , 12, 3714-25	39
1359	Structure-based organic synthesis of drug prototypes: a personal odyssey. 2006 , 1, 1301-30	40
1358	Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. 2006 , 27, 686-95	259
1357	15N relaxation study of the amyloid beta-peptide: structural propensities and persistence length. 2006 , 44 Spec No, S114-21	76
1356	Transforming growth factor beta2 autocrinally mediates neuronal cell death induced by amyloid-beta. 2006 , 83, 1039-47	23
1355	Insulin degrading enzyme is localized predominantly at the cell surface of polarized and unpolarized human cerebrovascular endothelial cell cultures. 2006 , 83, 1262-70	37
1354	Lack of neprilysin suffices to generate murine amyloid-like deposits in the brain and behavioral deficit in vivo. 2006 , 84, 1871-8	65
1353	Interface between tauopathies and synucleinopathies: a tale of two proteins. 2006 , 59, 449-58	204

1352	Role of neurofilament aggregation in motor neuron disease. 2006 , 60, 399-406	24
1351	Genetics of Parkinson's disease and parkinsonism. 2006 , 60, 389-98	252
1350	Rates of cerebral atrophy differ in different degenerative pathologies. 2007 , 130, 1148-58	125
1349	Early diagnostics and therapeutics for Alzheimer's disease--how early can we get there?. 2006 , 6, 1293-306	19
1348	Direct Observation of Amyloid Fibril Growth Monitored by Total Internal Reflection Fluorescence Microscopy. 2006 , 335-343	1
1347	The persistence of memory. 2006 , 355, 2697-8	2
1346	Inclusion-body myositis and Alzheimer disease: two sides of the same coin, or different currencies altogether?. 2006 , 66, S65-8	14
1345	Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. 2006 , 175, 541-6	180
1344	beta-Amyloid degradation and Alzheimer's disease. 2006 , 2006, 58406	133
1343	A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis. 2006 , 3, 81-90	54
1342	Genotoxicity in Alzheimer's disease: role of amyloid. 2006 , 3, 365-75	9
1341	Computer simulations of Alzheimer's amyloid beta-protein folding and assembly. 2006 , 3, 493-504	33
1340	Filling the gaps in the abeta cascade hypothesis of Alzheimer's disease. 2006 , 3, 421-30	111
1339	Proteolytic degradation of the amyloid beta-protein: the forgotten side of Alzheimer's disease. 2006 , 3, 431-5	17
1338	Changing the Course of Alzheimers Disease: Emerging Disease Modifying Therapies. 2006 , 2, 179-188	3
1337	Challenges in neuronal apoptosis. 2006 , 3, 377-91	66
1336	Untangling the tau gene association with neurodegenerative disorders. 2006 , 15 Spec No 2, R188-95	90
1335	Role of toll-like receptor signalling in Abeta uptake and clearance. 2006 , 129, 3006-19	389

1334	Lipophilic analogs of thioflavin S as novel amyloid-imaging agents. 2006 , 3, 259-66	11
1333	Amyloid beta: the alternate hypothesis. 2006 , 3, 75-80	82
1332	Vicious cycles within the neuropathophysiologic mechanisms of Alzheimer's disease. 2006 , 3, 95-108	41
1331	gamma-secretase as a therapeutic target for treatment of Alzheimer's disease. 2006 , 12, 661-70	28
1330	Pathways by which Abeta facilitates tau pathology. 2006 , 3, 437-48	148
1329	Induction of cellular prion protein gene expression by copper in neurons. 2006 , 290, C271-81	51
1328	Genetic and pharmacological basis for therapeutic inhibition of beta- and gamma-secretases in mouse models of Alzheimer's memory deficits. 2006 , 17, 429-54	25
1327	Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. 2006 , 12, 4377-87	167
1326	The role of the endoplasmic reticulum in the accumulation of beta-amyloid peptide in Alzheimer's disease. 2006 , 6, 119-33	32
1325	Treating Alzheimer's disease by inactivating bioactive amyloid beta peptide. 2006 , 3, 129-35	6
1324	Approaches to palliative therapies for Alzheimer's disease. 2006 , 6, 553-68	25
1323	Mapping genetic modulators of amyloid plaque deposition in TgCRND8 transgenic mice. 2006 , 15, 2313-23	22
1322	System Xc- and apolipoprotein E expressed by microglia have opposite effects on the neurotoxicity of amyloid-beta peptide 1-40. 2006 , 26, 3345-56	108
1321	Androgens regulate the development of neuropathology in a triple transgenic mouse model of Alzheimer's disease. 2006 , 26, 13384-9	125
1320	A new role for microRNA pathways: modulation of degeneration induced by pathogenic human disease proteins. 2006 , 5, 2835-8	64
1319	Neuritic deposits of amyloid-beta peptide in a subpopulation of central nervous system-derived neuronal cells. 2006 , 26, 4982-97	31
1318	A review of genome mutation and Alzheimer's disease. 2007 , 22, 15-33	41
1317	The yeast prion Ure2p native-like assemblies are toxic to mammalian cells regardless of their aggregation state. 2006 , 281, 15337-44	39

1316	Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-6-yl]-L-alanine (LY411,575) in the CRND8 mouse. 2006 , 319, 1133-43	
1315	Toxicity of recombinant beta-amyloid prefibrillar oligomers on the morphogenesis of the sea urchin <i>Paracentrotus lividus</i> . 2006 , 20, 1916-7	44
1314	Neuropathology of amnesic mild cognitive impairment. 2006 , 63, 645-6	8
1313	Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. 2006 , 103, 18787-92	134
1312	Presenilin mutations linked to familial Alzheimer's disease cause an imbalance in phosphatidylinositol 4,5-bisphosphate metabolism. 2006 , 103, 19524-9	109
1311	Therapeutic Uses of Cholinesterase Inhibitors in Neurodegenerative Diseases. 2006 , 25-33	1
1310	Commentary: understanding sources of complexity in chronic diseases--the importance of integration of genetics and epidemiology. 2006 , 35, 590-2; discussion 593-6	19
1309	Abeta induces cell death by direct interaction with its cognate extracellular domain on APP (APP 597-624). 2006 , 20, 1254-6	110
1308	Cleavage of amyloid-beta precursor protein (APP) by membrane-type matrix metalloproteinases. 2006 , 139, 517-26	52
1307	Phospholipases A2 mediate amyloid-beta peptide-induced mitochondrial dysfunction. 2006 , 26, 11111-9	93
1306	Subcutaneous Nogo receptor removes brain amyloid-beta and improves spatial memory in Alzheimer's transgenic mice. 2006 , 26, 13279-86	86
1305	Proteomic identification of lower apolipoprotein A-I in Alzheimer's disease. 2006 , 21, 155-61	60
1304	Increased BACE1 maturation contributes to the pathogenesis of Alzheimer's disease in Down syndrome. 2006 , 20, 1361-8	52
1303	Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease. 2006 , 103, 1953-8	181
1302	Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: long-term effects and safety. 2006 , 103, 9619-24	58
1301	NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease. 2006 , 103, 12867-72	103
1300	Wild-type presenilin 1 protects against Alzheimer disease mutation-induced amyloid pathology. 2006 , 281, 15330-6	60
1299	Distinct early folding and aggregation properties of Alzheimer amyloid-beta peptides Abeta40 and Abeta42: stable trimer or tetramer formation by Abeta42. 2006 , 281, 24414-22	168

1298	Signaling, polyubiquitination, trafficking, and inclusions: sequestosome 1/p62's role in neurodegenerative disease. 2006 , 2006, 62079	86
1297	Neuronal cell death in Alzheimer's disease and a neuroprotective factor, humanin. 2006 , 4, 139-47	93
1296	Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. 2006 , 103, 5644-51	699
1295	Silencing neurodegenerative disease: bringing RNA interference to the clinic. 2006 , 6, 223-33	12
1294	Inhibition of neprilysin by infusion of thiorphan into the hippocampus causes an accumulation of amyloid Beta and impairment of learning and memory. 2006 , 317, 334-40	36
1293	Therapeutic approaches to Alzheimer's disease. 2006 , 129, 2840-55	257
1292	RNAi therapy for neurodegenerative diseases. 2006 , 75, 73-92	20
1291	Emerging therapeutics for Alzheimer's disease. 2006 , 6, 695-704	27
1290	A functional polymorphism within plasminogen activator urokinase (PLAU) is associated with Alzheimer's disease. 2006 , 15, 2446-56	34
1289	Selectively increased oxidative modifications mapped to detergent-insoluble forms of Abeta and beta-III tubulin in Alzheimer's disease. 2006 , 20, 1473-83	25
1288	Proinflammatory cytokines released from microglia inhibit gap junctions in astrocytes: potentiation by beta-amyloid. 2006 , 20, 494-6	162
1287	Reductions in levels of the Alzheimer's amyloid beta peptide after oral administration of ginsenosides. 2006 , 20, 1269-71	127
1286	Down-regulation of endogenous amyloid precursor protein processing due to cellular aging. 2006 , 281, 2405-13	54
1285	AMPA receptor downscaling at the onset of Alzheimer's disease pathology in double knockin mice. 2006 , 103, 3410-5	175
1284	Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. 2006 , 26, 4717-28	133
1283	GGA1 is expressed in the human brain and affects the generation of amyloid beta-peptide. 2006 , 26, 12838-46	68
1282	DNA polymerase-beta is expressed early in neurons of Alzheimer's disease brain and is loaded into DNA replication forks in neurons challenged with beta-amyloid. 2006 , 26, 10949-57	67
1281	Real-time and single fibril observation of the formation of amyloid beta spherulitic structures. 2006 , 281, 33677-83	64

1280	Amyloid-beta-(1-42) increases ryanodine receptor-3 expression and function in neurons of TgCRND8 mice. 2006 , 281, 38440-7	77
1279	Nicotine attenuates beta-amyloid-induced neurotoxicity by regulating metal homeostasis. 2006 , 20, 1212-4	61
1278	Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. 2006 , 103, 5161-6	550
1277	Effects of a novel cognitive enhancer, spiro[imidazo-[1,2-a]pyridine-3,2-indan]-2(3H)-one (ZSET1446), on learning impairments induced by amyloid-beta1-40 in the rat. 2006 , 317, 1079-87	62
1276	Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. 2006 , 26, 5340-6	145
1275	Merger of laser capture microdissection and mass spectrometry: a window into the amyloid plaque proteome. 2006 , 412, 77-93	24
1274	Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic <i>Caenorhabditis elegans</i> . 2006 , 26, 13102-13	283
1273	Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. 2006 , 103, 11784-9	305
1272	Synaptic pathology in the brain cortex of old monkeys as an early alteration in senile plaque formation. 2006 , 9, 85-8	14
1271	Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans. 2006 , 9, 77-84	55
1270	Phosphorylation of actin-depolymerizing factor/cofilin by LIM-kinase mediates amyloid beta-induced degeneration: a potential mechanism of neuronal dystrophy in Alzheimer's disease. 2006 , 26, 6533-42	140
1269	Intra- or intercomplex binding to the gamma-secretase enzyme. A model to differentiate inhibitor classes. 2006 , 281, 31279-89	39
1268	ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced alpha-secretase cleavage of amyloid precursor protein. 2006 , 281, 16419-27	145
1267	Alzheimer precursor protein interaction with the Nogo-66 receptor reduces amyloid-beta plaque deposition. 2006 , 26, 1386-95	110
1266	Nepriylisin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. 2006 , 281, 17941-51	134
1265	Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. 2006 , 281, 1599-604	303
1264	BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome. 2006 , 20, 1369-76	123
1263	Aging of the brain, entropy, and Alzheimer disease. 2006 , 67, 1340-52	164

1262	Cellular events associated with the initial phase of AA amyloidogenesis: insights from a human monocyte model. 2007 , 14, 51-63	20
1261	Biomarkers for Alzheimer's disease. 2007 , 7, 1021-8	11
1260	Abeta40 inhibits amyloid deposition in vivo. 2007 , 27, 627-33	280
1259	Lipocalin-type prostaglandin D synthase/beta-trace is a major amyloid beta-chaperone in human cerebrospinal fluid. 2007 , 104, 6412-7	118
1258	Amyloid precursor protein mediates presynaptic localization and activity of the high-affinity choline transporter. 2007 , 104, 14140-5	76
1257	Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer's disease. 2007 , 104, 9434-9	220
1256	Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin. 2007 , 104, 12849-54	186
1255	Activation of PAR-1 kinase and stimulation of tau phosphorylation by diverse signals require the tumor suppressor protein LKB1. 2007 , 27, 574-81	65
1254	Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice. 2007 , 282, 26326-34	238
1253	Involvement of prostaglandin E2 in production of amyloid-beta peptides both in vitro and in vivo. 2007 , 282, 32676-88	57
1252	Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis. 2007 , 27, 3639-49	286
1251	Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. 2007 , 27, 2896-907	225
1250	Insensitivity to Abeta42-lowering nonsteroidal anti-inflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations. 2007 , 282, 24504-13	51
1249	In vitro polymerization of a functional Escherichia coli amyloid protein. 2007 , 282, 3713-9	140
1248	The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. 2007 , 104, 403-9	356
1247	Low-density lipoprotein receptor-related protein promotes amyloid precursor protein trafficking to lipid rafts in the endocytic pathway. 2007 , 21, 2742-52	61
1246	Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. 2007 , 282, 10873-80	285
1245	Identification and characterization of OGG1 mutations in patients with Alzheimer's disease. 2007 , 35, 2759-66	84

1244	A critical function for beta-amyloid precursor protein in neuronal migration revealed by in utero RNA interference. 2007 , 27, 14459-69	266
1243	Flow-induced alignment of amyloid protofilaments revealed by linear dichroism. 2007 , 282, 8978-83	32
1242	Traumatic brain injury and Alzheimer's disease: a review. 2007 , 161, 303-16	147
1241	Neuronal loss in primary long-term cortical culture involves neurodegeneration-like cell death via calpain and p35 processing, but not developmental apoptosis or aging. 2007 , 39, 14-26	28
1240	Disease-modifying therapies for Alzheimer disease: challenges to early intervention. 2007 , 69, 1622-34	217
1239	Immunotherapy as treatment for Alzheimer's disease. 2007 , 7, 1535-48	25
1238	Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees?. 2007 , 7, 473-85	36
1237	Aspartic proteases in drug discovery. 2007 , 13, 271-85	112
1236	Increased expression of the remodeling- and tumorigenic-associated factor osteopontin in pyramidal neurons of the Alzheimer's disease brain. 2007 , 4, 67-72	46
1235	Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer's disease therapeutics. 2007 , 4, 179-84	62
1234	Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. 2007 , 4, 191-7	284
1233	Novel Abeta immunogens: is shorter better?. 2007 , 4, 427-36	28
1232	Alzhemed: a potential treatment for Alzheimer's disease. 2007 , 4, 473-8	79
1231	An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes. 2007 , 7, 1600-29	114
1230	Probing amyloid fibril formation of the NFGAIL peptide by computer simulations. 2007 , 126, 065101	29
1229	Interleukin 18 gene polymorphisms predict risk and outcome of Alzheimer's disease. 2007 , 78, 807-11	39
1228	Advances on the understanding of the origins of synaptic pathology in AD. 2007 , 8, 486-508	28
1227	Inhaled anesthetic modulation of amyloid beta(1-40) assembly and growth. 2007 , 4, 233-41	36

1226	Recent advances in the development of amyloid imaging agents. 2007 , 7, 1773-89	67
1225	Blood-derived serum albumin contributes to neurodegeneration via astroglial stress fiber formation. 2007 , 80, 286-92	6
1224	Identification of a beta-amyloid-binding plasma protein, LRP1: implications for biomarker research and therapy in Alzheimer's disease. 2007 , 1, 347-8	2
1223	Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. 2007 , 68, 666-9	201
1222	How and when environmental agents and dietary factors affect the course of Alzheimer's disease: the "LEARn" model (latent early-life associated regulation) may explain the triggering of AD. 2007 , 4, 219-28	111
1221	Nogo receptor interacts with brain APP and Abeta to reduce pathologic changes in Alzheimer's transgenic mice. 2007 , 4, 568-70	24
1220	Bivalent ligands derived from Huperzine A as acetylcholinesterase inhibitors. 2007 , 7, 375-87	47
1219	Disrupting beta-amyloid aggregation for Alzheimer disease treatment. 2007 , 7, 115-26	143
1218	Stimulation of endogenous neurogenesis by anti-EFRH immunization in a transgenic mouse model of Alzheimer's disease. 2007 , 104, 1691-6	39
1217	Chromosome 17 and 21 aneuploidy in buccal cells is increased with ageing and in Alzheimer's disease. 2008 , 23, 57-65	73
1216	Complex translational regulation of BACE1 involves upstream AUGs and stimulatory elements within the 5' untranslated region. 2007 , 35, 2975-85	51
1215	BACE1 and mutated presenilin-1 differently modulate Abeta40 and Abeta42 levels and cerebral amyloidosis in APPDutch transgenic mice. 2007 , 4, 127-35	18
1214	Amyloid precursor protein and presenilin involvement in cell signaling. 2007 , 4, 101-11	14
1213	Alzheimer's disease. 2007 , 27, 32-41	83
1212	PIB-PET SEGMENTATION FOR AUTOMATIC SUVR NORMALISATION WITHOUT MR INFORMATION. 2007 ,	4
1211	Clinical immunologic approaches for the treatment of Alzheimer's disease. 2007 , 16, 819-28	16
1210	Geriatric Diabetes. 2007 ,	2
1209	Computational simulations of the early steps of protein aggregation. 2007 , 1, 3-8	59

1208	The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse. 2007 , 320, 552-8	78
1207	Cholesterol-like effects of selective cyclooxygenase inhibitors and fibrates on cellular membranes and amyloid-beta production. 2007 , 72, 141-51	30
1206	Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. 2007 , 282, 22376-86	83
1205	Monomer adds to preformed structured oligomers of Abeta-peptides by a two-stage dock-lock mechanism. 2007 , 104, 111-6	314
1204	Rer1p competes with APH-1 for binding to nicastrin and regulates gamma-secretase complex assembly in the early secretory pathway. 2007 , 176, 629-40	87
1203	A randomized trial of beta carotene supplementation and cognitive function in men: the Physicians' Health Study II. 2007 , 167, 2184-90	124
1202	Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity. 2007 , 66, 1136-46	199
1201	Moderate reduction of gamma-secretase attenuates amyloid burden and limits mechanism-based liabilities. 2007 , 27, 10849-59	70
1200	Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. 2007 , 27, 12721-31	81
1199	Memories: Molecules and Circuits. 2007 ,	2
1198	Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. 2007 , 27, 13357-65	243
1197	Advances in our Understanding of Neurodegeneration. 2007 , 1-58	3
1196	BIBLIOGRAPHY. 2007 , 417-599	
1195	Phenserine. 2007 , 16, 1087-97	48
1194	Beta-amyloid modulation of synaptic transmission and plasticity. 2007 , 27, 11832-7	94
1193	APP at a glance. 2007 , 120, 3157-61	62
1192	Pediatric respiratory and systemic effects of chronic air pollution exposure: nose, lung, heart, and brain pathology. 2007 , 35, 154-62	126
1191	Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. 2007 , 104, 10601-6	262

1190	Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. 2007 , 104, 9810-5	130
1189	In-cell aggregation of a polyglutamine-containing chimera is a multistep process initiated by the flanking sequence. 2007 , 282, 36736-43	54
1188	Signal peptide peptidase and gamma-secretase share equivalent inhibitor binding pharmacology. 2007 , 282, 36829-36	21
1187	Phagocytosis of amyloid-beta and inflammation: two faces of innate immunity in Alzheimer's disease. 2007 , 11, 457-63	93
1186	Proteomics analysis of the Alzheimer's disease hippocampal proteome. 2007 , 11, 153-64	190
1185	Kinesin gene variability may affect tau phosphorylation in early Alzheimer's disease. 2007 , 20, 233	2
1184	Alzheimer's disease: progress in the development of anti-amyloid disease-modifying therapies. 2007 , 12, 113-6, 119-23	25
1183	Chapter 7 Ubiquitinopathies. 2007 , 165-185	2
1182	PET and SPECT imaging in psychiatric disorders. 2007 , 52, 146-57	62
1181	Redox proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: insights into the progression of this dementing disorder. 2007 , 12, 61-72	109
1180	Chapter 1 Amyloid and Amyloid-Like Protein Aggregates in Neurodegenerative Disease. 2007 , 30, 1-32	
1179	Resveratrol oligomers from <i>Vitis amurensis</i> attenuate beta-amyloid-induced oxidative stress in PC12 cells. 2007 , 30, 1130-4	59
1178	Endoplasmic reticulum chaperones inhibit the production of amyloid-beta peptides. 2007 , 402, 581-9	103
1177	Synaptic memory mechanisms: Alzheimer's disease amyloid beta-peptide-induced dysfunction. 2007 , 35, 1219-23	122
1176	Increase of locomotor activity underlying the behavioral disinhibition in tg2576 mice. 2007 , 121, 340-4	52
1175	The pathogenesis of Alzheimer's disease and the role of Abeta42. 2007 , 12, 4-6	14
1174	Aluminum induces tau aggregation in vitro but not in vivo. 2007 , 11, 419-27	42
1173	Interaction between Alzheimer's Abeta1-42 peptide and DNA detected by surface plasmon resonance. 2007 , 12, 345-55	28

1172	Possible compensatory events in adult Down syndrome brain prior to the development of Alzheimer disease neuropathology: targets for nonpharmacological intervention. 2007 , 11, 61-76	68
1171	Liaisons dangereuses? General anaesthetics and long-term toxicity in the CNS. 2007 , 24, 107-15	18
1170	Protection against Abeta-induced memory loss by tripeptide D-Arg-L-Glu-L-Arg. 2007 , 18, 231-8	15
1169	Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. 2007 , 21, 292-9	92
1168	Cholesterol-lowering drugs and Alzheimer's disease. 2007 , 2, 423-432	13
1167	Enhancement of innate immunity by curcuminoids and hormones as a therapeutic strategy in neurodegenerative disorders. 2007 , 2, 125-127	
1166	Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. 2007 , 30, 317-25	133
1165	Therapeutic potential of amyloid-degrading enzymes in Alzheimer's disease. 2007 , 2, 133-137	
1164	Decreased proliferation of hippocampal progenitor cells in APP ^{swe} /PS1 ^{dE9} transgenic mice. 2007 , 18, 1801-5	66
1163	Protective substances against zinc-induced neuronal death after ischemia: carnosine as a target for drug of vascular type of dementia. 2007 , 2, 145-9	20
1162	Maladie d'Alzheimer. 2007 , 4, 1-26	0
1161	Amyloid imaging in Alzheimer's disease. 2007 , 20, 398-402	69
1160	Molecular determinants of Alzheimer's disease A β peptide neurotoxicity. 2007 , 2, 397-409	8
1159	Site-specific UB ¹ H amyloid-beta vaccine for immunotherapy of Alzheimer's disease. 2007 , 25, 3041-52	64
1158	Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents. 2007 , 82, 348-60	141
1157	Peripheral T cells overexpress MIP-1alpha to enhance its transendothelial migration in Alzheimer's disease. 2007 , 28, 485-96	95
1156	Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. 2007 , 28, 537-47	221
1155	Weak independent association signals between IDE polymorphisms, Alzheimer's disease and cognitive measures. 2007 , 28, 727-34	17

1154	Increased susceptibility to amyloid toxicity in familial Alzheimer's fibroblasts. 2007 , 28, 863-76	45
1153	Phospholipase D1 is associated with amyloid precursor protein in Alzheimer's disease. 2007 , 28, 1015-27	35
1152	Abeta42 neurotoxicity in primary co-cultures: effect of apoE isoform and Abeta conformation. 2007 , 28, 1139-47	57
1151	Occurrence and co-localization of amyloid beta-protein and apolipoprotein E in perivascular drainage channels of wild-type and APP-transgenic mice. 2007 , 28, 1221-30	46
1150	Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. 2007 , 28, 1206-14	132
1149	Inflammatory changes parallel the early stages of Alzheimer disease. 2007 , 28, 1821-33	167
1148	Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. 2007 , 56, 66-78	285
1147	Critical role of methionine-722 in the stimulation of human brain G-proteins and neurotoxicity induced by London familial Alzheimer's disease (FAD) mutated V717G-APP(714-723). 2007 , 144, 571-8	5
1146	Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. 2007 , 144, 950-60	88
1145	Overexpression of amyloid precursor protein reduces epsilon protein kinase C levels. 2007 , 146, 152-9	9
1144	Soluble amyloid beta1-42 reduces dopamine levels in rat prefrontal cortex: relationship to nitric oxide. 2007 , 147, 652-63	33
1143	Increased asynchronous release and aberrant calcium channel activation in amyloid precursor protein deficient neuromuscular synapses. 2007 , 149, 768-78	39
1142	18F-labeled styrylpyridines as PET agents for amyloid plaque imaging. 2007 , 34, 89-97	95
1141	Impact of amyloid imaging on drug development in Alzheimer's disease. 2007 , 34, 809-22	105
1140	Mitochondrial dysfunction: the first domino in brain aging and Alzheimer's disease?. 2007 , 9, 1659-75	160
1139	A new evidence for DNA nicking property of amyloid beta-peptide (1-42): relevance to Alzheimer's disease. 2007 , 463, 245-52	23
1138	Pin1 in Alzheimer's disease: multiple substrates, one regulatory mechanism?. 2007 , 1772, 422-9	63
1137	G protein-coupled receptor systems and their lipid environment in health disorders during aging. 2007 , 1768, 964-75	62

1136	Abeta ion channels. Prospects for treating Alzheimer's disease with Abeta channel blockers. 2007 , 1768, 1952-65	137
1135	A mechanistic link between oxidative stress and membrane mediated amyloidogenesis revealed by infrared spectroscopy. 2007 , 1768, 1913-22	26
1134	Berberine alters the processing of Alzheimer's amyloid precursor protein to decrease Abeta secretion. 2007 , 352, 498-502	144
1133	Reduced serum level of antibodies against amyloid beta peptide is associated with aging in Tg2576 mice. 2007 , 361, 800-4	10
1132	Methyl dynamics of the amyloid-beta peptides Abeta40 and Abeta42. 2007 , 362, 410-4	29
1131	Racemization of the amyloid beta Asp1 residue blocks the acceleration of fibril formation caused by racemization of the Asp23 residue. 2007 , 364, 464-9	21
1130	Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice. 2007 , 203, 241-5	260
1129	Long-lasting impairment in hippocampal neurogenesis associated with amyloid deposition in a knock-in mouse model of familial Alzheimer's disease. 2007 , 204, 77-87	162
1128	5-HT4 receptor and Alzheimer's disease: the amyloid connection. 2007 , 205, 325-9	51
1127	Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: an age-related selective uptake with reversal of learning impairment. 2007 , 206, 248-56	79
1126	Gamma-secretase: a complex target for Alzheimer's disease. 2007 , 7, 112-8	47
1125	Time resolved structure analysis of growing beta-amyloid fibers. 2007 , 159, 71-81	12
1124	Solution structure and dynamics of the N-terminal cytosolic domain of rhomboid intramembrane protease from <i>Pseudomonas aeruginosa</i> : insights into a functional role in intramembrane proteolysis. 2007 , 365, 109-22	19
1123	The structure of the Alzheimer amyloid beta 10-35 peptide probed through replica-exchange molecular dynamics simulations in explicit solvent. 2007 , 366, 275-85	125
1122	Abeta40 protects non-toxic Abeta42 monomer from aggregation. 2007 , 369, 909-16	73
1121	Formation of toxic fibrils of Alzheimer's amyloid beta-protein-(1-40) by monosialoganglioside GM1, a neuronal membrane component. 2007 , 371, 481-9	97
1120	Formation of amyloids by Abeta-(1-42) on NGF-differentiated PC12 cells: roles of gangliosides and cholesterol. 2007 , 371, 924-33	66
1119	The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. 2007 , 34, 621-8	193

1118	Immunotherapy for Alzheimer's disease: attacking amyloid-beta from the inside. 2007 , 28, 511-3	13
1117	Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis. 2007 , 50, 12-38	114
1116	Amyloid-beta 1-42 induced endocytosis and clusterin/apoJ protein accumulation in cultured human astrocytes. 2007 , 50, 540-7	25
1115	Toxicity of beta-amyloid in HEK293 cells expressing NR1/NR2A or NR1/NR2B N-methyl-D-aspartate receptor subunits. 2007 , 50, 872-80	44
1114	Myocyte enhancing factor-2A in Alzheimer's disease: genetic analysis and association with MEF2A-polymorphisms. 2007 , 411, 47-51	13
1113	The CDC2 I-G-T haplotype associated with the APOE epsilon4 allele increases the risk of sporadic Alzheimer's disease in Sicily. 2007 , 419, 195-8	8
1112	Upregulation of tPA/plasminogen proteolytic system in the periphery of amyloid deposits in the Tg2576 mouse model of Alzheimer's disease. 2007 , 423, 82-7	30
1111	Endosomal abnormalities related to amyloid precursor protein in cholesterol treated cerebral cortex neuronal cells derived from trisomy 16 mice, an animal model of Down syndrome. 2007 , 423, 172-7	13
1110	Taurine, an inducer for tau polymerization and a weak inhibitor for amyloid-beta-peptide aggregation. 2007 , 429, 91-4	44
1109	Microglial transplantation increases amyloid-beta clearance in Alzheimer model rats. 2007 , 581, 475-8	74
1108	Genetics and dementia: risk factors, diagnosis, and management. 2007 , 3, 418-27	25
1107	Selection and characterization of Affibody ligands binding to Alzheimer amyloid beta peptides. 2007 , 128, 162-83	98
1106	Longitudinal stability of CSF biomarkers in Alzheimer's disease. 2007 , 419, 18-22	145
1105	Características neuropatológicas y moleculares de la enfermedad de Alzheimer. 2007 , 42, 103-110	
1104	Evidence of a role for lactadherin in Alzheimer's disease. 2007 , 170, 921-9	74
1103	Treating the lesions, not the disease. 2007 , 170, 1457-9	12
1102	Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. 2007 , 171, 2012-20	198
1101	Magnetic resonance imaging of Alzheimer's pathology in the brains of living transgenic mice: a new tool in Alzheimer's disease research. 2007 , 13, 38-48	64

1100	Dual binding modes of Congo red to amyloid protofibril surface observed in molecular dynamics simulations. 2007 , 129, 1225-32	141
1099	Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. 2007 , 103, 334-45	122
1098	BACE1 expression and activity: relevance in Alzheimer's disease. 2007 , 4, 117-26	15
1097	Design of Inhibitors of Amyloid- β Misfolding and Aggregation for Alzheimer's Therapy. 2007 , 238-254	0
1096	Pharmacological Mechanisms in Alzheimer's Therapeutics. 2007 ,	1
1095	Polyfluorinated bis-styrylbenzene beta-amyloid plaque binding ligands. 2007 , 50, 4986-92	57
1094	Peptide Characterization and Application Protocols. 2007 ,	
1093	Neuropsychiatric Disorders An Integrative Approach. 2007 ,	4
1092	Humoral immune responses to peptides derived from the beta-amyloid peptide C-terminal sequence. 2007 , 14, 39-50	10
1091	GSK-3 inhibitors for Alzheimer's disease. 2007 , 7, 1527-33	64
1090	Aspects of beta-amyloid as a biomarker for Alzheimer's disease. 2007 , 1, 59-78	65
1089	Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of beta-secretase. 2007 , 50, 1124-32	141
1088	Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. 2007 , 282, 10311-24	547
1087	Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. 2007 , 21, 2135-48	125
1086	β Amyloid Protein Aggregation. 2007 , 203-225	4
1085	Amyloid-beta(1-42) rapidly forms protofibrils and oligomers by distinct pathways in low concentrations of sodium dodecylsulfate. 2007 , 46, 12451-62	126
1084	Disruption of neurofilament network with aggregation of light neurofilament protein: a common pathway leading to motor neuron degeneration due to Charcot-Marie-Tooth disease-linked mutations in NFL and HSPB1. 2007 , 16, 3103-16	100
1083	The genetics of Alzheimer's disease. 2007 , 22, 37-41	27

1082	Menopause: developing a rational treatment plan. 2007 , 23, 682-91	3
1081	Amyloid-beta reduction by memapsin 2 (beta-secretase) immunization. 2007 , 21, 3184-96	37
1080	Amyloid imaging in vivo: implications for Alzheimer's disease management. 2007 , 1, 337-49	3
1079	Lithium: a novel treatment for Alzheimer's disease?. 2007 , 6, 375-83	27
1078	Application of fragment screening by X-ray crystallography to beta-secretase. 2007 , 50, 1116-23	139
1077	Ganglioside G(M1)-mediated amyloid-beta fibrillogenesis and membrane disruption. 2007 , 46, 1913-24	66
1076	FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. 2007 , 130, 2616-35	431
1075	Visualization and classification of amyloid beta supramolecular assemblies. 2007 , 46, 15009-17	78
1074	New diphenylacetylenes as probes for positron emission tomographic imaging of amyloid plaques. 2007 , 50, 2415-23	28
1073	Analytical method for beta-amyloid fibrils using CE-laser induced fluorescence and its application to screening for inhibitors of beta-amyloid protein aggregation. 2007 , 79, 4887-91	39
1072	Fluoro-pegylated (FPEG) imaging agents targeting Abeta aggregates. 2007 , 18, 238-46	56
1071	Zinc binding to amyloid-beta: isothermal titration calorimetry and Zn competition experiments with Zn sensors. 2007 , 46, 13658-66	94
1070	Novel styrylpyridines as probes for SPECT imaging of amyloid plaques. 2007 , 50, 2157-65	40
1069	The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation. 2007 , 46, 1503-10	129
1068	Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. 2007 , 204, 1999-2008	227
1067	Morbo di Alzheimer. 2007 , 7, 1-26	
1066	Induction of complement proteins in a mouse model for cerebral microvascular A beta deposition. 2007 , 4, 22	31
1065	Role of electrostatic interactions in amyloid beta-protein (A beta) oligomer formation: a discrete molecular dynamics study. 2007 , 92, 4064-77	98

1064	Contact-induced structure transformation in transmembrane prion propagation. 2007 , 92, 2704-10	4
1063	Molecular dynamics simulations on the oligomer-formation process of the GNNQQNY peptide from yeast prion protein Sup35. 2007 , 93, 1484-92	68
1062	Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach. 2007 , 217-33	137
1061	New potent acetylcholinesterase inhibitors in the tetracyclic triterpene series. 2007 , 50, 5311-23	47
1060	Discovery of a novel warhead against beta-secretase through fragment-based lead generation. 2007 , 50, 5903-11	139
1059	Effects of Alzheimer's amyloid-beta and tau protein on mitochondrial function -- role of glucose metabolism and insulin signalling. 2007 , 113, 131-41	41
1058	Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency. 2007 , 50, 5912-25	197
1057	Amyloid-beta aggregation. 2007 , 4, 13-27	244
1056	Lewy Body Disorders. 2007 , 267-343	3
1055	Beta-amyloid peptide--nicotinic acetylcholine receptor interaction: the two faces of health and disease. 2007 , 12, 5030-8	63
1054	Amyloid-beta-induced mitochondrial dysfunction. 2007 , 12, 177-84	92
1053	Protein Aggregation Disorders. 2007 , 111-123	2
1052	Differences in extracellular matrix production and basic fibroblast growth factor response in skin fibroblasts from sporadic and familial Alzheimer's disease. 2007 , 13, 542-50	27
1051	Invertebrates as Powerful Genetic Models for Human Neurodegenerative Diseases. 2007 ,	
1050	Neuropathological and immunochemical studies of brain parenchyma in acetylcholinesterase knockout mice: implications in Alzheimer's disease. 2007 , 11, 481-9	8
1049	Die Rolle des Immunsystems bei der Alzheimer-Demenz. 2007 , 26, 867-875	
1048	References. 329-360	
1047	Amyloid-beta peptide forms monomeric complexes with Cu(II) and Zn(II) prior to aggregation. 2007 , 8, 163-5	82

1046	Redox chemistry of copper-amyloid-beta: the generation of hydroxyl radical in the presence of ascorbate is linked to redox-potentials and aggregation state. 2007 , 8, 1317-25	216
1045	Correlation of amyloid fibril beta-structure with the unfolded state of alpha-synuclein. 2007 , 8, 1671-4	58
1044	Amphetamine effects on brain protein structure and oxidative stress as revealed by FTIR microspectroscopy. 2007 , 86, 437-46	27
1043	Conformational solution studies of the SDS micelle-bound 11-28 fragment of two Alzheimer's beta-amyloid variants (E22K and A21G) using CD, NMR, and MD techniques. 2007 , 87, 23-39	15
1042	Cleavage agents for soluble oligomers of amyloid beta peptides. 2007 , 46, 7064-7	92
1041	Cleavage Agents for Soluble Oligomers of Amyloid β Peptides. 2007 , 119, 7194-7197	19
1040	The association study between DHCR24 polymorphisms and Alzheimer's disease. 2007 , 144B, 906-10	18
1039	Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. 2007 , 61, 446-53	67
1038	Neuronal LR11/sorLA expression is reduced in mild cognitive impairment. 2007 , 62, 640-7	83
1037	Presynaptic plasticity and associative learning are impaired in a Drosophila presenilin null mutant. 2007 , 67, 1598-613	23
1036	Rapid Sequencing of Split-and-Mix Peptide Receptor Libraries β Identification of Binding Partners for Val-Val-Ile-Ala in Aqueous Solution. 2007 , 2007, 1345-1356	5
1035	IFN-gamma-induced BACE1 expression is mediated by activation of JAK2 and ERK1/2 signaling pathways and direct binding of STAT1 to BACE1 promoter in astrocytes. 2007 , 55, 253-62	87
1034	A soluble amyloid fibril segment to study aggregate formation. 2007 , 2, 47-9	2
1033	Molecules that target beta-amyloid. 2007 , 2, 1674-92	93
1032	Magnetic resonance spectroscopy (MRS) and its application in Alzheimer's disease. 2007 , 30A, 40-64	36
1031	Spatial relationship between synapse loss and beta-amyloid deposition in Tg2576 mice. 2007 , 500, 311-21	110
1030	Transverse relaxation time reflects brain amyloidosis in young APP/PS1 transgenic mice. 2007 , 58, 179-84	30
1029	Intracerebroventricular passive immunization with anti-oligoA β antibody in TgCRND8. 2007 , 85, 451-63	26

1028	Abeta(25-35) and its C- and/or N-blocked derivatives: copper driven structural features and neurotoxicity. 2007 , 85, 623-33	30
1027	Inter-individual variability in the expression of the mutated form of hPS1M146L determined the production of Abeta peptides in the PS1xAPP transgenic mice. 2007 , 85, 787-97	9
1026	Differential binding and activation of caspase-3 in cultured hippocampal neurons by assembly forms of A beta 1-42. 2007 , 85, 1205-14	5
1025	Identification of molecular compounds critical to Alzheimer's-like plaque formation. 2007 , 85, 2037-44	5
1024	The use of conformation-specific ligands and assays to dissect the molecular mechanisms of neurodegenerative diseases. 2007 , 85, 2285-97	16
1023	Protective effect of benzothiazole derivative KHG21834 on amyloid beta-induced neurotoxicity in PC12 cells and cortical and mesencephalic neurons. 2007 , 239, 156-66	46
1022	Inhibitory activity of stilbenes on Alzheimer's beta-amyloid fibrils in vitro. 2007 , 15, 1160-7	202
1021	Dibenzothiazoles as novel amyloid-imaging agents. 2007 , 15, 2789-96	45
1020	Tetrahydroquinoline sulfonamides as gamma-secretase inhibitors. 2007 , 17, 205-7	32
1019	Discovery of gamma-secretase inhibitors efficacious in a transgenic animal model of Alzheimer's disease. 2007 , 17, 511-6	27
1018	Bis-styrylpyridine and bis-styrylbenzene derivatives as inhibitors for Abeta fibril formation. 2007 , 17, 1466-70	32
1017	Design, synthesis, and evaluation of tetrahydroquinoline and pyrrolidine sulfonamide carbamates as gamma-secretase inhibitors. 2007 , 17, 3010-3	27
1016	Derivatives of oxoisoaporphine alkaloids: a novel class of selective acetylcholinesterase inhibitors. 2007 , 17, 3765-8	45
1015	Radioiodinated aza-diphenylacetylenes as potential SPECT imaging agents for beta-amyloid plaque detection. 2007 , 17, 3581-4	12
1014	Ferulic acid and benzothiazole dimer derivatives with high binding affinity to beta-amyloid fibrils. 2007 , 17, 4022-5	26
1013	Design and synthesis of benzoazepinone-derived cyclic malonamides and aminoamides as potent gamma-secretase inhibitors. 2007 , 17, 3910-5	12
1012	Novel orally active, dibenzazepinone-based gamma-secretase inhibitors. 2007 , 17, 5918-23	33
1011	Small conformationally restricted piperidine N-arylsulfonamides as orally active gamma-secretase inhibitors. 2007 , 17, 5330-5	21

1010	Discovery of 2,4,6-trisubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors. 2007 , 17, 6290-4	22
1009	Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease. 2007 , 112, 30-8	49
1008	Development and characterization of beta-secretase monolithic micro-immobilized enzyme reactor for on-line high-performance liquid chromatography studies. 2007 , 1175, 217-26	28
1007	Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: a role for intraneuronal amyloid. 2007 , 31, 125-47	175
1006	Purification of recombinantly expressed and cytotoxic human amyloid-beta peptide 1-42. 2007 , 856, 229-33	13
1005	Role of the ubiquitin proteasome system in Alzheimer's disease. 2007 , 8 Suppl 1, S12	77
1004	Novel rat Alzheimer's disease models based on AAV-mediated gene transfer to selectively increase hippocampal Aβ levels. 2007 , 2, 11	56
1003	An AICD-based functional screen to identify APP metabolism regulators. 2007 , 2, 15	40
1002	Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau. 2007 , 2, 17	54
1001	Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms. 2007 , 2, 7	54
1000	Autophagy, organelles and ageing. 2007 , 211, 134-43	238
999	Proteomics of Alzheimer's disease: Unveiling protein dysregulation in complex neuronal systems. 2007 , 1, 1351-61	2
998	Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. 2007 , 9, 139-48	339
997	Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. 2007 , 8, 101-12	3692
996	The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. 2007 , 8, 904-16	521
995	Mitochondrial Ca ²⁺ as a key regulator of cell life and death. 2007 , 14, 1267-74	203
994	Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease. 2007 , 8, 141-6	266
993	Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. 2007 , 27, 909-18	495

992	SPF-5506-A4, a new peptaibol inhibitor of amyloid beta-peptide formation produced by <i>Trichoderma</i> sp. 2007 , 60, 184-90	17
991	Selective ablation of bone marrow-derived dendritic cells increases amyloid plaques in a mouse Alzheimer's disease model. 2007 , 26, 413-6	124
990	Impairment of hippocampal gamma-frequency oscillations in vitro in mice overexpressing human amyloid precursor protein (APP). 2007 , 26, 1280-8	59
989	Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration. 2007 , 26, 2458-68	21
988	Restoration of impaired phosphorylation of cyclic AMP response element-binding protein (CREB) by EGb 761 and its constituents in Abeta-expressing neuroblastoma cells. 2007 , 26, 2931-9	26
987	Calcium-binding protein secretagogin-expressing neurones in the human hippocampus are largely resistant to neurodegeneration in Alzheimer's disease. 2008 , 34, 23-32	30
986	Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease. 2007 , 64, 36-48	18
985	Neurodegenerative dementias involving aberrant protein aggregation. 2007 , 7, 114-117	8
984	Monoclonal antibodies that target pathological assemblies of Abeta. 2007 , 100, 23-35	271
983	Novel modulators of amyloid-beta precursor protein processing. 2007 , 100, 314-23	52
982	The same gamma-secretase accounts for the multiple intramembrane cleavages of APP. 2007 , 100, 1234-46	35
981	Degradation of nicastrin involves both proteasome and lysosome. 2007 , 101, 982-92	32
980	Effects of the monomeric, oligomeric, and fibrillar Abeta42 peptides on the proliferation and differentiation of adult neural stem cells from subventricular zone. 2007 , 102, 493-500	63
979	Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice. 2007 , 102, 1053-63	67
978	Cerebral clearance of human amyloid-beta peptide (1-40) across the blood-brain barrier is reduced by self-aggregation and formation of low-density lipoprotein receptor-related protein-1 ligand complexes. 2007 , 103, 2482-90	64
977	Congo red and thioflavin-T analogs detect Abeta oligomers. 2008 , 104, 457-68	165
976	Complement component C1q inhibits beta-amyloid- and serum amyloid P-induced neurotoxicity via caspase- and calpain-independent mechanisms. 2008 , 104, 696-707	74
975	The integrity of the blood-brain barrier in Alzheimer's disease. 2007 , 115, 403-8	58

974	High-resolution NMR studies of the zinc-binding site of the Alzheimer's amyloid beta-peptide. 2007 , 274, 46-59	191
973	Conformational stability of Abeta-(25-35) in the presence of thiazolidine derivatives. 2007 , 69, 111-8	11
972	Combining the rapid MTT formazan exocytosis assay and the MC65 protection assay led to the discovery of carbazole analogs as small molecule inhibitors of Abeta oligomer-induced cytotoxicity. 2007 , 1130, 223-34	53
971	Evidence of oxidative stress-induced BNIP3 expression in amyloid beta neurotoxicity. 2007 , 1138, 221-30	30
970	Susceptibility of hippocampal neurons to Abeta peptide toxicity is associated with perturbation of Ca ²⁺ homeostasis. 2007 , 1143, 11-21	79
969	Nepriylsin protects neurons against Abeta peptide toxicity. 2007 , 1152, 191-200	45
968	Dopamine release in prefrontal cortex in response to beta-amyloid activation of alpha7 * nicotinic receptors. 2007 , 1182, 82-9	28
967	Insights into amyloid-beta-induced mitochondrial dysfunction in Alzheimer disease. 2007 , 43, 1569-73	82
966	Omental transposition in treatment of Alzheimer disease. 2007 , 205, 800-4	17
965	Immunoreactivity of calcium binding protein secretagogin in the human hippocampus is restricted to pyramidal neurons. 2007 , 42, 215-22	19
964	Beta-amyloid(1-42) induces a reduction in the parallel fiber responses of Purkinje cells: possible involvement of pro-inflammatory processes. 2007 , 42, 951-62	4
963	Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. 2008 , 12, 38-55	164
962	Therapeutic RNA interference for neurodegenerative diseases: From promise to progress. 2007 , 114, 34-55	38
961	Mechanisms of disease II: cellular protein quality control. 2007 , 14, 15-25	19
960	Up-regulation of Bcl-2 in APP transgenic mice is associated with neuroprotection. 2007 , 25, 179-88	22
959	Excess of nicastrin in brain results in heterozygosity having no effect on endogenous APP processing and amyloid peptide levels in vivo. 2007 , 25, 291-6	8
958	BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. 2007 , 26, 134-45	236
957	Ageing and amyloid-beta peptide deposition contribute to an impaired brain tissue plasminogen activator activity by different mechanisms. 2007 , 27, 164-73	48

956	Interleukin 10 and TNFalpha synergistically enhance the expression of the G protein-coupled formylpeptide receptor 2 in microglia. 2007 , 27, 90-8	9
955	Getting a grip on Alzheimer's disease: imaging amyloid in the brain. 2007 , 6, 204-6	2
954	Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. 2007 , 1097, 114-45	151
953	Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. 2007 , 68, 1809-14	209
952	Dementia: The Significance of Cerebral Metabolic Disturbances in Alzheimer's Disease. Relation to Parkinson's Disease. 2007 , 189-232	
951	Surface plasmon resonance and nuclear magnetic resonance studies of ABAD-Abeta interaction. 2007 , 46, 1724-31	57
950	The anti-amyloidogenic effect is exerted against Alzheimer's beta-amyloid fibrils in vitro by preferential and reversible binding of flavonoids to the amyloid fibril structure. 2007 , 46, 1888-99	129
949	Surface structure of amyloid-beta fibrils contributes to cytotoxicity. 2007 , 46, 9805-12	87
948	Potassium-dependent oriented growth of amyloid Aβ5 fibrils on mica. 2007 , 18, 345102	34
947	A quasi-spontaneous amyloid route in a DNA binding gene regulatory domain: The papillomavirus HPV16 E2 protein. 2007 , 16, 744-54	11
946	The first step of hen egg white lysozyme fibrillation, irreversible partial unfolding, is a two-state transition. 2007 , 16, 815-32	55
945	Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in Alzheimer's disease. 2007 , 9, 157-68	12
944	Localizations of endogenous APP/APP-proteolytic products are consistent with microtubular transport. 2007 , 31, 59-68	3
943	Tauopathies. 2007 , 64, 2219-33	226
942	Alzheimer disease--no target for statin treatment. A mini review. 2007 , 32, 695-706	20
941	Does Abeta 42 have a function related to blood homeostasis?. 2007 , 32, 833-5	23
940	Indices of metabolic dysfunction and oxidative stress. 2007 , 32, 717-22	21
939	Brain-specific aminopeptidase: from enkephalinase to protector against neurodegeneration. 2007 , 32, 2062-71	34

938	Positioning of the Alzheimer Abeta(1-40) peptide in SDS micelles using NMR and paramagnetic probes. 2007 , 39, 63-72	118
937	Metals ions and neurodegeneration. 2007 , 20, 639-54	153
936	Plaques, tangles, and memory loss in mouse models of neurodegeneration. 2007 , 37, 79-100	113
935	Tauopathies and synucleinopathies: do cerebrospinal fluid beta-amyloid peptides reflect disease-specific pathogenesis?. 2007 , 114, 919-27	32
934	Histologically confirmed amyloid deposition and low CSF Abeta42 in a cognitively normal subject. 2007 , 254, 970-1	1
933	Somatostatin genetic variants modify the risk for Alzheimer's disease among Finnish patients. 2007 , 254, 1504-8	22
932	Lack of association between mtDNA haplogroups and Alzheimer's disease in Tuscany. 2007 , 28, 142-7	38
931	Rethinking Alzheimer's disease: the role of age-related changes. 2007 , 7, 265-8	5
930	Laboratory biomarkers in Alzheimer's disease. 2007 , 7, 381-7	6
929	Alzheimer's disease. 2007 , 33, 58-64	9
928	Protective effects of phytoestrogen alpha-zearalanol on beta amyloid25-35 induced oxidative damage in cultured rat hippocampal neurons. 2007 , 32, 206-11	9
927	F(2)-isoprostanes as biomarkers of late-onset Alzheimer's disease. 2007 , 33, 114-9	55
926	Metal-amyloid-peptide interactions: a preliminary investigation of molecular mechanisms for Alzheimer's disease. 2007 , 50, 453-467	1
925	Application of Surface-Enhanced Raman Spectroscopy for Detection of Beta Amyloid Using Nanoshells. 2007 , 2, 55-64	60
924	Determination of a novel gamma-secretase inhibitor in human plasma and cerebrospinal fluid using automated 96 well solid phase extraction and liquid chromatography/tandem mass spectrometry. 2008 , 863, 36-45	11
923	Non-cholinergic effects of huperzine A: beyond inhibition of acetylcholinesterase. 2008 , 28, 173-83	61
922	Disruption of Calcium Homeostasis in Alzheimer's Disease. 2008 , 40, 385-392	8
921	Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity. 2008 , 33, 526-32	92

920	Differentiation increases the resistance of neuronal cells to amyloid toxicity. 2008 , 33, 2516-31	24
919	A differential proteomic approach reveals an evolutionary conserved regulation of Nme proteins by Fe65 in <i>C. elegans</i> and mouse. 2008 , 33, 2547-55	5
918	Why Alzheimer's is a disease of memory: the attack on synapses by A beta oligomers (ADDLs). 2008 , 12, 51S-7S	74
917	Understanding BACE1: essential protease for amyloid-beta production in Alzheimer's disease. 2008 , 65, 3265-89	70
916	Disease progression, drug action and Parkinson's disease: why time cannot be ignored. 2008 , 64, 207-16	25
915	Oriented epitaxial growth of amyloid fibrils of the N27C mutant beta 25-35 peptide. 2008 , 37, 1133-7	19
914	Amyloid plaque imaging in vivo: current achievement and future prospects. 2008 , 35 Suppl 1, S46-50	60
913	Acetylcholine receptors in dementia and mild cognitive impairment. 2008 , 35 Suppl 1, S30-45	97
912	[Current immune therapy for Alzheimer's disease]. 2008 , 79, 832-5	3
911	Maximizing the potential of plasma amyloid-beta as a diagnostic biomarker for Alzheimer's disease. 2008 , 10, 195-207	28
910	Mitochondrial medicine for aging and neurodegenerative diseases. 2008 , 10, 291-315	161
909	Workflow and methods of high-content time-lapse analysis for quantifying intracellular calcium signals. 2008 , 6, 97-108	4
908	Dendritic spine loss and synaptic alterations in Alzheimer's disease. 2008 , 37, 73-82	209
907	Computational study of the binding of Cull to Alzheimer's amyloid-beta peptide: do Abeta42 and Abeta40 bind copper in identical fashion?. 2008 , 13, 1197-204	26
906	L-dopa modulates motor cortex excitability in Alzheimer's disease patients. 2008 , 115, 1313-9	34
905	Transgenic tomatoes expressing human beta-amyloid for use as a vaccine against Alzheimer's disease. 2008 , 30, 1839-45	37
904	Inter-laboratory comparison of neuropathological assessments of beta-amyloid protein: a study of the BrainNet Europe consortium. 2008 , 115, 533-46	73
903	Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. 2008 , 115, 599-609	240

902	Lysosomes in iron metabolism, ageing and apoptosis. 2008 , 129, 389-406	209
901	Ginkgolides protect against amyloid-beta1-42-mediated synapse damage in vitro. 2008 , 3, 1	58
900	Changes in gamma-secretase activity and specificity caused by the introduction of consensus aspartyl protease active motif in Presenilin 1. 2008 , 3, 6	8
899	The N-domain of angiotensin-converting enzyme specifically hydrolyzes the Arg-5-His-6 bond of Alzheimer's Abeta-(1-16) peptide and its isoAsp-7 analogue with different efficiency as evidenced by quantitative matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. 2008 , 22, 231-9	44
898	Inhibition of cholinesterase and amyloid-beta aggregation by resveratrol oligomers from Vitis amurensis. 2008 , 22, 544-9	77
897	Lipid membrane templates the ordering and induces the fibrillogenesis of Alzheimer's disease amyloid-beta peptide. 2008 , 72, 1-24	109
896	Folding and dimerization of the ionic peptide EAK 16-IV. 2008 , 72, 150-62	11
895	Multifunction of myricetin on A beta: neuroprotection via a conformational change of A beta and reduction of A beta via the interference of secretases. 2008 , 86, 368-77	82
894	Loss of presenilin function causes Alzheimer's disease-like neurodegeneration in the mouse. 2008 , 86, 1615-25	38
893	Amyloid beta peptide toxicity in differentiated PC12 cells: calpain-calpastatin, caspase, and membrane damage. 2008 , 86, 2314-25	23
892	Synthesis of a [18F]fluorobenzothiazole as potential amyloid imaging agent. 2008 , 51, 137-145	14
891	Ligand-induced flocculation of neurotoxic fibrillar Abeta(1-42) by noncovalent crosslinking. 2008 , 9, 748-57	5
890	Isomerization of the Asp7 residue results in zinc-induced oligomerization of Alzheimer's disease amyloid beta(1-16) peptide. 2008 , 9, 1564-7	55
889	Tauopathy with paired helical filaments in an aged chimpanzee. 2008 , 509, 259-70	105
888	Design, structural, and immuno-analytical properties of antigenic bioconjugates comprising a beta-amyloid-plaque specific epitope. 2008 , 90, 94-104	7
887	Thermodynamic and kinetic origins of Alzheimer's and related diseases: A chemical engineer's perspective. 2008 , 54, 1956-1962	11
886	Association of complement factor H Y402H gene polymorphism with Alzheimer's disease. 2008 , 147B, 720-6	55
885	Inhibition and modulation of gamma-secretase for Alzheimer's disease. 2008 , 5, 391-8	119

884	Qualitative and quantitative characterization of the amyloid beta peptide (Abeta) population in biological matrices using an immunoprecipitation-LC/MS assay. 2008 , 168, 465-74	22
883	Design, synthesis, and biological evaluation of glycine-based molecular tongs as inhibitors of Abeta1-40 aggregation in vitro. 2008 , 16, 4810-22	22
882	Development of novel beta-amyloid probes based on 3,5-diphenyl-1,2,4-oxadiazole. 2008 , 16, 6867-72	42
881	Synthesis of scyllo-inositol derivatives and their effects on amyloid beta peptide aggregation. 2008 , 16, 7177-84	57
880	2-Phenoxy-indan-1-one derivatives as acetylcholinesterase inhibitors: a study on the importance of modifications at the side chain on the activity. 2008 , 16, 7646-53	22
879	Design, synthesis, and acetylcholinesterase inhibitory activity of novel coumarin analogues. 2008 , 16, 8011-21	104
878	Achiral oligoamines as versatile tool for the development of aspartic protease inhibitors. 2008 , 16, 8574-86	14
877	Design, synthesis and SAR of potent statine-based BACE-1 inhibitors: exploration of P1 phenoxy and benzyloxy residues. 2008 , 16, 9471-86	27
876	Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. 2008 , 18, 423-6	171
875	Synthesis and evaluation of stilbenylbenzoxazole and stilbenylbenzothiazole derivatives for detecting beta-amyloid fibrils. 2008 , 18, 1534-7	11
874	Acylguanidine inhibitors of beta-secretase: optimization of the pyrrole ring substituents extending into the S1' substrate binding pocket. 2008 , 18, 767-71	34
873	Synthesis and biological evaluation of ^{99m} Tc, Re-monoamine-monoamide conjugated to 2-(4-aminophenyl)benzothiazole as potential probes for beta-amyloid plaques in the brain. 2008 , 18, 1442-5	42
872	Isoindol-1,3-dione and isoindol-1-one derivatives with high binding affinity to beta-amyloid fibrils. 2008 , 18, 1628-31	14
871	Design, synthesis and evaluation of isaindigotone derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors. 2008 , 18, 3790-3	34
870	Synthesis and evaluation of indolinyl- and indolylphenylacetylenes as PET imaging agents for beta-amyloid plaques. 2008 , 18, 4823-7	14
869	Aminostyrylbenzofuran derivatives as potent inhibitors for Abeta fibril formation. 2008 , 18, 5591-3	49
868	Metal complexes as artificial proteases: toward catalytic drugs. 2008 , 12, 207-13	61
867	Substituted 2-oxo-azepane derivatives are potent, orally active gamma-secretase inhibitors. 2008 , 18, 304-8	20

866	Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors. 2008 , 18, 215-9	32
865	[(18)F]-labeled isoindol-1-one and isoindol-1,3-dione derivatives as potential PET imaging agents for detection of beta-amyloid fibrils. 2008 , 18, 5701-4	15
864	Rapid label-free detection of metal-induced Alzheimer's amyloid β peptide aggregation by electrochemical method. 2008 , 10, 1797-1800	31
863	Do red blood cell-beta-amyloid interactions alter oxygen delivery in Alzheimer's disease?. 2008 , 614, 29-35	42
862	Soluble Oligomers of the Amyloid β Protein: Impair Synaptic Plasticity and Behavior. 2008 , 89-102	4
861	Yeast as a model for studying human neurodegenerative disorders. 2008 , 3, 325-38	59
860	New approaches to the immunotherapy of Alzheimer's disease with the synthetic fragments of β subunit of the acetylcholine receptor. 2008 , 34, 43-48	0
859	Synthesis of the β amyloid fragment 5RHDSGY10 and its isomers. 2008 , 2, 288-292	2
858	Conditionally inducible tau mice--designing a better mouse model of neurodegenerative diseases. 2008 , 7 Suppl 1, 12-27	13
857	Cerebral amyloid angiopathy: pathogenetic mechanisms and link to dense amyloid plaques. 2008 , 7 Suppl 1, 67-82	62
856	Active gamma-secretase is localized to detergent-resistant membranes in human brain. 2008 , 275, 1174-87	72
855	Lipid-induced conformational transition of the amyloid core fragment Abeta(28-35) and its A30G and A30I mutants. 2008 , 275, 2415-27	11
854	Secondary structure conversions of Alzheimer's Abeta(1-40) peptide induced by membrane-mimicking detergents. 2008 , 275, 5117-28	85
853	Formation of highly toxic soluble amyloid beta oligomers by the molecular chaperone prefoldin. 2008 , 275, 5982-93	51
852	Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. 2008 , 451, 720-4	774
851	Integration of metabolism and inflammation by lipid-activated nuclear receptors. 2008 , 454, 470-7	608
850	Alzheimer's disease: Moving towards a vaccine. 2008 , 454, 418-20	34
849	Materials science: A tale of two tilings. 2008 , 454, 420-1	10

848	Amyloid precursor protein expression is upregulated in adipocytes in obesity. 2008 , 16, 1493-500	68
847	Metal swap between Zn7-metlothionein-3 and amyloid-beta-Cu protects against amyloid-beta toxicity. 2008 , 4, 366-72	161
846	Biosensing with plasmonic nanosensors. 2008 , 7, 442-53	5354
845	Beta-amyloid expression, release and extracellular deposition in aged rat brain slices. 2008 , 13, 939-52	46
844	Developing preventive therapies for chronic diseases: lessons learned from Alzheimer's disease. 2007 , 65, S239-43	29
843	The role of the immune system in clearance of Abeta from the brain. 2008 , 18, 267-78	80
842	Type 2 diabetes mellitus and cognitive decline in two large cohorts of community-dwelling older adults. 2008 , 56, 1028-36	109
841	Androgens regulate neprilysin expression: role in reducing beta-amyloid levels. 2008 , 105, 2477-88	65
840	High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice. 2008 , 106, 475-85	257
839	Concomitant degradation of beta-catenin and GSK-3 beta potently contributes to glutamate-induced neurotoxicity in rat hippocampal slice cultures. 2008 , 106, 1066-77	23
838	Lipid peroxidation up-regulates BACE1 expression in vivo: a possible early event of amyloidogenesis in Alzheimer's disease. 2008 , 107, 197-207	83
837	Effects of gamma-secretase cleavage-region mutations on APP processing and Abeta formation: interpretation with sequential cleavage and alpha-helical model. 2008 , 107, 722-33	15
836	Role of methionine 35 in the intracellular Ca ²⁺ homeostasis dysregulation and Ca ²⁺ -dependent apoptosis induced by amyloid beta-peptide in human neuroblastoma IMR32 cells. 2008 , 107, 1070-82	25
835	Down-regulation of insulin-degrading enzyme by presenilin 1 V97L mutant potentially underlies increased levels of amyloid beta 42. 2008 , 27, 2425-32	9
834	Ageing in a eusocial insect: molecular and physiological characteristics of life span plasticity in the honey bee. 2008 , 22, 407-421	92
833	The contribution of cerebral vascular semicarbazide-sensitive amine oxidase to cerebral amyloid angiopathy in Alzheimer's disease. 2008 , 34, 194-204	31
832	Effects of beta-amyloid peptide on the density of M2 muscarinic acetylcholine receptor protein in the hippocampus of the rat: relationship with GABA-, calcium-binding protein and somatostatin-containing cells. 2008 , 34, 506-22	11
831	Lentivirus Tau (P301S) expression in adult amyloid precursor protein (APP)-transgenic mice leads to tangle formation. 2008 , 34, 523-31	12

830	Targeting age-related macular degeneration with Alzheimer's disease based immunotherapies: anti-amyloid-beta antibody attenuates pathologies in an age-related macular degeneration mouse model. 2008 , 48, 339-45	81
829	Amyloid-beta peptide degradation in cell cultures by mycoplasma contaminants. 2008 , 1, 38	24
828	The role of glycogen synthase kinase 3 in the early stages of Alzheimers' disease. 2008 , 582, 3848-54	61
827	Alcohol enhances Abeta42-induced neuronal cell death through mitochondrial dysfunction. 2008 , 582, 4185-90	4
826	Protective effect of new S-acylglutathione derivatives against amyloid-induced oxidative stress. 2008 , 44, 1624-36	29
825	Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease. 2008 , 44, 2051-7	254
824	Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models. 2008 , 45, 219-30	87
823	Increased oxidative stress and astrogliosis responses in conditional double-knockout mice of Alzheimer-like presenilin-1 and presenilin-2. 2008 , 45, 1493-9	30
822	High content analysis of gamma-secretase activity reveals variable dominance of presenilin mutations linked to familial Alzheimer's disease. 2008 , 1783, 1551-60	16
821	Inhibition of basal activity of c-jun-NH2-terminal kinase (JNK) represses the expression of presenilin-1 by a p53-dependent mechanism. 2008 , 1207, 19-31	17
820	Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls. 2008 , 1219, 169-79	23
819	Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. 2008 , 1216, 92-103	205
818	Interhemispheric EEG differences in olfactory bulbectomized rats with different cognitive abilities and brain beta-amyloid levels. 2008 , 1232, 185-94	25
817	Androgen regulation of beta-amyloid protein and the risk of Alzheimer's disease. 2008 , 57, 444-53	73
816	Potential therapeutic targets of huperzine A for Alzheimer's disease and vascular dementia. 2008 , 175, 396-402	75
815	Amyloid flirting with synaptic failure: towards a comprehensive view of Alzheimer's disease pathogenesis. 2008 , 585, 109-18	47
814	The use of the hippocampal slice preparation in the study of Alzheimer's disease. 2008 , 585, 50-9	15
813	Catabolic attacks of membrane-bound angiotensin-converting enzyme on the N-terminal part of species-specific amyloid-beta peptides. 2008 , 588, 18-25	29

812	[3H]BMS-599240--a novel tritiated ligand for the characterization of BACE1 inhibitors. 2008 , 593, 10-5	7
811	A novel diol-derivative of chalcone produced by bioconversion, 3-(2,3-dihydroxyphenyl)-1-phenylpropan-1-one, activates PKA/MEK/ERK signaling and antagonizes Abeta-inhibition of the cascade in cultured rat CNS neurons. 2008 , 600, 10-7	15
810	Near-infrared spectroscopy: potential clinical benefits in surgery. 2008 , 206, 761-2	0
809	Knee-jerk dogma. 2008 , 206, 762-3; author reply 763	2
808	Amyloid-beta immunisation for Alzheimer's disease. 2008 , 7, 805-11	122
807	Neural stem cells improve neuronal survival in cultured postmortem brain tissue from aged and Alzheimer patients. 2008 , 12, 1611-21	25
806	The ubiquitin-proteasome system in Alzheimer's disease. 2008 , 12, 363-73	178
805	Biomarkers for early diagnosis of Alzheimer disease: 'ALzheimer ASsociated gene'--a new blood biomarker?. 2008 , 12, 1094-117	37
804	Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. 2008 , 12, 762-80	164
803	Pharmacotherapeutic targets in Alzheimer's disease. 2009 , 13, 61-86	44
802	Mutant amyloid-beta-sensitized dendritic cells as Alzheimer's disease vaccine. 2008 , 200, 1-10	12
801	Triptolide inhibits amyloid-beta1-42-induced TNF-alpha and IL-1beta production in cultured rat microglia. 2008 , 205, 32-6	55
800	Muscarinic acetylcholine receptors as CNS drug targets. 2008 , 117, 232-43	320
799	Plasma C-peptide levels and rates of cognitive decline in older, community-dwelling women without diabetes. 2008 , 33, 455-61	19
798	Thalidomide inhibition of perturbed vasculature and glial-derived tumor necrosis factor-alpha in an animal model of inflamed Alzheimer's disease brain. 2008 , 29, 254-66	80
797	LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-beta peptide in a blood-brain barrier in vitro model. 2008 , 30, 94-102	82
796	TGF-beta 1 protects against Abeta-neurotoxicity via the phosphatidylinositol-3-kinase pathway. 2008 , 30, 234-42	66
795	A transgenic rat that develops Alzheimer's disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment. 2008 , 31, 46-57	84

794	Increased expression of the oligopeptidase THOP1 is a neuroprotective response to Abeta toxicity. 2008 , 31, 145-58	25
793	The beta amyloid peptide can act as a modular aggregation domain. 2008 , 32, 420-5	6
792	Amyloid imaging in Alzheimer's disease. 2008 , 46, 1636-41	58
791	S14G-Humanin ameliorates Abeta25-35-induced behavioral deficits by reducing neuroinflammatory responses and apoptosis in mice. 2008 , 42, 557-67	50
790	Structural studies of the transmembrane C-terminal domain of the amyloid precursor protein (APP): does APP function as a cholesterol sensor?. 2008 , 47, 9428-46	137
789	Role of water in mediating the assembly of Alzheimer amyloid-beta Abeta16-22 protofilaments. 2008 , 130, 11066-72	180
788	Nanofluidic biosensing for beta-amyloid detection using surface enhanced Raman spectroscopy. 2008 , 8, 1729-35	166
787	Evaluation of Various Drugs Influence on Alzheimer's Disease Progress Using a New Analytical Model Based on Cellular Automata.	
786	var. Improves Cognitive Impairment under Amyloid Beta-Induced Alzheimer's Disease Model.. 2022 , 2022, 4513998	1
785	Multifocal Cerebral Microinfarcts Modulate Early Alzheimer's Disease Pathology in a Sex-Dependent Manner.. 2021 , 12, 813536	0
784	Using intracerebral microdialysis to probe the efficacy of repurposed drugs in Alzheimer's disease pathology.	
783	Interaction between polyphenols and amyloids: from the view of prevention of protein misfolding disorders related diseases. 2022 , 2, 1-15	
782	In Vivo C Magnetic Resonance Spectroscopy for Assessing Brain Biochemistry in Health and Disease.. 2022 , 47, 1183	0
781	Neurogenetic disorders across the lifespan: from aberrant development to degeneration.. 2022 ,	4
780	Robust Pharmacodynamic Effect of LY3202626, a Central Nervous System Penetrant, Low Dose BACE1 Inhibitor, in Humans and Nonclinical Species.. 2022 , 6, 1-15	1
779	PROTACs technology for treatment of Alzheimer's disease: Advances and perspectives.. 2022 , 1, 24-41	1
778	The Impact of Systemic Inflammation on Alzheimer's Disease Pathology.. 2021 , 12, 796867	6
777	Conformation-reconstructed multivalent antibody mimic for amplified mitigation of human islet amyloid polypeptide amyloidogenesis.. 2022 ,	2

776	A short peptide from sAPP β binding to BACE1-APP action site rescues Alzheimer-like pathology.. 2021 , 770, 136397	0
775	Mechanistic and therapeutic role of Drp1 in the pathogenesis of Alzheimer's Disease.. 2022 ,	2
774	TAPPING into the potential of inducible tau/APP transgenic mice.. 2022 ,	
773	Anti-Dementia Medications and Anti-Alzheimer β Disease Drugs: Side Effects, Contraindications, and Interactions. 2022 , 1-10	0
772	Quantitative systems pharmacology model for Alzheimer's disease to predict effect of aducanumab on brain amyloid.. 2022 ,	2
771	Application of Repetitive Transcranial Magnetic Stimulation over the Dorsolateral Prefrontal Cortex in Alzheimer's Disease: A Pilot Study.. 2022 , 11,	1
770	A Dual-Pronged Approach: A Ruthenium(III) Complex That Modulates Amyloid- β Aggregation and Disrupts Its Formed Aggregates.. 2022 ,	0
769	Phospholipase D3 contributes to Alzheimer β disease risk via disruption of A β clearance and microglia response to amyloid plaques.	
768	Can dietary patterns prevent cognitive impairment and reduce Alzheimer's disease risk: exploring the underlying mechanisms of effects.. 2022 , 104556	2
767	Astrocytes deficient in circadian clock gene Bmal1 show enhanced activation responses to amyloid-beta pathology without changing plaque burden.. 2022 , 12, 1796	2
766	Are you more impulsive with age? Examining age, marital status, and gender on cognitive ageing.. 2022 , 1-13	0
765	Development of naringenin-O-carbamate derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease.. 2022 , 60, 128574	1
764	Amyloid β interaction with model cell membranes - What are the toxicity-defining properties of amyloid β 2022 , 200, 520-531	1
763	Targeting hippocampal amyloidogenesis with SV2A protein modulator levetiracetam.. 2022 , 197, 114927	
762	Dapagliflozin diminishes memory and cognition impairment in Streptozotocin induced diabetes through its effect on Wnt/ β Catenin and CREB pathway.. 2022 ,	0
761	Early derailment of firing properties in CA1 pyramidal cells of the ventral hippocampus in an Alzheimer's disease mouse model.. 2021 , 113969	1
760	Synthesis of carbon quantum dots for application of alleviating amyloid- β mediated neurotoxicity.. 2022 , 212, 112373	5
759	Protective Role of Microglia on Neuronal Survival after Exposure to Amyloid Beta.. 2022 , 58, 13-17	

758	Advances in aptamers against A β and applications in A β detection and regulation for Alzheimer's disease.. 2022 , 12, 2095-2114	3
757	Anatomy and formation mechanisms of early amyloid- β oligomers with lateral branching: graph network analysis on large-scale simulations.. 2022 , 13, 2649-2660	
756	A Synopsis of Multitarget Potential Therapeutic Effects of Huperzine A in Diverse Pathologies-Emphasis on Alzheimer's Disease Pathogenesis.. 2022 , 47, 1166	0
755	Network pharmacology-based approach to investigate the mechanisms of Zingiber officinale Roscoe in the treatment of neurodegenerative diseases.. 2022 , e14068	
754	Nutrient-sensing amyloid metastasis.. 2022 ,	1
753	Arsenic as an environmental and human health antagonist: A review of its toxicity and disease initiation. 2022 , 5, 100052	6
752	EEG/ERP evidence of possible hyperexcitability in older adults with elevated beta-amyloid.. 2022 , 11, 8	2
751	Association of Performance on the Financial Capacity Instrument-Short Form With Brain Amyloid Load and Cortical Thickness in Older Adults. 10.1212/CPJ.0000000000001157	
750	Computational strategies to identify new drug candidates against neuroinflammation.. 2022 ,	1
749	Marked Response of Rat Ileal and Colonic Microbiota After the Establishment of Alzheimer's Disease Model With Bilateral Intraventricular Injection of A β (1-42).. 2022 , 13, 819523	1
748	Exosomes Mediate APP Dysregulation APP-miR-185-5p Axis.. 2022 , 10, 793388	0
747	Long-term running exercise improves cognitive function and promotes microglial glucose metabolism and morphological plasticity in the hippocampus of APP/PS1 mice.. 2022 , 19, 34	4
746	Lipid flippase dysfunction as a therapeutic target for endosomal anomalies in Alzheimer's disease.. 2022 , 25, 103869	1
745	Insertion of the Icelandic Mutation (A673T) by Prime Editing: A Potential Preventive Treatment for Familial and Sporadic Alzheimer's Disease.. 2022 ,	2
744	Comparing tau status determined via plasma pTau181, pTau231 and [F]MK6240 tau-PET.. 2022 , 76, 103837	1
743	Protective Role of Capsaicin in Neurological Disorders: An Overview.. 2022 , 1	2
742	Multifaceted neuroprotective effects of (-)-epigallocatechin-3-gallate (EGCG) in Alzheimer's disease: an overview of pre-clinical studies focused on β amyloid peptide. 2022 , 11, 483-493	4
741	Heparan sulfate from porcine mucosa promotes amyloid-beta clearance in APP/PS1 mice and alleviates Alzheimer's pathology.. 2022 , 285, 119205	2

740	Antidementia Medications: Pharmacology and Biochemistry. 2022 , 1-16	
739	Targeting MicroRNA-485-3p Blocks Alzheimer's Disease Progression. 2021 , 22,	3
738	The gut metabolite, trimethylamine N-oxide inhibits protein folding by affecting cis-trans isomerization and induces cell cycle arrest.. 2021 , 79, 12	1
737	Role of nutraceuticals on neurodegenerative diseases: neuroprotective and immunomodulant activity.. 2021 , 1-18	15
736	Neuron-like function of the nephron central command.	0
735	Physiological clearance of A β by spleen and splenectomy aggravates Alzheimer-type pathogenesis.. 2021 , e13533	4
734	A Review of the Current Mammalian Models of Alzheimer's Disease and Challenges That Need to Be Overcome. 2021 , 22,	4
733	Drug Therapy of Alzheimer's Disease: Cholinesterase Inhibitors, NMDA Antagonists. 2021 , 95-110	
732	Food bioactives: the food image behind the curtain of health promotion and prevention against several degenerative diseases. 2022 , 391-421	1
731	Syndapin-2 mediated transcytosis of amyloid- β across the blood-brain barrier.. 2022 , 4, fcac039	0
730	Porous Optical Chemosensors for Early Detection and Monitoring of Heavy Metals Correlated with Alzheimer's Disease.	
729	Nanoparticle-mediated delivery of AChE inhibitors for the treatment of Alzheimer's disease. 2022 , 223-242	
728	Simultaneous binding of heme and Cu with amyloid β peptides: active site and reactivities.. 2022 ,	2
727	Probing Protein Aggregation Using the Coarse-Grained UNRES Force Field.. 2022 , 2340, 79-104	
726	Neuro-Symbolic Neurodegenerative Disease Modeling as Probabilistic Programmed Deep Kernels. 2022 , 49-64	1
725	Moyamoya disease: A human model for chronic hypoperfusion and intervention in Alzheimer's disease.. 2022 , 8, e12285	
724	Prophylaxis Through Marine-Derived Bioactive Compounds Toward Neurodegenerative Disorders. 2022 , 101-120	
723	Molecular dynamics simulations of amyloid- β peptides in heterogeneous environments. 2022 ,	0

722	Nanomedical drug delivery for neurodegenerative disease. 2022 , 67-79	
721	Dynamics of Amyloid Formation from Simplified Representation to Atomistic Simulations.. 2022 , 2405, 95-113	
720	Inhibition of Amyloid Aggregation by p-Terphenyl Derivatives Isolated from Boletopsis leucomelas. 2022 , 104, 925	0
719	Novel Mathematical Model Based on Cellular Automata for Study of Alzheimer's Disease Progress.	
718	Exercise-Eating Pattern and Social Inclusion (EES) is an Effective Modulator of Pathophysiological Hallmarks of Alzheimer's Disease.	
717	APOE mediated neuroinflammation and neurodegeneration in Alzheimer's disease.. 2022 , 101594	5
716	Epigenetic axis of SNHG19/miR-137/TNFAIP1 modulates amyloid beta peptide 25-35-induced SH-SY5Y cytotoxicity.. 2022 ,	0
715	Development of naringenin-alkylamine derivatives as multifunctional agents for the treatment of Alzheimer's disease.. 2022 , 37, 792-816	0
714	Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease.. 2022 ,	2
713	Alzheimer's disease amyloid- β pathology in the lens of the eye.. 2022 , 108974	1
712	Model of glymphatic clearance of aggregating proteins from the brain interstitium.. 2022 , 105, 024405	0
711	The Multifaceted Role of Neuroprotective Plants in Alzheimer's Disease Treatment.. 2022 , 7,	3
710	Epigenetic Modifications by Estrogen and Androgen in Alzheimer's Disease.. 2022 ,	
709	Optogenetics: implications for Alzheimer's disease research and therapy.. 2022 , 15, 20	1
708	Interaction of Mitochondrial Calcium and ROS in Neurodegeneration.. 2022 , 11,	8
707	Dissection of the polygenic architecture of neuronal A β production using a large sample of individual iPSC lines derived from Alzheimer's disease patients. 2022 , 2, 125-139	0
706	Advances in stem cell therapy in Alzheimer's disease: a comprehensive clinical trial review.. 2022 , 9, 2	0
705	Calcium Signaling Regulated by Cellular Membrane Systems and Calcium Homeostasis Perturbed in Alzheimer's Disease.. 2022 , 10, 834962	1

704	Supramolecular Copolymers of Peptides and Lipidated Peptides and Their Therapeutic Potential.. 2022 , 144, 5562-5574	0
703	A Privileged Dual Action Alzheimer's Disease Therapeutic Platform Targeting Immunopathic and Proteopathic Mechanisms: (E)-3-Styrylindoles as Inhibitors of Indoleamine 2,3-Dioxygenase-Mediated Tryptophan Metabolism and β -Amyloid Aggregation.	
702	Structure optimization of the toxic conformation model of amyloid β 2 by intramolecular disulfide bond formation.. 2022 ,	1
701	Tailoring a Nanochaperone to Regulate β Synuclein Assembly.. 2022 ,	1
700	Chiral Linked Systems as a Model for Understanding D-Amino Acids Influence on the Structure and Properties of Amyloid Peptides.. 2022 , 23,	2
699	Chronic PPAR δ Stimulation Shifts Amyloidosis to Higher Fibrillarity but Improves Cognition.. 2022 , 14, 854031	1
698	Microglial activation in Alzheimer's disease: The role of flavonoids and microRNAs.. 2022 ,	2
697	Association of the Protein-Quality-Control Protein Ubiquilin-1 With Alzheimer's Disease Both and .. 2022 , 16, 821059	
696	Rational design and synthesis of a novel BODIPY-based probe for selective imaging of tau tangles in human iPSC-derived cortical neurons.. 2022 , 12, 5257	0
695	Transmission of Cerebral β Amyloidosis Among Individuals.. 2022 ,	0
694	Combined Effect of Co-administration of Stromal Cell-Derived Factor-1 and Granulocyte-Colony Stimulating Factor on Model of Alzheimer's Disease.. 2022 , 16, 796230	0
693	Hsp104 N-terminal Domain Interaction with Substrates Plays a Regulatory Role in Protein Disaggregation.. 2022 ,	0
692	Finding Cures for Alzheimer's Disease. 2022 , 51-83	
691	Potential Mechanisms Underlying Resistance to Dementia in Non-Demented Individuals with Alzheimer's Disease Neuropathology.. 2022 ,	1
690	Whole-genome sequencing reveals novel ethnicity-specific rare variants associated with Alzheimer's disease.. 2022 ,	3
689	Novel Psychoactive Substances: The Razor's Edge between Therapeutical Potential and Psychoactive Recreational Misuse.. 2022 , 9,	2
688	Design, synthesis, and evaluation of 8-aminoquinoline-melatonin derivatives as effective multifunctional agents for Alzheimer's disease.. 2022 , 10, 303	
687	Drug Development for Alzheimer's Disease: An Historical Perspective. 2022 , 25-33	

- 686 Metal-Organic Framework Based Drug Delivery for Alzheimer Therapy and Clinical Progress. **2022**, 19,
- 685 Increased Serum Beta-Secretase 1 Activity is an Early Marker of Alzheimer's Disease.. **2022**,
- 684 Alzheimer's disease - the journey of a healthy brain into organ failure.. **2022**, 17, 18 3
- 683 Amelioration of Experimental Autoimmune Encephalomyelitis in Alzheimer's Disease Mouse Models: A Potential Role for A β **2022**, 11, 0
- 682 Network pharmacology analysis reveals neuroprotection of *Gynostemma pentaphyllum* (Thunb.) Makino in Alzheimer' disease.. **2022**, 22, 57
- 681 Microbiota in 'neuroinflammation' and 'synaptic dysfunction': a focus on Alzheimer's disease.. **2022**, 17, 19 5
- 680 Tailoring a Nanochaperone to Regulate β synuclein Assembly.
- 679 Amyloid- β oligomers interact with NMDA receptors containing GluN2B subunits and metabotropic glutamate receptor 1 in primary cortical neurons: relevance to the synapse pathology of Alzheimer's disease.. **2022**, 0
- 678 Decreased CSF clearance and increased brain amyloid in Alzheimer's disease.. **2022**, 19, 21 4
- 677 Screen-Printed Electrodes on Tyvek Substrate as Low-Cost Device to Applications in Alzheimer β Disease Detection. **2022**, 169, 037505
- 676 Association of Emerging β Amyloid and Tau Pathology With Early Cognitive Changes in Clinically Normal Older Adults.. **2022**, 1
- 675 Progress and Development of Carbazole Scaffold based as Potential Anti-Alzheimer Agents using MTDL Approach.. **2022**, 19, 1
- 674 Alterations of the Sympathoadrenal Axis Related to the Development of Alzheimer's Disease in the 3xTg Mouse Model.. **2022**, 11,
- 673 Composite of gold nanoclusters and basified human serum albumin significantly boosts the inhibition of Alzheimer's β Amyloid by photo-oxygenation.. **2022**, 2
- 672 Immunotherapy for Alzheimer's disease: targeting β Amyloid and beyond.. **2022**, 11, 18 9
- 671 Preclinical Longitudinal In Vivo Biomarker Platform for Alzheimer β Disease Drug Discovery. **2022**, 106-122
- 670 Applications of nanodiamonds in the diagnosis and treatment of neurological diseases. **2022**, 24, 1
- 669 Degradation and Inhibition of Epigenetic Regulatory Protein BRD4 Exacerbate Alzheimer's Disease-Related Neuropathology in Cell Models.. **2022**, 101794 1

668	"Aducanumab" making a comeback in Alzheimer's disease: An old wine in a new bottle.. 2022 , 148, 112746	4
667	βSecretase in Alzheimer's disease.. 2022 ,	6
666	Magnetic resonance elastography to study the effect of amyloid plaque accumulation in a mouse model.. 2022 ,	0
665	Small molecules from Bacopa monneiri as potent inhibitors against Neurodegenerative disorders.	
664	Dissecting the clinical heterogeneity of early-onset Alzheimer's disease.. 2022 ,	3
663	Phytochemical Composition, Antioxidant Activity, βGlucosidase and Acetylcholinesterase Inhibitory Activity of Quinoa Extract and Its Fractions.. 2022 , 27,	0
662	Plasma extracellular vesicles from the periphery as spreading vectors of Alzheimer's disease pathogenesis?. 2022 , 78, 103961	
661	A time-to-event exposure-response model for amyloid-related imaging abnormalities following administration of aducanumab to subjects with early alzheimer's disease.. 2022 ,	1
660	Positive feedback regulation of microglial glucose metabolism by histone H4 lysine 12 lactylation in Alzheimer's disease.. 2022 ,	7
659	Exploration of salient risk factors involved in mild cognitive impairment.. 2022 ,	0
658	Effects of heparan sulfate from porcine mucosa on Aβ-induced neurotoxicity in vitro and in vivo.. 2022 , 206, 823-836	
657	Design, synthesis and evaluation of novel scutellarin and scutellarein-N,N-bis-substituted carbamate-l-amino acid derivatives as potential multifunctional therapeutics for Alzheimer's disease.. 2022 , 122, 105760	0
656	Exploring the journey of emodin as a potential neuroprotective agent: Novel therapeutic insights with molecular mechanism of action.. 2022 , 149, 112877	11
655	Cell models for Alzheimer's and Parkinson's disease: At the interface of biology and drug discovery. 2022 , 149, 112924	2
654	Advancements in the development of multi-target directed ligands for the treatment of Alzheimer's disease.. 2022 , 61, 116742	3
653	Ion flux-independent NMDA receptor signaling.. 2022 , 109019	2
652	Solvent modulated structural transition of self-assemblies formed by bola-form hexapeptide amphiphiles. 2022 , 355, 118940	
651	An improved graph Laplacian regularization method for identifying biomarkers of Alzheimer's disease.. 2022 , 543, 111121	

650	Assembly of redox active metallo-enzymes and metallo-peptides on electrodes: Abiological constructs to probe natural processes.. 2022 , 68, 102142	1
649	Preparation and characterization of five 3D crystalline adducts from caffeine and organic acids. 2022 , 1260, 132697	3
648	Drug delivery of memantine with carbon dots for Alzheimer's disease: blood-brain barrier penetration and inhibition of tau aggregation.. 2022 , 617, 20-31	2
647	Effects of transcranial ultrasound stimulation pulsed at 40'Hz on A β plaques and brain rhythms in 5BAD mice. 2021 , 10, 48	3
646	In vitro transcytosis of Helicobacter pylori histidine-rich protein through gastric epithelial-like cells and the blood-brain barrier.. 2021 ,	
645	No evidence of aberrant amyloid β and phosphorylated tau expression in herpes simplex virus-infected neurons of the trigeminal ganglia and brain.. 2021 , e13044	0
644	Towards mechanistic models of mutational effects: Deep Learning on Alzheimer's A β peptide.	0
643	Small Angle X-ray Scattering Sensing Membrane Composition: The Role of Sphingolipids in Membrane-Amyloid β Peptide Interaction.. 2021 , 11,	0
642	GlyCEST: Magnetic Resonance Imaging of Glycine-Distribution in the Normal Murine Brain and Alterations in 5xFAD Mice.. 2021 , 2021, 8988762	
641	STAT3 inhibitor mitigates cerebral amyloid angiopathy and parenchymal amyloid plaques while improving cognitive functions and brain networks.. 2021 , 9, 193	3
640	Design, synthesis, and evaluation of chalcone-Vitamin E-donepezil hybrids as multi-target-directed ligands for the treatment of Alzheimer's disease.. 2022 , 37, 69-85	4
639	China Registry Study on Cognitive Impairment in the Elderly: Protocol of a Prospective Cohort Study.. 2021 , 13, 797704	
638	Self-assembled nanochaperones enable the disaggregation of amyloid insulin fibrils. 2022 , 65, 353-362	0
637	BACE1 β but not BACE2 β function is critical for metabolic disorders induced by high-fat diets in C57BL/6N mice.	0
636	Nanocomposites Facilitate the Removal of A β Fibrils for Neuroprotection. 1	
635	Predicting Tau Accumulation in Cerebral Cortex with Multivariate MRI Morphometry Measurements, Sparse Coding, and Correntropy.. 2021 , 12088,	1
634	Lack of association between cortical amyloid deposition and glucose metabolism in early stage Alzheimer's disease patients.. 2021 ,	
633	Alzheimer's Disease: Current Perspectives and Advances in Physiological Modeling.. 2021 , 8,	1

- 632 Conformational Models of APP Processing by Gamma Secretase Based on Analysis of Pathogenic Mutations.. **2021**, 22, 0
- 631 Perspectives on the Role of as a Therapeutic Target for Alzheimer's Disease.. **2021**, 5, 899-910
- 630 Cellular and Molecular Mechanisms of Proinflammatory Monocytes Participation in the Pathogenesis of Mental Disorders. Part 3. **2021**, 19, 125-134
- 629 Rational Design of a Cu Chelator that Mitigates Cu-Induced ROS Production by Amyloid Beta. **2021**,
- 628 Amylin Pharmacology in Alzheimer's Disease Pathogenesis and Treatment. **2021**, 0
- 627 Ketogenic diet ameliorates cognitive impairment and neuroinflammation in a mouse model of Alzheimer's disease. **2021**, 5
- 626 Cross-Modality Generation of Amyloid PET from FDG PET for Alzheimer's Disease Diagnosis. **2021**, 1
- 625 Charged Tubular Supramolecule Boosting Multivalent Interactions for the Drastic Suppression of A β Fibrillation. **2021**, 0
- 624 Diet, Life Style and Immunity. 09-12
- 623 Presenilin 2 N141I mutation induces hyperactive immune response through the epigenetic repression of REV-ERB α . **2022**, 13, 1972 0
- 622 The Role of the Gut Microbiota and Microbial Metabolites in the Pathogenesis of Alzheimer's Disease.. **2022**, 0
- 621 Aberrant miR-339-5p/neuronatin signaling causes prodromal neuronal calcium dyshomeostasis in mutant presenilin mice.. **2022**, 132, 2
- 620 Recent Advances in the Treatment of Alzheimer's Disease Using Nanoparticle-Based Drug Delivery Systems.. **2022**, 14, 5
- 619 Clinical and Molecular Findings in a Turkish Family Who Had a (c.879-1G>A) Splicing Variant in PSEN1 Gene with A Rare Condition: The Variant Alzheimer's Disease with Spastic Paraparesis.. **2022**, 0
- 618 PSEN1 G417S mutation in a Chinese pedigree causing early-onset parkinsonism with cognitive impairment.. **2022**, 115, 70-76
- 617 Differentiating amyloid beta spread in autosomal dominant and sporadic Alzheimer's disease.
- 616 Altered peripheral factors affecting the absorption, distribution, metabolism, and excretion of oral medicines in Alzheimer's disease.. **2022**, 114282 1
- 615 Co-treatment with the herbal medicine SIP3 and donepezil improves memory and depression in the mouse model of Alzheimer's disease.. **2022**, 1

- 614 Neuroprotective Effects of PARP Inhibitors in Models of Alzheimer's Disease.. **2022**, 11, 1
- 613 Synthesis and Evaluation of Novel Ferulic Amide Derivatives and the Treatment of Alzheimer's Disease. **2022**, 7,
- 612 Hippocampal-subfield microstructures and their relation to plasma biomarkers in Alzheimer's disease.. **2022**, 0
- 611 Ziziphi Spinosae Semen: An updated review on pharmacological activity, quality control, and application.. **2022**, e14153 0
- 610 A Kinetic Map of the Influence of Biomimetic Lipid Membrane Models on A β 2 Aggregation.
- 609 Impairment of ciliary dynamics in an APP knock-in mouse model of Alzheimer's disease.. **2022**, 610, 85-91 1
- 608 Table_1.XLSX. **2020**,
- 607 Table_2.XLSX. **2020**,
- 606 Data_Sheet_1.pdf. **2020**,
- 605 Table_1.DOCX. **2020**,
- 604 DataSheet_1.docx. **2020**,
- 603 Table_1.XLSX. **2019**,
- 602 Data_Sheet_1.PDF. **2020**,
- 601 Data_Sheet_1.pdf. **2018**,
- 600 Data_Sheet_1.PDF. **2018**,
- 599 Data_Sheet_1.pdf. **2018**,
- 598 Table_1.DOCX. **2018**,
- 597 Data_Sheet_1.doc. **2019**,

596 Data_Sheet_1.PDF. 2019,

595 Data_Sheet_1.PDF. 2019,

594 Data_Sheet_2.PDF. 2019,

593 Data_Sheet_3.PDF. 2019,

592 Data_Sheet_4.PDF. 2019,

591 Data_Sheet_1.zip. 2019,

590 Table_1.DOCX. 2020,

589 Table_2.docx. 2020,

588 Table_1.pdf. 2019,

587 Data_Sheet_1.DOCX. 2020,

586 Data_Sheet_1.PDF. 2018,

585 Image_1.TIF. 2018,

584 Image_2.TIF. 2018,

583 Table_1.pdf. 2018,

582 Image_1.tiff. 2020,

581 Image_2.tiff. 2020,

580 Image_3.tiff. 2020,

579 Image_4.tiff. 2020,

578 Image_5.tiff. **2020**,

577 Image_6.tiff. **2020**,

576 Table_1.DOCX. **2020**,

575 Data_Sheet_1.pdf. **2018**,

574 Data_Sheet_1.docx. **2018**,

573 Data_Sheet_1.docx. **2018**,

572 Table_1.xlsx. **2018**,

571 Table_1.DOCX. **2020**,

570 Table_1.XLSX. **2020**,

569 Table_2.XLSX. **2020**,

568 Table_3.docx. **2020**,

567 Data_Sheet_1.docx. **2019**,

566 Data_Sheet_1.docx. **2019**,

565 Image_1.pdf. **2020**,

564 Image_2.pdf. **2020**,

563 Image_3.pdf. **2020**,

562 Table_1.pdf. **2020**,

561 Data_Sheet_1.docx. **2019**,

560 Table_1.xlsx. 2019,

559 Image_1.tif. 2019,

558 Image_1.TIF. 2019,

557 Image_2.TIF. 2019,

556 Table_1.docx. 2020,

555 Image_1.TIF. 2020,

554 Image_2.TIF. 2020,

553 Data_Sheet_1.docx. 2019,

552 Data_Sheet_1.PDF. 2018,

551 Data_Sheet_1.pdf. 2018,

550 Table_1.docx. 2019,

549 Image_1.TIF. 2020,

548 Image_2.TIF. 2020,

547 Image_3.TIF. 2020,

546 Image_4.TIF. 2020,

545 Image_5.TIF. 2020,

544 Image_6.TIF. 2020,

543 Table_1.XLSX. 2020,

542 DataSheet_1.docx. **2020**,

541 DataSheet_1.docx. **2020**,

540 Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment.. **2022**, 5, e228392 5

539 Biophysical characterization as a tool to predict amyloidogenic and toxic properties of amyloid- β peptides.. **2022**, 0

538 Design and Synthesis of Novel Dual Cholinesterase Inhibitors: In Vitro Inhibition Studies Supported with Molecular Docking.. **2022**, e202200015 0

537 Disease-Modifying Therapies for Alzheimer's Disease: More Questions than Answers.. **2022**, 1 2

536 The lateral entorhinal cortex is a hub for local and global dysfunction in early Alzheimer's disease states.. **2022**, 271678X221082016 0

535 Recent Trend of Nano-Particulate Carriers for the Diagnosis and Treatment of Alzheimer's disease.. **2022**,

534 [Progress on loss-of-function hypothesis of presenilin-1 mutations in Alzheimer diseases]. **2020**, 49, 487-499 1

533 Two statins and cromolyn as possible drugs against the cytotoxicity of A β (1-35) and A β (25-35) peptides: a comparative study by advanced computer simulation methods.. **2022**, 12, 13352-13366

532 Amyloid- β in Brain Aging and Alzheimer's Disease. **2022**, 335-354

531 Mitochondrial Dysfunction in Aging and Neurodegeneration. **2022**, 253-278

530 Combination Therapy in Alzheimer's Disease: Is It Time?. **2022**, 0

529 The Role of Extracellular Matrix Components in the Spreading of Pathological Protein Aggregates.. **2022**, 16, 844211 3

528 Blood Phosphorylated Tau 181 as a Biomarker for Amyloid Burden on Brain PET in Cognitively Healthy Adults.. **2022**,

527 Alzheimer's Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint.. **2022**, 16, 837390 0

526 Transcriptomics. **2022**, 133-161

525 Second Sphere Interactions in Amyloidogenic Diseases.. **2022**, 3

- 524 Amyloid-beta targeted therapeutic approaches for Alzheimer's disease: long road ahead.. **2022**, 0
- 523 Cannabidiol Enhances Microglial Beta-Amyloid Peptide Phagocytosis and Clearance via Vanilloid Family Type 2 Channel Activation. **2022**, 23, 5367 2
- 522 Transgenic Mouse Models of Alzheimer's Disease: An Integrative Analysis. **2022**, 23, 5404 2
- 521 Resilient Hippocampal Gamma Rhythmogenesis and Parvalbumin-Expressing Interneuron Function Before and After Plaque Burden in 5xFAD Alzheimer's Disease Model. **2022**, 14, 0
- 520 Cross-seeding between A β and SEVI indicates a pathogenic link and gender difference between alzheimer diseases and AIDS.. **2022**, 5, 417 2
- 519 Multifunctional Anti-Alzheimer's Disease Effects of Natural Xanthone Derivatives: A Primary Structure-Activity Evaluation. **2022**, 10, 1
- 518 Mechanism of NLRP3 inflammasome activation and its role in Alzheimer's disease. 229-244
- 517 Alzheimer's neuroinflammation: A crosstalk between immune checkpoint PD1-PDL1 and ApoE-Heparin interactions?. **2022**, 164, 110865
- 516 Immunity and Autoimmune system-a review. 03-07
- 515 Nontoxic silicene photothermal agents with high near-infrared absorption for disassembly of Alzheimer's amyloid-fibrils. **2022**, 112575 0
- 514 β Amyloid activates nitric oxide synthesis and causes neuronal death in hippocampal astrocytes. **2008**, 2, 8-13
- 513 Concomitant Retinal Alterations in Neuronal Activity and TNF β Pathway Are Detectable during the Pre-Symptomatic Stage in a Mouse Model of Alzheimer's Disease. **2022**, 11, 1650 1
- 512 Alzheimer disease neuropathology in a patient previously treated with aducanumab.. **2022**, 1
- 511 Rational Design of Quinoxalinone-Based Red-Emitting Probes for High-Affinity and Long-Term Visualizing Amyloid- β In Vivo.. **2022**, 3
- 510 A genome-wide association study for melatonin secretion.. **2022**, 12, 8025
- 509 Periodontitis as a Risk Factor for Alzheimer's Disease: The Experimental Journey So Far, with Hope of Therapy. **2022**, 241-260 0
- 508 Recombinant Integrin α 5 Signal Peptide Blocks Gliosis Induced by A β Oligomers. **2022**, 23, 5747 0
- 507 Protein interaction networks in neurodegenerative diseases: from physiological function to aggregation. **2022**, 102062 1

506	Aggregation-induced emission: An emerging concept in brain science. 2022 , 286, 121581	1
505	p-Coumaric acid mitigates passive avoidance memory and hippocampal synaptic plasticity impairments in aluminum chloride-induced Alzheimer's disease rat model. 2022 , 94, 105117	1
504	Thirty years post-injury: Impact of traumatic brain injury on later Alzheimer's disease. 2022 , 27-38	
503	Amyloid-Dependent and -Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease. 10.1212/WNL.0000000000200605	0
502	Partial Destabilization of Amyloid-Protofibril by Methionine Photo-oxidation: A Molecular Dynamic Simulation Study.	
501	Diagnostic, Prognostic, and Mechanistic Biomarkers of Diabetes Mellitus-Associated Cognitive Decline. 2022 , 23, 6144	2
500	Neurogenesis Is Increased in Human Neural Stem Cells by A β 0 Peptide. 2022 , 23, 5820	
499	Molecular details of aluminium-amyloid β peptide interaction by nuclear magnetic resonance.	
498	The Neuroprotective Effect of GM-1 Ganglioside on the Amyloid-Beta-Induced Oxidative Stress in PC-12 Cells Mediated by Nrf-2/ARE Signaling Pathway.	0
497	Mesenchymal Stem Cells Improve Cognitive Impairment and Reduce A β Deposition via Promoting AQP4 Polarity and Relieving Neuroinflammation in Rats With Chronic Hypertension-Induced Cerebral Small-Vessel Disease. 14,	
496	Non-Alcoholic Fatty Liver Disease: Does This Metabolic Condition Have Brain Function Sequelae?. 10.1212/WNL.00000000	
495	Ube2c-inhibition alleviated amyloid pathology and memory deficits in APP/PS1 mice model of AD. 2022 , 102298	0
494	Revisiting Preclinical Observations of Several Histamine H3 Receptor Antagonists/Inverse Agonists in Cognitive Impairment, Anxiety, Depression, and Sleep/Wake Cycle Disorder. 13,	1
493	N-terminally truncated A β -x proteoforms and their relevance for Alzheimer's pathophysiology. 2022 , 11,	0
492	Non-Coding RNAs as Novel Regulators of Neuroinflammation in Alzheimer's Disease. 13,	2
491	Phloroglucinol, a clinical-used antispasmodic, inhibits amyloid aggregation and degrades the pre-formed amyloid proteins. 2022 ,	
490	Neuroprotective Mechanisms of Ginsenoside Rb1 in Central Nervous System Diseases. 13,	1
489	Chemical analysis of amyloid aggregation inhibitors derived from Geranium thunbergii. 2022 , 68, 116840	

488	Site specific NMR characterization of abeta-40 oligomers cross seeded by abeta-42 oligomers.	1
487	Cerebral A β deposition in an A β precursor protein-transgenic rhesus monkey. 2022 , 2, 100044	1
486	Dual Functional Amphiphilic Sugar-Coated AIE-Active Fluorescent Organic Nanoparticles for the Monitoring and Inhibition of Insulin Amyloid Fibrillation Based on Carbohydrate-Protein Interactions.	0
485	Physiological Roles of Monomeric Amyloid- β and Implications for Alzheimer's Disease Therapeutics. 2022 , 31, 65-88	3
484	Inhibition Mechanisms of (E)-Epigallocatechin-3-gallate and Genistein on Amyloid-beta 42 Peptide of Alzheimer's Disease via Molecular Simulations. 2022 , 7, 19665-19675	1
483	14-3-3 γ Does Not Protect against Behavioral or Pathological Deficits in Alzheimer's Disease Mouse Models. 2022 , 9, ENEURO.0368-21.2022	
482	Modeling the Competition between Misfolded A β Conformers That Produce Distinct Types of Amyloid Pathology in Alzheimer's Disease. 2022 , 12, 886	
481	Current Progress on Neuroprotection Induced by Artemisia, Ginseng, Astragalus, and Ginkgo Traditional Chinese Medicines for the Therapy of Alzheimer's Disease. 2022 , 2022, 1-21	
480	CONCEPTUAL ADVANCEMENT: SOCIAL HEALTH AS A FACILITATOR IN THE USE OF COGNITIVE RESERVE.	0
479	Exploring the Involvement of the Amyloid Precursor Protein A673T Mutation against Amyloid Pathology and Alzheimer's Disease in Relation to Therapeutic Editing Tools. 2022 , 14, 1270	0
478	Non-classical glycosylation determines intracellular trafficking of APP and A β production.	
477	p38 MAPK Is a Major Regulator of Amyloid Beta-Induced IL-6 Expression in Human Microglia.	1
476	Therapeutic potential for amyloid surface inhibitor: only amyloid- β oligomers formed by secondary nucleation disrupt lipid membrane integrity.	0
475	Regional associations of white matter hyperintensities and early cortical amyloid pathology.	1
474	Far infrared light irradiation enhances A β clearance via increased exocytotic microglial ATP and ameliorates cognitive deficit in Alzheimer's disease-like mice. 2022 , 19,	2
473	Amyloid- β impairs mitochondrial dynamics and autophagy in Alzheimer's disease experimental models. 2022 , 12,	1
472	Inter-organellar Communication in Parkinson's and Alzheimer's Disease: Looking Beyond Endoplasmic Reticulum-Mitochondria Contact Sites. 16,	0
471	Ganglioside Nanocluster-Targeting Peptidyl Inhibitor Prevents Amyloid β Fibril Formation on the Neuronal Membrane.	0

- 470 Rational Design of a Theranostic Agent Triggered by Endogenous Nitric Oxide in a Cellular Model of Alzheimer's Disease. 0
- 469 The Role of Mesenchymal Stem Cells in Regulating Astrocytes-Related Synapse Dysfunction in Early Alzheimer's Disease. 16, 1
- 468 Insulin Deficiency Increases Sirt2 Level in Streptozotocin-Treated Alzheimer's Disease-Like Mouse Model: Increased Sirt2 Induces Tau Phosphorylation Through ERK Activation.
- 467 Blood BMP6 Associated with Cognitive Performance and Alzheimer's Disease Diagnosis: A Longitudinal Study of Elders. **2022**, 1-11 0
- 466 CDiP technology for reverse engineering of sporadic Alzheimer's disease.
- 465 Mouse Models of Alzheimer's Disease. 15, 1
- 464 B Lymphocytes in Alzheimer's Disease. A Comprehensive Review. **2022**, 1-22 1
- 463 Anesthésie du patient avec déficit cognitif. **2022**,
- 462 Insulin and Its Key Role for Mitochondrial Function/Dysfunction and Quality Control: A Shared Link between Dysmetabolism and Neurodegeneration. **2022**, 11, 943 1
- 461 Behavioral Abnormalities of Gut Microbiota and Progression of Dementia. **2022**, 273-309
- 460 Application of Declarative Programming in Neurobiology. **2022**, 216-221
- 459 CARs-DB: A Database of Cryptic Amyloidogenic Regions in Intrinsically Disordered Proteins. 9, 0
- 458 White matter pathology in Alzheimer's transgenic mice with chronic exposure to low-level ambient fine particulate matter. **2022**, 19, 0
- 457 Phytochemical Based Modulation of Endoplasmic Reticulum Stress in Alzheimer's Disease.. **2022**, 22, 1
- 456 The Interplay between cGMP and Calcium Signaling in Alzheimer's Disease. **2022**, 23, 7048 2
- 455 Protective effects of Liensinine, Isoliensinine, and Neferine on PC12 cells injured by amyloid- β
- 454 ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer's disease. 1-13 0
- 453 Possible Neuropathology of Sleep Disturbance Linking to Alzheimer's Disease: Astrocytic and Microglial Roles. 16, 0

- 452 Rationally Designed Molecules Synergistically Modulate Multifaceted A β Toxicity, Microglial Activation, and Neuroinflammation. 0
- 451 Targeting Microglia in Alzheimer's Disease: From Molecular Mechanisms to Potential Therapeutic Targets for Small Molecules. **2022**, 27, 4124 1
- 450 Peptidomic Approaches and Observations in Neurodegenerative Diseases. **2022**, 23, 7332
- 449 Polygenic risk score analysis identifies deleterious protein-coding variants in novel immune pathway genes ATP8B4, FCGR1A, and LILRB1 that associate with Alzheimer's disease.
- 448 Regulation of the Human IL-10RB Gene Expression by Sp8 and Sp9. **2022**, 1-17
- 447 Extraversion Is Associated With Lower Brain Beta-Amyloid Deposition in Cognitively Normal Older Adults. 14,
- 446 Hippocampal neural circuit connectivity alterations in an Alzheimer's disease mouse model revealed by monosynaptic rabies virus tracing. **2022**, 105820 0
- 445 Resolution exchange with tunneling for enhanced sampling of protein landscapes. **2022**, 106, 0
- 444 Repopulated microglia induce expression of Cxcl13 with differential changes in Tau phosphorylation but do not impact amyloid pathology. **2022**, 19, 2
- 443 Exploration of Isoquinoline Alkaloids as Potential Inhibitors against Human Islet Amyloid Polypeptide. 3
- 442 The association of serum uric acid with cognitive impairment and ATN biomarkers. 14, 0
- 441 Joint Computational/Cell-Based Oligomerization for Screening Inhibitors of Tau Assembly: A Proof-of-Concept Study. **2022**, 1-13 0
- 440 Insights Into the Role of Mortalin in Alzheimer's Disease, Parkinson's Disease, and HIV-1-Associated Neurocognitive Disorders. 10, 0
- 439 Aspartic Acid-Modified Phospholipids Regulate Cell Response and Rescue Memory Deficits in APP/PS1 Transgenic Mice.
- 438 Implementing a Scoring Function Based on Interaction Fingerprint for Autogrow4: Protein Kinase CK1 as a Case Study. 9, 4
- 437 Novel donepezil-chalcone-rivastigmine hybrids as potential multifunctional anti-Alzheimer's agents: Design, synthesis, in vitro biological evaluation, in vivo and in silico studies. **2022**, 127, 106007 3
- 436 Increased occurrence of Treponema spp. and double-species infections in patients with Alzheimer's disease. **2022**, 844, 157114 0
- 435 Mathematical model of Alzheimer's disease with prion proteins interactions and treatment. **2022**, 433, 127377 1

- 434 Genetic Inhibition of PDK1 Robustly Reduces Plaque Deposition and Ameliorates Gliosis in the 5EAD Mouse Model of Alzheimer's Disease. 0
- 433 Inhibition of Rac1 in ventral hippocampal excitatory neurons improves social recognition memory and synaptic plasticity. 14, 0
- 432 Seed-induced A β deposition alters neuronal function and impairs olfaction in a mouse model of Alzheimer's disease. 0
- 431 Assessments of Ceanothanes Triterpenes as Cholinesterase Inhibitors: An Investigation of Potential Agents with Novel Inspiration for Drug Treatment of Neurodegenerative Diseases. **2022**, 12, 668
- 430 Hallmarks of Neurodegenerative Disease: A Systems Pharmacology Perspective. 0
- 429 miR-143-3p Inhibits Aberrant Tau Phosphorylation and Amyloidogenic Processing of APP by Directly Targeting DAPK1 in Alzheimer's Disease. **2022**, 23, 7992 3
- 428 Early β amyloid accumulation and hypoconnectivity in the default mode network are related to its disengagement from global brain activity. 0
- 427 Coumarin derivatives against amyloid-beta 40 β 42 peptide and tau protein. **2022**,
- 426 Molecular signatures underlying neurofibrillary tangle susceptibility in Alzheimer's disease. **2022**, 1
- 425 Epigenetic Peripheral Biomarkers for Early Diagnosis of Alzheimer's Disease. **2022**, 13, 1308 2
- 424 Novel coumarin derivatives as multifunctional anti-AD agents: Design, synthesis, X-ray crystal structure and biological evaluation. **2022**, 1268, 133747 0
- 423 Relationship between Brain Metabolic Disorders and Cognitive Impairment: LDL Receptor Defect. **2022**, 23, 8384 1
- 422 Effects of Aducanumab on treating Alzheimer's disease: targets and clinical trials. 6, 292-301
- 421 Pleiotropic roles of evolutionarily conserved signaling intermediate in toll pathway (ECSIT) in pathophysiology. 0
- 420 β secretase inhibition prevents structural spine plasticity deficits in AppNL-G-F mice. 14, 1
- 419 Oxidative Stress: Glutathione and Its Potential to Protect Methionine-35 of A β Peptide from Oxidation. **2022**, 7, 27052-27061 1
- 418 SorCS1 inhibits amyloid- β binding to neurexin and rescues amyloid- β induced synaptic pathology.
- 417 An Alzheimer's disease patient-derived olfactory cell model identifies gene expression changes associated with cognition.

- 416 The Potential of Small Molecules to Modulate the Mitochondria-Endoplasmic Reticulum Interplay in Alzheimer's Disease. 10, 0
- 415 A β 2 oligomers can seed the fibrillization of A β 40 peptides.
- 414 Moxifloxacin Disrupts and Attenuates A β 2 Fibril and Oligomer Formation: Plausibly Repositioning an Antibiotic as Therapeutic against Alzheimer's Disease. **2022**, 13, 2529-2539 0
- 413 Rational Design, Synthesis of Fluorescence Probes for Quantitative Detection of Amyloid- β in Alzheimer's Disease Based on Rhodamine-Metal Complex.
- 412 Brain ethanolamine phospholipids, neuropathology and cognition: A comparative post-mortem analysis of structurally specific plasmalogen and phosphatidyl species. 10,
- 411 Farnesyltransferase inhibitor LNK-754 attenuates axonal dystrophy and reduces amyloid pathology in mice. **2022**, 17, 0
- 410 Binding Models of A β 2 Peptide with Membranes Explored by Molecular Simulations. 2
- 409 Peptide backbone-copper ring structure: A molecular insight into copper-induced amyloid toxicity. 0
- 408 Correlations between APOE4 allele and regional amyloid and tau burdens in cognitively normal older individuals. **2022**, 12, 0
- 407 Prediction of Aggregation of Biologically-Active Peptides with the UNRES Coarse-Grained Model. **2022**, 12, 1140 0
- 406 Stable Cavitation Interferes with A β 62 Oligomerization. **2022**, 62, 3885-3895 1
- 405 EGCG promotes A β clearance of microglia through blockage of the HDAC6-PI3K/AKT/mTOR signalling axis followed by autophagy activation.
- 404 Targeting GRK2 and GRK5 for treating chronic degenerative diseases: Advances and future perspectives. **2022**, 114668 0
- 403 Atypical Alzheimer's disease phenotypes with normal or borderline PET biomarker profiles. 0
- 402 cAMP -induced decrease in cell-surface laminin receptor and cellular prion protein attenuates amyloid- β uptake and amyloid- β induced neuronal cell death.
- 401 Oral microbiome and serological analyses on association of Alzheimer's disease and periodontitis. 0
- 400 Elevated Levels of Naturally-Occurring Autoantibodies Against the Extracellular Domain of p75NTR Aggravate the Pathology of Alzheimer's Disease.
- 399 Alzheimer's Amyloid- β Accelerates Cell Senescence and Suppresses the SIRT1/NRF2 Pathway in Human Microglial Cells. **2022**, 2022, 1-17 0

- 398 Enhancing the Amyloid- β Anti-Aggregation Properties of Curcumin via Arene-Ruthenium(II) Derivatization. **2022**, 23, 8710 2
- 397 The emerging role of furin in neurodegenerative and neuropsychiatric diseases. **2022**, 11, 2
- 396 Virtual screening and molecular dynamics study of natural products against Rab10 for the treatment of Alzheimer's disease. 1-21
- 395 Neuropharmacology in Alzheimer and Huntington Disease. **2022**, 218-260
- 394 Redox Active β -Lipoic Acid Differentially Improves Mitochondrial Dysfunction in a Cellular Model of Alzheimer and Its Control Cells. **2022**, 23, 9186 0
- 393 Tachykinin Neuropeptides and Amyloid β (25-35) Assembly: Friend or Foe?. **2022**, 144, 14614-14626 0
- 392 Early Changes in Transcriptomic Profiles in Synaptodendrosomes Reveal Aberrant Synaptic Functions in Alzheimer's Disease. **2022**, 23, 8888
- 391 Dual PET-fMRI reveals a link between neuroinflammation, amyloid binding and compensatory task-related brain activity in Alzheimer's disease. **2022**, 5,
- 390 International Nuclear Medicine Consensus on the Clinical Use of Amyloid Positron Emission Tomography in Alzheimer's Disease.
- 389 Clinical Significance of EZH2 in Acute Myeloid Leukemia. **2022**, 2022, 1-5 0
- 388 Spatial Extent of Amyloid- β Levels and Associations With Tau-PET and Cognition. 0
- 387 Dimethyl Itaconate Reduces Cognitive Impairment and Neuroinflammation in APP^{swe}/PS1^{E9} Transgenic Mouse Model of Alzheimer's Disease. 1
- 386 Endophenotypic effects of the SORL1 variant rs2298813 on regional brain volume in patients with late-onset Alzheimer's disease. 14,
- 385 Linking glycosphingolipids to Alzheimer's amyloid- β extracellular vesicles and functional plant materials. 1
- 384 Glutaminy cyclases, the potential targets of cancer and neurodegenerative diseases. **2022**, 931, 175178
- 383 Anti-Alzheimer's disease potential of traditional chinese medicinal herbs as inhibitors of BACE1 and AChE enzymes. **2022**, 154, 113576 1
- 382 Synthesis and biological evaluation of 4-hydroxy-methylpiperidinyl-N-benzyl-acylarylhydrazone hybrids designed as novel multifunctional drug candidates for Alzheimer's disease. **2022**, 71, 116952 0
- 381 Comparative efficacy of lithium and aducanumab for cognitive decline in patients with mild cognitive impairment or Alzheimer's disease: A systematic review and network meta-analysis. **2022**, 81, 101709 2

- 380 MOF-derived N-doped porous carbon with active magnesium sites as an efficient oxidase mimic for biosensing. **2022**, 370, 132409 1
- 379 Deciphering the enigmatic crosstalk between prostate cancer and Alzheimer's disease: A current update on molecular mechanisms and combination therapy. **2022**, 1868, 166524
- 378 Neuronal network-based biomimetic chip for long-term detection of olfactory dysfunction model in early-stage Alzheimer's disease. **2022**, 216, 114619
- 377 Recent advances of small molecule JNK3 inhibitors for Alzheimer's disease. **2022**, 128, 106090 0
- 376 Longitudinal change in ATN biomarkers in cognitively normal individuals. **2022**, 14, 0
- 375 Iron in Alzheimer's Disease: From Physiology to Disease Disabilities. **2022**, 12, 1248 2
- 374 A systematic review on drugs for synaptic plasticity in the treatment of dementia. **2022**, 81, 101726 1
- 373 The role of LRP1 in A β efflux transport across the blood-brain barrier and cognitive dysfunction in diabetes mellitus. **2022**, 160, 105417 0
- 372 Membrane estrogen receptor ER α activation improves tau clearance via autophagy induction in a tauopathy cell model. **2022**, 1795, 148079 1
- 371 Influence of genetic and cardiometabolic risk factors in Alzheimer's disease. **2022**, 81, 101723 1
- 370 Rational design of molecular rotor-based fluorescent probes with bi-aromatic rings for efficient in vivo detection of amyloid- β plaques in Alzheimer's disease. **2022**, 243, 114715 0
- 369 Bidirectional associations of intellectual and social activities with cognitive function among middle-aged and elderly adults in China. **2022**, 319, 83-89 0
- 368 Discovery of potent and selective dual cholinesterases and β secretase inhibitors in pomegranate as a treatment for Alzheimer's disease. **2022**, 129, 106137 1
- 367 Knockdown of astrocytic Grin2a exacerbated sleep deprivation-induced cognitive impairments and elevation of amyloid-beta. **2022**, 100, 280-290 0
- 366 Biomarkers in cerebrospinal fluid and blood aid diagnosis of dementia. **2023**, 47-68 0
- 365 Peptide-based nanomaterials: applications and challenges. **2023**, 133-171 0
- 364 A Pilot Study of Whole-Brain Low-Intensity Pulsed Ultrasound Therapy for Early Stage of Alzheimer's Disease (LIPUS-AD): A Randomized, Double-Blind, Placebo-Controlled Trial. **2022**, 1 1
- 363 Blood-Brain barrier (BBB)-on-a-chip: a promising breakthrough in brain disease research. **2022**, 22, 3579-3602 1

362	The Microbiome and Mental Health Across the Lifespan. 2022,	0
361	Applications of metalphenolic networks in nanomedicine: a review.	0
360	Endocytosis in amyloid biology and Alzheimer disease. 2022, 111-131	0
359	Dementia Prevention and Aromatherapy in Japan. 2022, 65, 184-190	0
358	Adenosine. 2022, 45-71	0
357	The destructive mechanism of A β 25 protofibrils by norepinephrine revealed via molecular dynamics simulations. 2022, 24, 19827-19836	2
356	Heme/Cu-oxygen intermediates of amyloid peptides associated with Alzheimer's disease. 2022,	0
355	Basics of amyloid protein in Alzheimer disease. 2022, 73-89	0
354	Combined Treatment with Curcumin and Ferulic Acid Suppressed the A β -Induced Neurotoxicity More than Curcumin and Ferulic Acid Alone. 2022, 23, 9685	0
353	Apolipoprotein E in Cardiometabolic and Neurological Health and Diseases. 2022, 23, 9892	3
352	Recently Reported Ru-Metal Organic Coordination Complexes and Their Application (A Review). 2022, 92, 1546-1561	0
351	Evidence for the Existence of a Bacterial Etiology for Alzheimer Disease and for a Temporal-Spatial Development of a Pathogenic Microbiome in the Brain.	0
350	Controversial Effects of Diverse Types of Toxoplasma gondii on the Anxiety-like Behavior and Cognitive Impairments in the Animal Model of Alzheimer's Disease. 2022, 16,	0
349	Cellular transcriptional alterations of peripheral blood in Alzheimer disease. 2022, 20,	0
348	IL-37 expression reduces acute and chronic neuroinflammation and rescues cognitive impairment in an Alzheimer disease mouse model. 11,	1
347	Structural Scaffolds as Anti- Alzheimer Agents. 2022, 18,	0
346	Precocious emergence of cognitive and synaptic dysfunction in 3xTg-AD mice exposed prenatally to ethanol. 2022,	0
345	A Machine LearningBased Approach to Discrimination of Tauopathies Using [18 F] PM-PBB3 PET Images.	1

344	Expression Changes in Mitochondrial Genes Affecting Mitochondrial Morphology, Transmembrane Potential, Fragmentation, Amyloidosis, and Neuronal Cell Death Found in Brains of Alzheimer's Disease Patients. 2022 , 1-19	0
343	Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals.	0
342	Elevating microglia TREM2 reduces amyloid seeding and suppresses disease-associated microglia. 2022 , 219,	0
341	Pin1 and Alzheimer's Disease. 2022 ,	0
340	Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease.	2
339	Distribution of cortical atrophy associated with cognitive decline in Alzheimer's disease: a cross-sectional quantitative structure MRI study from PUMCH dementia cohort. 2022 , 19,	0
338	Comparative analysis of transcriptome remodeling in plaque-associated and plaque-distant microglia during amyloid- β pathology progression in mice. 2022 , 19,	0
337	Elevated ganglioside GM2 activator (GM2A) in human brain tissue reduces neurite integrity and spontaneous neuronal activity. 2022 , 17,	0
336	Identifying the Template for Oligomer to Fibril Conversion for Amyloid- β (1-42) Oligomers using Hamiltonian Replica Exchange Molecular Dynamics.	0
335	Effects of a plant cyclotide on conformational dynamics and destabilization of β amyloid fibrils through molecular dynamics simulations. 9,	0
334	Photobiomodulation for Hypertension and Alzheimer's Disease. 2022 , 1-10	2
333	Optimization of the Linker Length in the Dimer Model of E22P- $\text{A}\beta$ 0 Tethered at Position 38. 2022 , 13, 2913-2923	0
332	The Role of Glymphatic System in Alzheimer's and Parkinson's Disease Pathogenesis. 2022 , 10, 2261	2
331	Predicting conversion of brain β amyloid positivity in amyloid-negative individuals. 2022 , 14,	0
330	Genetic, clinical underpinnings of subtle early brain change along Alzheimer's dimensions.	0
329	MicroRNA-650 regulates the pathogenesis of Alzheimer's Disease through targeting Cyclin-Dependent Kinase 5.	0
328	How can secondary dementia prevention trials of Alzheimer's disease be clinically meaningful?.	0
327	Genetics, Functions, and Clinical Impact of Presenilin-1 (PSEN1) Gene. 2022 , 23, 10970	1

326	Near-Infrared Photothermally Enhanced Photo-Oxygenation for Inhibition of Amyloid- β Aggregation Based on RVG-Conjugated Porphyrinic Metal-Organic Framework and Indocyanine Green Nanoplatform. 2022 , 23, 10885	3
325	Combination therapy for the treatment of Alzheimer's disease: recent progress and future prospects. 2022 , 22,	1
324	Graphene quantum dots as a potential diagnostic and therapeutic tool for the management of Alzheimer's disease.	3
323	Synthesizing Images of Tau Pathology from Cross-modal Neuroimaging using Deep Learning.	0
322	Effects of Simvastatin on Plasma Amyloid- β Transport in Patients with Hyperlipidemia: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial. 2022 , 1-14	0
321	Building in vitro models of the brain to understand the role of APOE in Alzheimer's disease. 2022 , 5, e202201542	0
320	Human antimicrobial peptide LL-37 contributes to Alzheimer's disease progression.	0
319	Gene-Environment interactions in Alzheimer disease: the emerging role of epigenetics.	3
318	BACE1 Aptamer-Modified Tetrahedral Framework Nucleic Acid to Treat Alzheimer's Disease in an APP-PS1 Animal Model. 2022 , 14, 44228-44238	1
317	A Haptoglobin (HP) Structural Variant Alters the Effect of APOE Alleles on Alzheimer's Disease.	0
316	Clinical relevance of biomarkers, new therapeutic approaches, and role of post-translational modifications in the pathogenesis of Alzheimer's disease. 14,	0
315	HSPA1A, HSPA2, and HSPA8 Are Potential Molecular Biomarkers for Prognosis among HSP70 Family in Alzheimer's Disease. 2022 , 2022, 1-16	1
314	Cognition-enhancing effect of YL-IPA08, a potent ligand for the translocator protein (18 kDa) in the 5 FAD transgenic mouse model of Alzheimer's pathology. 2022 , 36, 1176-1187	0
313	Interleukin 22 and its association with neurodegenerative disease activity. 13,	0
312	Astrocytes regulate neuronal network activity by mediating synapse remodeling. 2022 ,	0
311	A β PP family member dimeric complexes are formed predominantly in synaptic compartments	0
310	Patlak plot based on the first 30 minutes post-injection dynamic 18F-florbetaben positron emission tomography scan separates amyloid- β positive from negative studies.	0
309	Altered CD8+ T cell associated aging gene signature in the peripheral blood of patients with Alzheimer's disease	0

- 308 Microglial hexokinase 2 deficiency increases ATP generation through lipid metabolism leading to amyloid clearance. 0
- 307 Targeting the cannabinoid system to counteract the deleterious effects of stress in Alzheimer's disease. 14, 0
- 306 Environmental exposure to metals and the development of tauopathies, synucleinopathies, and TDP-43 proteinopathies: A systematic evidence map protocol. **2022**, 169, 107528 0
- 305 Inflamasi dalam Patologi Penyakit Alzheimer. **2020**, 33, 65-71 0
- 304 Gray matter network properties show distinct associations with CSF p-tau 181 levels and amyloid status in individuals without dementia. **2022**, 2, 100054 0
- 303 Getting drugs to the brain: advances and prospects of organic nanoparticle delivery systems for assisting drugs to cross the blood-brain barrier. 0
- 302 Big dynorphin is a neuroprotector scaffold against amyloid peptide aggregation and cell toxicity. **2022**, 20, 5672-5679 1
- 301 Amphiphilic stilbene derivatives attenuate the neurotoxicity of soluble A β 2 oligomers by controlling their interactions with cell membranes. 0
- 300 Telomere-induced senescence increases aberrant intraneuronal amyloid- β accumulation by impairing autophagy in a mouse model of Alzheimer's disease. 0
- 299 Roles of ZnT86D in Neurodevelopment and Pathogenesis of Alzheimer Disease in a *Drosophila melanogaster* Model. **2022**, 23, 11832 0
- 298 Exercise Training Prevents the Loss of Wall Thickness and Lowers Expression of Alzheimer's Related Proteins in 3xTg Mouse Jejunum. **2022**, 19, 14164 0
- 297 Advances in the roles and mechanisms of lignans against Alzheimer's disease. 13, 0
- 296 Gradual cerebral hypoperfusion in a knock-in mouse model of Alzheimer's disease triggers cortical network dysfunctions. 0
- 295 Tetrandrine ameliorates cognitive deficits and mitigates tau aggregation in cell and animal models of tauopathies. **2022**, 29, 2 2
- 294 Alzheimer's disease-associated U1 snRNP splicing dysfunction causes neuronal hyperexcitability and cognitive impairment. **2022**, 2, 923-940 0
- 293 The role of sleep deprivation in streptozotocin-induced Alzheimer's disease-like sporadic dementia in rats with respect to the serum level of oxidative and inflammatory markers. 0
- 292 Predictive Network Analysis Identifies JMJD6 and Other Novel Key Drivers in Alzheimer's Disease. 0
- 291 Alzheimer's Disease: Challenges and a Therapeutic Opportunity to Treat It with a Neurotrophic Compound. **2022**, 12, 1409 0

- 290 Directed functional brain connectivity is altered in sub-threshold amyloid- β accumulators. 0
- 289 Insights into Molecular Mechanisms of EGCG and Apigenin on Disrupting Amyloid-Beta Protofibrils Based on Molecular Dynamics Simulations. **2022**, 126, 8155-8165 0
- 288 Stochastic kinetic study of protein aggregation and molecular crowding effects of A β 0 and A β 2. 0
- 287 Alzheimer's Disease: From Immune Homeostasis to Neuroinflammatory Condition. **2022**, 23, 13008 3
- 286 Multifunctional Carbon-Dot-Photosensitizer Nanoassemblies for Inhibiting Amyloid Aggregates, Suppressing Microbial Infection, and Overcoming the Blood-Brain Barrier. **2022**, 14, 47432-47444 1
- 285 Lecanemab, Aducanumab, and Gantenerumab Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease. 4
- 284 An Alzheimer's Disease Patient-Derived Olfactory Stem Cell Model Identifies Gene Expression Changes Associated with Cognition. **2022**, 11, 3258 0
- 283 An update on the novel and approved drugs for Alzheimer disease. **2022**, 2 0
- 282 Early Aggregation of Amyloid- β (142) Studied by Fluorescence Correlation Spectroscopy. **2023**, 1-14 0
- 281 Altered serum amyloid beta and cerebral perfusion and their associations with cognitive function in patients with subcortical ischemic vascular disease. 16, 0
- 280 The significance of glycolysis index and its correlations with immune infiltrates in Alzheimer's disease. 13, 0
- 279 Neuroprotective effects of donepezil against A β 5-35-induced neurotoxicity. **2022**, 27, 0
- 278 Familial Early-Onset Alzheimer's Caused by Novel Genetic Variant and APP Duplication: A Cross-Sectional Study. **2022**, 20, 0
- 277 Cholinergic basal forebrain degeneration due to sleep-disordered breathing exacerbates pathology in a mouse model of Alzheimer's disease. **2022**, 13, 1
- 276 Functional insights from targeted imaging BACE1 : The first near-infrared fluorescent probe for Alzheimer's disease diagnosis. 0
- 275 Transcranial Deep-tissue Phototherapy for Alzheimer's Disease using Low-Dose X-ray-Activated Long-Afterglow Scintillators. **2022**, 0
- 274 Small-molecule drugs development for Alzheimer's disease. 14, 0
- 273 Inhibition of Amyloid Protein Aggregation Using Selected Peptidomimetics. 1

- 272 Treatment of Alzheimer's disease with small-molecule photosensitizers. **2022**, 107966 0
- 271 Solid state synthesis of bispyridyl-ferrocene conjugates with unusual site selective 1,4-Michael addition, as potential inhibitor and electrochemical probe for fibrillation in amyloidogenic protein. **2023**, 1273, 134362 0
- 270 Anti-dementia Medications and Anti-Alzheimer's Disease Drugs: Side Effects, Contraindications, and Interactions. **2022**, 2779-2788 0
- 269 Anti-dementia Medications: Pharmacology and Biochemistry. **2022**, 2649-2664 0
- 268 Hypothesis on ontogenesis and pathophysiology of Alzheimer's disease. **2022**, 20, 0
- 267 Amyloidogenesis: What Do We Know So Far?. **2022**, 23, 13970 2
- 266 Aggregation controlled by condensate rheology. **2022**, 0
- 265 Design, Synthesis, and Biological Evaluation of Novel Chromanone Derivatives as Multifunctional Agents for the Treatment of Alzheimer's Disease. 0
- 264 Intranasally Co-administered Berberine and Curcumin Loaded in Transfersomal Vesicles Improved Inhibition of Amyloid Formation and BACE-1. 0
- 263 Polyunsaturated Fatty Acids Mend Macrophage Transcriptome, Glycome, and Phenotype in the Patients with Neurodegenerative Diseases, Including Alzheimer's Disease. **2022**, 1-18 0
- 262 Childhood lead exposure is associated with lower cognitive functioning at older ages. **2022**, 8, 0
- 261 Monitoring Amyloidogenesis with a 3D Deep-Learning-Guided Biolaser Imaging Array. 1
- 260 Protein conformation characterization via a silicon resonator-based optical sensor based on the combination of wavelength interrogation and dual polarization detection. 0
- 259 Long-Term Repeatable In Vivo Monitoring of Amyloid- β Plaques and Vessels in Alzheimer's Disease Mouse Model with Combined TPEF/CARS Microscopy. **2022**, 10, 2949 0
- 258 Emerging roles of innate and adaptive immunity in Alzheimer's disease. **2022**, 1
- 257 Distinct brain pathologies associated with Alzheimer's disease biomarker-related phospho-tau 181 and phospho-tau 217 in App knock-in mouse models of amyloid- β amyloidosis. 0
- 256 *Holothuria scabra* extracts confer neuroprotective effect in *C. elegans* model of Alzheimer's disease by attenuating amyloid- β aggregation and toxicity. **2022**, 0
- 255 Whole-brain microscopy reveals distinct temporal and spatial efficacy of anti-A β therapies. 0

- 254 Therapeutic Potential of Targeting Mitochondria for Alzheimer's Disease Treatment. **2022**, 11, 6742 ○
- 253 Ginsenoside Rg1 alleviates learning and memory impairments and A β disposition through inhibiting NLRP1 inflammasome and autophagy dysfunction in APP/PS1 mice. **2022**, 27, ○
- 252 Nanozymes in the Treatment of Diseases Caused by Excessive Reactive Oxygen Specie. Volume 15, 6307-6328 1
- 251 Natural product-based pharmacological studies for neurological disorders. 13, 1
- 250 Co-aggregation with Apolipoprotein E modulates the function of Amyloid- β in Alzheimer's disease. ○
- 249 Proteomic mapping reveals dysregulated angiogenesis in the cerebral arteries of rats with early-onset hypertension. ○
- 248 Intermittent fasting protects against Alzheimer's disease in mice by altering metabolism through remodeling of the gut microbiota. **2022**, 2, 1024-1039 ○
- 247 Endocannabinoid System Biomarkers in Alzheimer's Disease. ○
- 246 C3N Nanodots Impede A β Peptides Aggregation Pathogenic Path in Alzheimer's Disease. ○
- 245 Natural products as sources of acetylcholinesterase inhibitors: Synthesis, biological activities, and molecular docking studies of osthole-based ester derivatives. 13, ○
- 244 Role of amyloid beta (25 β 5) neurotoxicity in the ferroptosis and necroptosis as modalities of regulated cell death in Alzheimer's disease. **2023**, 94, 71-86 ○
- 243 Deep mutational scanning to probe specificity determinants in proteins. **2023**, 31-71 ○
- 242 The application of the Fischer indole synthesis in medicinal chemistry. **2022**, ○
- 241 Cationic Amphiphilic Peptide Chaperone Rescues A β 2 Aggregation and Cytotoxicity. ○
- 240 Carrier-free Chinese herbal small molecules self-assembly with 3D-porous crystal framework as a synergistic anti-AD agent. **2023**, 630, 122458 ○
- 239 Discriminative patterns of white matter changes in Alzheimer's. **2023**, 328, 111576 ○
- 238 Effects of diverse Types of Toxoplasma gondii on the outcome of Alzheimer's disease in the rat model. **2023**, 174, 105931 ○
- 237 Inhibitory effects of fluorinated benzenesulfonamides on insulin fibrillation. **2023**, 227, 590-600 1

- 236 Intercommunication between metal ions and amyloidogenic peptides or proteins in protein misfolding disorders. **2023**, 478, 214978 ○
- 235 Application of aminobenzoic acid electrodeposited screen-printed carbon electrode in the beta-amyloid electrochemical impedance spectroscopy immunoassay. **2023**, 254, 124154 ○
- 234 Longitudinal CSF Alzheimer's disease biomarker changes from middle age to late adulthood. **2022**, 14, ○
- 233 Amyloid Cascade Hypothesis for the Treatment of Alzheimer's Disease: Progress and Challenges. **2022**, 13, 1745 1
- 232 Spin state dependent peroxidase activity of heme bound amyloid β peptides relevant to Alzheimer's disease. **2022**, 13, 14305-14319 ○
- 231 The CircRNAs for Diagnostic, Prognostic, and Therapy in Alzheimer's Disease. **2022**, 13, 507-526 ○
- 230 Improved Prediction of Amyloid- β and Tau Burden Using Hippocampal Surface Multivariate Morphometry Statistics and Sparse Coding. **2022**, 1-15 ○
- 229 Neuroprotective Properties of Eudesmin on a Cellular Model of Amyloid- β Peptide Toxicity. **2022**, 1-12 ○
- 228 Nutritional and Pharmaceutical Applications of Under-Explored Knottin Peptide-Rich Phytomedicines. **2022**, 11, 3271 ○
- 227 A Review of the Recent Advances in Alzheimer's Disease Research and the Utilization of Network Biology Approaches for Prioritizing Diagnostics and Therapeutics. **2022**, 12, 2975 1
- 226 Efficacy and safety of hypoglycemic drugs in improving cognitive function in patients with Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis. **2022**, 13, ○
- 225 Increase in Tau Pathology in P290SMaptKnock-In Mice Crossed with AppNL-G-FMice. **2022**, 9, ENEURO.0247-22.2022 ○
- 224 Experimental evidence for temporal uncoupling of brain A β deposition and neurodegenerative sequelae. **2022**, 13, ○
- 223 The role of β sheet structure in amyloidogenesis: characterization and implications. **2022**, 12, ○
- 222 Linking Cerebrovascular Dysfunction to Age-Related Hearing Loss and Alzheimer's Disease: Are Systemic Approaches for Diagnosis and Therapy Required?. **2022**, 12, 1717 ○
- 221 Differential compartmentalization of myeloid cell phenotypes and responses towards the CNS in Alzheimer's disease. **2022**, 13, ○
- 220 dNAGLU Extends Life Span and Promotes Fitness and Stress Resistance in Drosophila. **2022**, 23, 14433 ○
- 219 Development of Alkaline Phosphatase-Fused Mouse Prion Protein and Its Application in Toxic A β Oligomer Detection. **2022**, 23, 14588 ○

218	Research Evidence of the Role of the Glymphatic System and Its Potential Pharmacological Modulation in Neurodegenerative Diseases. 2022 , 11, 6964	0
217	Benefit and safety of antibiotics for Alzheimer's disease: Protocol for a systematic review and meta-analysis. 2022 , 101, e31637	0
216	Race, polygenic risk and their association with incident dementia among older US adults. 2022 , 4,	0
215	Concentration Effect, Structural Properties, and Driving Force on A β 8 Dimerization with and without Zn 2+ Cooperation: Learning from Replica Exchange Sampling**.	0
214	New Insights into lncRNAs in A β Cascade Hypothesis of Alzheimer's Disease. 2022 , 12, 1802	0
213	Neuroinflammation is independently associated with brain network dysfunction in Alzheimer's disease.	0
212	Type 2 Diabetes Mellitus and Alzheimer's Disease: Shared Molecular Mechanisms and Potential Common Therapeutic Targets. 2022 , 23, 15287	2
211	APOE Allele Frequency in Southern Greece: Exploring the Role of Geographical Gradient in the Greek Population. 2023 , 8, 1	0
210	Journeying to Ixtlan: Ethics of Psychedelic Medicine and Research for Alzheimer's Disease and Related Dementias. 1-17	0
209	Recognition of social health: A conceptual framework in the context of dementia research. 13,	1
208	Molecular Basis of Role of Insulin Resistance in Pathophysiology of Alzheimer's Disease. 200-219	0
207	The Interaction Between NF- κ B and Estrogen in Alzheimer's Disease.	1
206	Recent advances in characterization of citrullination and its implication in human disease research: From method development to network integration. 2200286	0
205	Capillary dysfunction correlates with cortical amyloid load in early Alzheimer's Disease. 2022 ,	0
204	Therapeutic modulation of JAK-STAT, mTOR, and PPAR- γ signaling in neurological dysfunctions.	0
203	Vitamin D in Neurological Diseases. 2023 , 24, 87	0
202	Molecular tweezers - supramolecular hosts with broad-spectrum biological applications. PHARMREV-AR-2022-000654	0
201	Oligomer Formation by Amyloid- β 2 in a Membrane-Mimicking Environment in Alzheimer's Disease. 2022 , 27, 8804	0

- 200 N-Substituted piperidine-3-carbohydrazide-hydrazones against Alzheimer's disease: Synthesis and evaluation of cholinesterase, beta-amyloid inhibitory activity, and antioxidant capacity. 0
- 199 Intracellular and intercellular transport of RNA organelles in CXG repeat disorders: The strength of weak ties. 9, 0
- 198 Blood-Brain barrier penetrating neprilysin degrades monomeric amyloid-beta in a mouse model of Alzheimer's disease. **2022**, 14, 0
- 197 Alignment of Human Aquaporin 4 and beta-amyloid proteins may indicate involvement of beta-amyloid in prevention of brain edema. 0
- 196 Sexual Dimorphism in Neurodegenerative Diseases and in Brain Ischemia. **2023**, 13, 26 2
- 195 Disease-Modifying Activity of Huperzine A on Alzheimer's Disease: Evidence from Preclinical Studies on Rodent Models. **2022**, 23, 15238 0
- 194 Regenerative medicine improve neurodegenerative diseases. 0
- 193 Action of the purinergic and cholinergic anti-inflammatory pathways on oxidative stress in patients with Alzheimer's disease in the context of the COVID-19 pandemic. **2022**, 0
- 192 MiR-191-5p Attenuates Tau Phosphorylation, A β Generation, and Neuronal Cell Death by Regulating Death-Associated Protein Kinase 1. **2022**, 13, 3554-3566 1
- 191 Role of Tau in Various Tauopathies, Treatment Approaches, and Emerging Role of Nanotechnology in Neurodegenerative Disorders. 0
- 190 Epigallocatechin gallate-derived carbonized polymer dots: A multifunctional scavenger targeting Alzheimer's β amyloid plaques. **2022**, 0
- 189 Functional insights from targeted imaging BACE1: the first near-infrared fluorescent probe for Alzheimer's disease diagnosis. **2022**, 26, 0
- 188 De Novo Transmembrane Aggregation of A β 100 Peptides in an Anionic Lipid Bilayer. **2022**, 62, 6228-6241 0
- 187 Vascular contributions to Alzheimer's disease. **2022**, 1
- 186 Emerging point-of-care autologous cellular therapy using adipose-derived stromal vascular fraction for neurodegenerative diseases. **2022**, 12, 0
- 185 Alzheimer's Disease: Clinical Trials and the Amyloid Hypothesis. **2011**, 40, 304-306 0
- 184 Experimental Approach to Alzheimer's Disease with Emphasis on Insulin Resistance in the Brain. **2022**, 1657-1708 0
- 183 Development of monoclonal antibody therapeutics for alzheimer's disease. **2022**, 36, 148 0

- 182 Ageing at Molecular Level: Role of MicroRNAs. **2023**, 195-248
- 181 Zebrafish: A Model Deciphering the Impact of Flavonoids on Neurodegenerative Disorders. **2023**, 12, 252
- 180 The cellular model for Alzheimer's disease research: PC12 cells. 15,
- 179 Apolipoprotein E4 inhibits β secretase activity via binding to the β secretase complex.
- 178 Alzheimer's Disease and Synapse Loss: What Can We Learn from Induced Pluripotent Stem Cells?. **2023**,
- 177 Ability of Azathiacyclen Ligands to Stop Cu(A β)-Induced Production of Reactive Oxygen Species: [3N1S] is the Right Donor Set.
- 176 Neurodegeneration in a novel invertebrate model system: Failed microtubule-mediated cell adhesion and unraveling of macroglia.
- 175 Design, synthesis, anti-acetylcholinesterase evaluation and molecular modelling studies of novel coumarin-chalcone hybrids. 1-13
- 174 Prion Protein Complex with mGluR5 Mediates Amyloid- β Synaptic Loss in Alzheimer's Disease. **2023**, 467-481
- 173 Cell type-specific histone acetylation profiling of Alzheimer's disease subjects and integration with genetics. 15,
- 172 Bioinspired synthetic polymers-based inhibitors of Alzheimer's amyloid- β peptide aggregation.
- 171 Identification and characterization of peptides from marine crustacean crabs and their bioactive properties; An approach to develop novel drugs for Alzheimer's disease.
- 170 Blood brain barrier-on-a-chip to model neurological diseases. **2023**, 104174
- 169 Early Mitochondrial Defects in the 5xFAD Mouse Model of Alzheimer's Disease. **2023**, 1-16
- 168 A Genome-Wide Functional Screen Identifies Enhancer and Protective Genes for Amyloid Beta-Peptide Toxicity. **2023**, 24, 1278
- 167 Identification of novel regulators involved in AD pathogenesis using the CRISPR-Cas9 system. **2023**, 158, 21-25
- 166 The paradigm of amyloid precursor protein in amyotrophic lateral sclerosis: The potential role of the 682YENPTY687 motif. **2023**, 21, 923-930
- 165 The interactions of amyloid β aggregates with phospholipid membranes and the implications for neurodegeneration.

- 164 Examining the effect of the crown ether, 18-crown-6, on lysozyme fibrillation. 0
- 163 Ex vivo analysis platforms for monitoring amyloid precursor protein cleavage. 15, 0
- 162 Characterization of exposure-Clinical Dementia Rating-Sum of Boxes relationship in subjects with early Alzheimer's disease from the aducanumab Phase 3 trials. 0
- 161 Effects of methionine intake on cognitive function in mild cognitive impairment patients and APP/PS1 Alzheimer's Disease model mice: Role of the cystathionine-β-synthase/H2S pathway. **2023**, 59, 102595 2
- 160 Structurally Altered, Not Wild-Type, Pentameric C-Reactive Protein Inhibits Formation of Amyloid-β Fibrils. **2022**, 209, 1180-1188 1
- 159 Beneficial Effect of ACI-24 Vaccination on Aβ Plaque Pathology and Microglial Phenotypes in an Amyloidosis Mouse Model. **2023**, 12, 79 0
- 158 Extensive Summary of the Important Roles of Indole Propionic Acid, a Gut Microbial Metabolite in Host Health and Disease. **2023**, 15, 151 0
- 157 Ganglioside GM1 produces Aβ₄₀ cytotoxic protofibril structure. 0
- 156 ALZHEIMER'S DISEASE: MODERN VIEWS ON THE PATHOGENESIS OF THE DISEASE. **2022**, 7, 39-41 0
- 155 Molecular Mechanisms of Emerging Therapeutic Targets in Alzheimer's Disease: A Systematic Review. **2022**, 16, 443-455 0
- 154 A Kinetic Map of the Influence of Biomimetic Lipid Model Membranes on Aβ₂ Aggregation. **2023**, 14, 323-329 1
- 153 The methylenetetrahydrofolate reductase C677T and A1298C genetic polymorphisms and plasma homocysteine in Alzheimer's disease in an Algerian population. 1-6 0
- 152 The Contribution of Transgenic Models to the Understanding of Alzheimer's Disease Progression and Therapeutic Development. **2011**, 1-14 0
- 151 Transgenic Mice Overexpressing GSK-3β as Animal Models for Alzheimer's Disease. **2011**, 52-68 0
- 150 Animal Models of Amyloid/PS-1 Pathology. **2011**, 15-38 0
- 149 Molecular mechanisms of amyloid-β peptide fibril and oligomer formation: NMR-based challenges. **2023**, 0
- 148 Lecanemab for Alzheimer's disease: new hope or another false dawn?. **2023**, 27, 4-6 0
- 147 PGAGP: Predicting pathogenic genes based on adaptive network embedding algorithm. 13, 0

- 146 Gut-derived β amyloid: Likely a centerpiece of the gut-brain axis contributing to Alzheimer's pathogenesis. **2023**, 15, 4
- 145 QSAR modeling and molecular docking studies of 2-oxo-1, 2-dihydroquinoline-4- carboxylic acid derivatives as p-glycoprotein inhibitors for combating cancer multidrug resistance. **2023**, 9, e13020 0
- 144 Role of neurogenesis in regenerative medicine. **2023**, 455-475 0
- 143 SorCS1 inhibits amyloid-binding to neurexin and rescues amyloid-induced synaptic pathology. **2023**, 6, e202201681 1
- 142 Analysis of Non-Amyloidogenic Mutations in APP Supports Loss of Function Hypothesis of Alzheimer's Disease. **2023**, 24, 2092 0
- 141 AlphaFold Prediction of Structural Ensembles of Disordered Proteins. 0
- 140 MicroRNA-650 Regulates the Pathogenesis of Alzheimer's Disease Through Targeting Cyclin-Dependent Kinase 5. 0
- 139 Biomarkers of Mild Cognitive Impairment and Alzheimer's Disease. **2008**, 37, 406-410 0
- 138 Molecular Imaging of Neuroinflammation in Alzheimer's Disease and Mild Cognitive Impairment. **2023**, 301-326 0
- 137 The Strategy of Targeting Peroxisome Proliferator-Activated Receptor (PPAR) in the Treatment of Neuropsychiatric Disorders. **2023**, 513-535 0
- 136 Towards mechanistic models of mutational effects: Deep learning on Alzheimer's A β peptide. **2023**, 21, 2434-2445 0
- 135 A novel rhein-huprine hybrid ameliorates disease-modifying properties in preclinical mice model of Alzheimer's disease exacerbated with high fat diet. **2023**, 13, 0
- 134 Partial Destabilization of Amyloid- β Protofibril by Methionine Photo-Oxidation: A Molecular Dynamic Simulation Study. **2023**, 8, 10148-10159 0
- 133 Small Molecule Decoys of Aggregation for Elimination of A β Peptide Toxicity. 0
- 132 Early Detection of Alzheimer's Disease-Related Pathology Using a Multi-Disease Diagnostic Platform Employing Autoantibodies as Blood-Based Biomarkers. **2023**, 92, 1077-1091 0
- 131 Aspirin Use and Risk of Alzheimer's Disease: A 2-Sample Mendelian Randomization Study. **2023**, 92, 989-1000 0
- 130 CRISPR/Cas9 system and its applications in nervous system diseases. **2023**, 0
- 129 The Labyrinthine Landscape of APP Processing: State of the Art and Possible Novel Soluble APP-Related Molecular Players in Traumatic Brain Injury and Neurodegeneration. **2023**, 24, 6639 0

- 128 A triterpenoid saponin bacoside-A3 from the aerial parts of *Bacopa monnieri* (L.) Wettst with acetylcholinesterase enzyme combating Alzheimer's disease. **2023**, 156, 177-185 ○
- 127 Amyloid β pathology in Alzheimer's disease: A nano delivery approach. **2023**, 126, 103510 ○
- 126 Role of microbial dysbiosis in the pathogenesis of Alzheimer's disease. **2023**, 229, 109478 ○
- 125 Hyperoside alleviates toxicity of β amyloid via endoplasmic reticulum-mitochondrial calcium signal transduction cascade in APP/PS1 double transgenic Alzheimer's disease mice. **2023**, 61, 102637 1
- 124 An overview of in vitro 3D models of the blood-brain barrier as a tool to predict the in vivo permeability of nanomedicines. **2023**, 196, 114816 ○
- 123 Brain targeted peptide-functionalized chitosan nanoparticles for resveratrol delivery: Impact on insulin resistance and gut microbiota in obesity-related Alzheimer's disease. **2023**, 310, 120714 ○
- 122 Role of N6-methyladenosine modification in central nervous system diseases and related therapeutic agents. **2023**, 162, 114583 ○
- 121 Beneficial effect of electroacupuncture on the distribution of foreign substances in the brain of rats developing depression-like behavior. **2023**, 14, 398-406 ○
- 120 Treatment of Alzheimer's disease by microcapsule regulates neurotransmitter release via microfluidic technology. **2023**, 4, 183-192 ○
- 119 Intrinsic mechanisms for the inhibition effect of graphene oxide on the catalysis activity of alpha amylase. **2023**, 453, 131389 ○
- 118 . 306-308 ○
- 117 My Genome, My Right. 183-199 ○
- 116 Personalised Medicine and the Politics of Human Nuclear Genome Transfer. 17-36 ○
- 115 Index. 302-305 ○
- 114 Bibliography. 261-301 ○
- 113 I Run, You Run, We Run. 226-244 ○
- 112 Personalising Future Health Risk through Biological Insurance 52-76 ○
- 111 The Best Me I Can Possibly Be 200-225 ○

110	When There Is No Cure. 113-132	0
109	DNAzyme-driven bipedal DNA walker triggered to hybridize silver nanoparticle probes for electrochemical detection of amyloid-β oligomer. 2023 , 1246, 340889	0
108	Clinical Application of Acupuncture Treatment of Alzheimer's Disease Based on the Theory of Regulating Qi and Treating Spirit 2023 , 12, 261-266	0
107	A Flower-like Brain Targeted Selenium Nanocluster Lowers the Chlorogenic Acid Dose for Ameliorating Cognitive Impairment in APP/PS1 Mice. 2023 , 71, 2883-2897	0
106	Deletion of UCP1 in Tg2576 Mice Increases Body Temperature and Exacerbates Alzheimer's Disease-Related Pathologies. 2023 , 24, 2741	0
105	AVE 0991 Suppresses Astrocyte-Mediated Neuroinflammation of Alzheimer's Disease by Enhancing Autophagy. Volume 16, 391-406	1
104	Vanillin Benzothiazole Derivative Reduces Cellular Reactive Oxygen Species and Detects Amyloid Fibrillar Aggregates in Alzheimer's Disease Brain. 2023 , 14, 773-786	0
103	Effect of Pathway-specific Polygenic Risk Scores for Alzheimer's Disease (AD) on Rate of Change in Cognitive Function and AD-related Biomarkers among Asymptomatic Individuals.	0
102	Integrative in situ mapping of single-cell transcriptional states and tissue histopathology in a mouse model of Alzheimer's disease.	0
101	Adult hippocampal neurogenesis in Alzheimer's disease: A roadmap to clinical relevance. 2023 , 30, 120-136	0
100	C/EBPβ/AEP Signaling Drives Alzheimer's Disease Pathogenesis.	0
99	Toxic Tau Aggregation in AD. 2023 , 1-30	0
98	Structural Proteomic Profiling of Cerebrospinal Fluids to Reveal Novel Conformational Biomarkers for Alzheimer's Disease. 2023 , 34, 459-471	0
97	Revealing the Nanoarchitectonics of Amyloid β Aggregation on Two-Dimensional Biomimetic Membranes by Surface-Enhanced Infrared Absorption Spectroscopy. 2023 , 12,	0
96	The Curcumin Derivative GT863 Protects Cell Membranes in Cytotoxicity by Aβ Oligomers. 2023 , 24, 3089	0
95	Osteocalcin ameliorates cognitive dysfunctions in a mouse model of Alzheimer's Disease by reducing amyloid β burden and upregulating glycolysis in neuroglia. 2023 , 9,	0
94	Mitochondria Profoundly Influence Apolipoprotein E Biology. 2023 , 92, 591-604	1
93	Revisiting the intersection of microglial activation and neuroinflammation in Alzheimer's disease from the perspective of ferroptosis. 2023 , 375, 110387	0

- 92 The effects of age, genotype and diet on hippocampal subfield iron dysregulation and Alzheimer's disease biomarkers in an ApoE mouse model. **2023**, 57, 1033-1047 ○
- 91 The Strategies of Development of New Non-Toxic Inhibitors of Amyloid Formation. **2023**, 24, 3781 ○
- 90 Multivalent Nanobody Conjugate with Rigid, Reactive Oxygen Species Scavenging Scaffold for Multi-Target Therapy of Alzheimer's Disease. 2210879 ○
- 89 The Alzheimer's Disease Mitochondrial Cascade Hypothesis: A Current Overview. **2023**, 92, 751-768 ○
- 88 Stability of the A β 2 Peptide in Mixed Solutions of Denaturants and Proline. **2023**, 127, 1572-1585 ○
- 87 Neuromodulatory effect of plant metabolites. **2022**, 1, 47-69 ○
- 86 Molecular dynamics simulations reveal the importance of amyloid-beta oligomer β sheet edge conformations in membrane permeabilization. **2023**, 299, 103034 ○
- 85 Hallmarks of neurodegenerative diseases. **2023**, 186, 693-714 1
- 84 Cooperation of N- and C-terminal substrate transmembrane domain segments in intramembrane proteolysis by β secretase. **2023**, 6, ○
- 83 Aggregation Limiting Cell-Penetrating Peptides Derived from Protein Signal Sequences. **2023**, 24, 4277 ○
- 82 Genome-wide methylomic regulation of multiscale gene networks in Alzheimer's disease. ○
- 81 The effects of microglia-associated neuroinflammation on Alzheimer's disease. 14, ○
- 80 Design, Synthesis, and Pharmacological Evaluation of Embelin-Aryl/alkyl Amine Hybrids as Orally Bioavailable Blood-Brain Barrier Permeable Multitargeted Agents with Therapeutic Potential in Alzheimer's Disease: Discovery of SB-1448. **2023**, 14, 1193-1219 ○
- 79 Intrahippocampal Inoculation of A β 2 Peptide in Rat as a Model of Alzheimer's Disease Identified MicroRNA-146a-5p as Blood Marker with Anti-Inflammatory Function in Astrocyte Cells. **2023**, 12, 694 ○
- 78 Peptide Self-Assembly into Amyloid Fibrils at Hard and Soft Interfaces—from Corona Formation to Membrane Activity. 2200576 ○
- 77 Soluble and insoluble protein aggregates, endoplasmic reticulum stress, and vascular dysfunction in Alzheimer's disease and cardiovascular diseases. ○
- 76 Neurocognitive Disorders. **2023**, 407-435 ○
- 75 Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer's Disease. ○

- 74 BMP9 ameliorates amyloid pathology by promoting low-density lipoprotein receptor-related protein 1 expression in APP/PS1 transgenic mice. **2023**, 801, 137159 ○
- 73 Design, Synthesis, and Neuroprotective Activity of Phenoxyindole Derivatives on Anti-amyloid Beta (A β) Aggregation, Anti-acetylcholinesterase, and Antioxidant Activities. **2023**, 16, 355 ○
- 72 The Amyloid Cascade Hypothesis in Alzheimer's Disease: Should We Change Our Thinking?. **2023**, 13, 453 ○
- 71 Tetramodal Chemical Imaging Delineates the Lipid-Amyloid Peptide Interplay at Single Plaques in Transgenic Alzheimer's Disease Models. **2023**, 95, 4692-4702 ○
- 70 Metal-mediated nanobody assemblies as potent alleviators of human islet amyloid polypeptide aggregation. 1
- 69 RyR2-dependent modulation of neuronal hyperactivity: A potential therapeutic target for treating Alzheimer's disease. ○
- 68 Effects of Sideritis scardica Extract on Scopolamine-Induced Learning and Memory Impairment in Mice. **2023**, 92, 1289-1302 1
- 67 Pathways explaining racial/ethnic disparities in incident all-cause dementia among middle-aged US adults. ○
- 66 Circadian Rhythms and Time-Restricted Eating in Healthy Aging and Longevity. **2023**, 425-443 ○
- 65 Cellular response to A β amyloid neurotoxicity in Alzheimer's disease and implications in new therapeutics. **2023**, 6, 3-9 ○
- 64 Loss of the m6A methyltransferase METTL3 in monocyte-derived macrophages ameliorates Alzheimer's disease pathology in mice. **2023**, 21, e3002017 1
- 63 Heparan sulfate proteoglycan in Alzheimer's disease: aberrant expression and functions in molecular pathways related to amyloid- β metabolism. **2023**, 324, C893-C909 ○
- 62 Citicoline loaded nanoemulsion enriched with D-alpha-Tocopherol acetate and protein: Formulation and in-silico study. **2023**, 82, 104340 ○
- 61 Enhancing the Therapeutic Effect in Alzheimer's Disease Drugs: The role of Polypharmacology and Cholinesterase inhibitors. **2023**, 8, ○
- 60 Neuroinflammation and neuroimmunology in Alzheimer's disease: The role of T-lymphocytes in Alzheimer's disease. ○
- 59 β -Carotene, a Potent Amyloid Aggregation Inhibitor, Promotes Disordered A β Fibrillar Structure. **2023**, 24, 5175 ○
- 58 Sex differences in hippocampal A β amyloid accumulation in the triple-transgenic mouse model of Alzheimer's disease and the potential role of local estrogens. 17, ○
- 57 Beyond the amyloid cascade: An update of Alzheimer's disease pathophysiology. **2023**, ○

- 56 Modulations of SIRTUINs and Management of Brain Disorders. **2023**, 47-81 ○
- 55 Intracellular Amyloid- β Detection from Human Brain Sections Using a Microfluidic Immunoassay in Tandem with MALDI-MS. **2023**, 95, 5522-5531 ○
- 54 A Polyaminobiaryl-Based β -Secretase Modulator Alleviates Cognitive Impairments, Amyloid Load, Astrogliosis, and Neuroinflammation in APPSwe/PSEN1 Δ E9 Mice Model of Amyloid Pathology. **2023**, 24, 5285 1
- 53 TGF- β signalling in Alzheimer's pathology and cytoskeletal reorganization: a specialized Tau perspective. **2023**, 20, ○
- 52 Early mitochondrial dysfunction preceds neuroinflammation, synaptic alteration, and autophagy impairment in hippocampus of Appknock-in Alzheimer mouse models. ○
- 51 Soluble TREM2 in body fluid in Alzheimer's disease and Parkinson's disease. ○
- 50 Effect of Ovocystatin on Amyloid β -42 Aggregation In Vitro Studies. **2023**, 24, 5433 ○
- 49 Light, Water, and Melatonin: The Synergistic Regulation of Phase Separation in Dementia. **2023**, 24, 5835 ○
- 48 MicroRNAs in tear fluids predict underlying molecular changes associated with Alzheimer's disease. **2023**, 6, e202201757 ○
- 47 Small-Molecule Cdc25A Inhibitors Protect Neuronal Cells from Death Evoked by NGF Deprivation and 6-Hydroxydopamine. **2023**, 14, 1226-1237 ○
- 46 Amyloid inhibition by molecular chaperones in vitro can be translated to Alzheimer's pathology in vivo. ○
- 45 PARP16-Mediated Stabilization of Amyloid Precursor Protein mRNA Exacerbates Alzheimer's Disease Pathogenesis. **2023**, 0 ○
- 44 Single-cell multiomic analysis reveals the involvement of Type I interferon-responsive CD8+ T cells in amyloid beta-associated memory loss. ○
- 43 Research Progress on the Etiology and Pathogenesis of Alzheimer's Disease from the Perspective of Chronic Stress. **2022**, 0 ○
- 42 CNTN1 Aggravates Neuroinflammation and Triggers Cognitive Deficits in Male Mice by Boosting Crosstalk between Microglia and Astrocytes. **2023**, 0 ○
- 41 Oligomeric β -Amyloid Suppresses Hippocampal β Oscillations through Activation of the mTOR/S6K1 Pathway. **2023**, 0 ○
- 40 Neurodegeneration: Cerebrum. **2013**, 947-947.e19 ○
- 39 Classification and pathogenesis of neurodegenerative diseases. **2013**, 549-553 ○

- 38 Neuroprotective effects of ferrostatin and necrostatin against entorhinal amyloidopathy- induced electrophysiological alterations mediated by voltage-gated Ca²⁺ channels in the dentate gyrus granular cells. ○
- 37 Atomistic molecular simulations of A β Zn conformational ensembles. ○
- 36 Deficits in mitochondrial function and glucose metabolism seen in sporadic and familial Alzheimer β disease derived Astrocytes are ameliorated by increasing hexokinase 1 expression. ○
- 35 Identification and characterization of bioactive peptides from marine crustacean crabs: a possible drug candidate for Alzheimer β disease. ○
- 34 Profiling and Cellular Analyses of Obesity-Related circRNAs in Neurons and Glia under Obesity-like In Vitro Conditions. **2023**, 24, 6235 ○
- 33 Pioneering the Early Diagnosis of Alzheimer β Disease: A β Oligomers-Sensing Probe for Cerebrospinal Fluid Analysis in Patients. ○
- 32 Frontier Review of the Molecular Mechanisms and Current Approaches of Stem Cell-Derived Exosomes. **2023**, 12, 1018 ○
- 31 Directed Functional Brain Connectivity is Altered in Sub-threshold Amyloid- β Accumulation in Cognitively Normal Individuals. **2023**, 18, 263310552311616 ○
- 30 Alignment of human aquaporin 4 and β amyloid proteins may indicate involvement of β amyloid in brain water homeostasis and prevention of brain edema. ○
- 29 Brain p3-A β peptide restores neuronal viability impaired by Alzheimer's amyloid β peptide. ○
- 28 Myelin in Alzheimer β disease: culprit or bystander?. **2023**, 11, ○
- 27 Molecular Imaging in Neurology. **2023**, 375-423 ○
- 26 New Insights into Alzheimer β Disease: Novel Pathogenesis, Drug Target and Delivery. **2023**, 15, 1133 ○
- 25 20S-Protopanaxatriol improves cognitive function of Alzheimer's disease by promoting endogenous neurogenesis. ○
- 24 A β Chronic Exposure Promotes an Activation State of Microglia through Endocannabinoid Signalling Imbalance. **2023**, 24, 6684 ○
- 23 Association of overexpressed carboxyl-terminal amyloid precursor protein in brains with altered glucose metabolism and liver toxicity. **2023**, 27, 103-111 ○
- 22 Mitochondria-Directing Fluorogenic Probe: An Efficient Amyloid Marker for Imaging Lipid Metabolite-Induced Protein Aggregation in Live Cells and *Caenorhabditis elegans*. **2023**, 95, 6341-6350 ○
- 21 Vascular Effects on Cerebrovascular Permeability and Neurodegeneration. **2023**, 13, 648 ○

- 20 Contribution of A-to-I RNA editing, M6A RNA Methylation, and Alternative Splicing to physiological brain aging and neurodegenerative diseases.. **2023**, 111807 ○
- 19 Imbalance of Essential Metals in Traumatic Brain Injury and Its Possible Link with Disorders of Consciousness. **2023**, 24, 6867 ○
- 18 Hypochlorous Acid-Activated UCNPs-LMB/VQIVYK Multifunctional Nanosystem for Alzheimer's Disease Treatment. **2023**, 14, 207 ○
- 17 Differential and substrate-specific inhibition of β -secretase by the C-terminal region of ApoE2, ApoE3, and ApoE4. **2023**, ○
- 16 Memophenol™ Prevents Amyloid- β Deposition and Attenuates Inflammation and Oxidative Stress in the Brain of an Alzheimer's Disease Rat. **2023**, 24, 6938 ○
- 15 Triazole-peptide Conjugate as a Modulator of A β Aggregation, Metal-Mediated A β Aggregation, and Cytotoxicity. ○
- 14 Electrostatics-Induced Nucleated Conformational Transition of Protein Aggregation. **2023**, 130, ○
- 13 Deciphering mechanisms of action of ACE inhibitors in neurodegeneration using Drosophila models of Alzheimer's disease. 17, ○
- 12 Inorganic ion-sensitive imaging probes for biomedical applications. ○
- 11 Metals in Alzheimer's Disease. **2023**, 11, 1161 ○
- 10 A haptoglobin (HP) structural variant alters the effect of APOE alleles on Alzheimer's disease. ○
- 9 Inhibition of NLRP1 inflammasome improves autophagy dysfunction and A β disposition in APP/PS1 mice. **2023**, 19, ○
- 8 Exploring the Therapeutic Effect of Neurotrophins and Neuropeptides in Neurodegenerative Diseases: at a Glance. ○
- 7 N-terminal truncation of peptide effects on human serum albumin and beta amyloid peptide interaction. **2023**, 101004 ○
- 6 Enlarged perivascular spaces and plasma A β 2/A β 0 ratio in older adults without dementia. **2023**, ○
- 5 Study on molecular mechanisms of destabilizing A β (1-42) protofibrils by licochalcone A and licochalcone B using molecular dynamics simulations. **2023**, 108500 ○
- 4 Programmed ageing: decline of stem cell renewal, immunosenescence, and Alzheimer's disease. ○
- 3 Potential Implication of Treatments for Alzheimer's Disease: Current and Future. **2023**, 36, 3-10 ○

2 Redox Imbalance in Neurological Disorders in Adults and Children. **2023**, 12, 965 ○

1 Improving the Treatment Effect of Carotenoids on Alzheimer's Disease through Various Nano-Delivery Systems. **2023**, 24, 7652 ○